+

US20180311316A1 - Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5 - Google Patents

Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5 Download PDF

Info

Publication number
US20180311316A1
US20180311316A1 US16/025,832 US201816025832A US2018311316A1 US 20180311316 A1 US20180311316 A1 US 20180311316A1 US 201816025832 A US201816025832 A US 201816025832A US 2018311316 A1 US2018311316 A1 US 2018311316A1
Authority
US
United States
Prior art keywords
group
insulin
chosen
radical
lantus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/025,832
Inventor
Gerard Soula
Olivier Soula
Jeff Tonnar
Alexandre GEISSLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1157291A external-priority patent/FR2978918B1/en
Priority claimed from FR1162445A external-priority patent/FR2984749A1/en
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to US16/025,832 priority Critical patent/US20180311316A1/en
Publication of US20180311316A1 publication Critical patent/US20180311316A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the invention relates to therapies by injection of insulin(s) for treating diabetes.
  • Insulin therapy or diabetes therapy by injecting insulin, has made remarkable progress in recent years by virtue especially of the development of novel insulins that offer correction of patients' glycaemia, which enables better simulation of the physiological activity of the pancreas.
  • prandial insulins or rapid-acting insulins
  • basal insulins or slow-acting insulins
  • Prandial insulins allow rapid management (metabolization and/or storage) of the glucose provided by meals and snacks.
  • the patient must inject a prandial insulin before each food intake, i.e. about 2 to 3 injections per day.
  • the prandial insulins most commonly used are: the recombinant human insulin, NovoLog® (aspart insulin from Novo Nordisk), Humalog® (lispro insulin from Eli Lilly) and Apidra® (glulisine insulin from Sanofi-Aventis).
  • Basal insulins maintain the patient's glycaemic homeostasis, outside periods of food intake. They act essentially by blocking the endogenous production of glucose (hepatic glucose).
  • the daily dose of basal insulin generally corresponds to 40-50% of the total daily insulin needs. Depending on the basal insulin used, this dose is dispensed in 1 or 2 injections, regularly distributed throughout the day.
  • the basal insulins most commonly used are Levemir® (detemir insulin from Novo Nordisk) and Lantus® (glargine insulin from Sanofi-Aventis).
  • NPH NPH insulin, for Neutral Protamine Hagedorn; Humuline NPH®, Insulatard®
  • This formulation is the result of a precipitation of human insulin (anionic at neutral pH) with a cationic protein, protamine.
  • These microcrystals are dispersed in an aqueous suspension and dissolve slowly after subcutaneous injection. This slow dissolution ensures sustained release of the insulin. However, this release does not ensure a constant concentration of insulin over time.
  • the release profile is bell-shaped and lasts only between 12 and 16 hours. It is thus injected twice a day.
  • This NPH basal insulin is much less efficient than the modern basal insulins Levemir® and Lantus®.
  • NPH is an intermediate-acting basal insulin.
  • NPH The principle of NPH changed with the appearance of rapid insulin analogues to give “Premix” products that afford both rapid action and intermediate action.
  • NovoLog Mix® Novo Nordisk
  • Humalog Mix® Eli Lilly
  • These formulations thus contain microcrystals of insulin whose action is said to be intermediate, and a proportion of insulin which has remained soluble, whose action is rapid.
  • These formulations do indeed offer the advantage of a rapid insulin, but they also have the defect of NPH, i.e. a duration of action limited to between 12 and 16 hours and a bell-shaped release of insulin.
  • these products enable the patient to carry out a single injection of an intermediate-acting basal insulin with a rapid-acting prandial insulin. In point of fact, many patients are desirous to reduce their number of injections.
  • the basal insulins currently marketed and currently under clinical development may be categorized as a function of the technical solution for obtaining sustained action, and two approaches are used at the present time.
  • the first, that of insulin detemir, is the binding to albumin in vivo. It is an analogue, soluble at pH 7, which comprises a fatty acid (tetradecanoyl) side chain attached to position B29 which, in vivo, enables this insulin to combine with albumin. Its sustained action is mainly due to this affinity for albumin after subcutaneous injection.
  • Degludec® also comprises a fatty acid side chain attached to insulin (hexadecandioyl- ⁇ -L-Glu).
  • the second, that of insulin glargine, is the precipitation at physiological pH.
  • This is an analogue of human insulin obtained by elongation of the C-terminal part of the B chain of human insulin with two arginine residues, and by substitution of the asparagine residue A21 with a glycine residue (U.S. Pat. No. 5,656,722).
  • the addition of the two arginine residues was conceived to adjust the pI (isoelectric point) of insulin glargine at physiological pH, and thus make this insulin analogue insoluble in physiological medium.
  • A21 The substitution of A21 was conceived in order to make insulin glargine stable at acidic pH and thus to be able to formulate it in the form of an injectable solution at acidic pH.
  • an acidic pH pH 4-4.5
  • a physiological pH neutral pH
  • the slow redissolution of the insulin glargine microparticles ensures a slow and sustained action.
  • hypoglycaemic effect of insulin glargine is virtually constant over a period of 24 hours, which allows the majority of patients to limit themselves to a single injection per day.
  • Insulin glargine is nowadays considered as the best basal insulin marketed.
  • the acidic pH of the formulations of basal insulins the isoelectric point of which is between 5.8 and 8.5, of insulin glargine type, prevents any pharmaceutical combination with other proteins and in particular prandial insulins, since the latter are unstable at acidic pH.
  • basal insulins of insulin glargine type, outlined above, namely that they are soluble at acidic pH and precipitate at physiological pH, dissuades a person skilled in the art from any solution in which insulin of insulin glargine type would be dissolved at pH 6-8 while maintaining its essential property, which is that of precipitating in subcutaneous medium.
  • the impossibility of formulating a prandial insulin, at acidic pH arises from the fact that a prandial insulin undergoes, under these conditions, a deamidation side reaction in position A21; this does not make it possible to satisfy the requirement of the US Pharmacopeia, namely less than 5% of by-product after 4 weeks at 30° C.
  • this acidic pH of formulations of basal insulins the isoelectric point of which is between 5.8 and 8.5, of insulin glargine type, even prevents any extemporaneous combination with prandial insulins at neutral pH.
  • the instructions for use for Lantus® the commercial product based on insulin glargine from the company Sanofi-Aventis, explicitly indicates to users that they should not mix it with a solution of prandial insulin, whichever it may be, on account of the serious risk of modifying the pharmacokinetics and pharmacodynamics of the insulin glargine and/or of the mixed prandial insulin.
  • compositions comprising a basal insulin and a prandial insulin at a pH of between 3.0 and 4.2 in the presence of a chelating agent and polyacids.
  • This patent teaches how to make a prandial insulin compatible at acidic pH in the presence of an insulin of insulin glargine type. It does not teach how to prepare a combination of insulin of insulin glargine type and of a prandial insulin at neutral pH.
  • compositions according to the invention make it possible to dissolve, at pH 7, a basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention allow maintenance of the duration of the hypoglycaemic activity of the basal insulin whose isoelectric point is between 5.8 and 8.5, despite its dissolution at pH 7 before injection.
  • This noteworthy property arises from the fact that the insulin of insulin glargine type dissolved at pH 7 in the composition of the invention precipitates in subcutaneous medium by means of a change of composition of the medium.
  • the factor triggering the precipitation of the insulin of insulin glargine type is no longer the pH modification, but a modification of composition of the environment during the passage of the pharmaceutical composition into the physiological medium.
  • the rapid action of the prandial insulin is preserved despite the precipitation of the insulin of insulin glargine type in subcutaneous medium.
  • the invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, comprising at least:
  • the -(f-[A]-COOH) n radical is such that:
  • the -(g-[B]-k-[D]) m radical is such that:
  • the -(f-[A]-COOH) n radical is such that:
  • the dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals is of formula III:
  • the dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals is of formula IV:
  • the structure drawn corresponds to the representation commonly used to represent dextran, which is a polysaccharide predominantly composed of (1,6) linkages between glucoside units, which is the representation adopted.
  • Dextran also comprises (1,3) linkages at approximately 5% in general, which are deliberately not represented but which are, of course, included within the scope of the invention.
  • basic insulin whose isoelectric point is between 5.8 and 8.5 is understood to mean an insulin which is insoluble at pH 7 and which has a duration of action of between 8 and 24 hours or more in the standard models of diabetes.
  • basal insulins whose isoelectric point is between 5.8 and 8.5 are recombinant insulins, the primary structure of which has been modified mainly by introduction of basic amino acids, such as arginine or lysine. They are described, for example, in the following patents, patent applications or publications: WO 2003/053339, WO 2004/096854, U.S. Pat. No. 5,656,722 and U.S. Pat. No. 6,100,376.
  • the basal insulin whose isoelectric point is between 5.8 and 8.5 is insulin glargine.
  • compositions according to the invention comprise 100 IU/ml (i.e., approximately 3.6 mg/ml) of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise 40 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise 200 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise 300 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise 400 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise 500 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 0.2 and 5.
  • the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 0.2 and 4.
  • the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 0.2 and 3.
  • the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 0.5 and 3.
  • the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 0.8 and 3.
  • the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 1 and 3.
  • the concentration of substituted dextran is between 1 and 100 mg/ml.
  • the concentration of substituted dextran is between 1 and 80 mg/ml.
  • the concentration of substituted dextran is between 1 and 60 mg/ml.
  • the concentration of substituted dextran is between 1 and 50 mg/ml.
  • the concentration of substituted dextran is between 1 and 30 mg/ml.
  • the concentration of substituted dextran is between 1 and 20 mg/ml.
  • the concentration of substituted dextran is between 1 and 10 mg/ml.
  • the concentration of polysaccharide is between 5 and 20 mg/ml.
  • the concentration of polysaccharide is between 5 and 10 mg/ml.
  • compositions according to the invention additionally comprise a prandial insulin.
  • Prandial insulins are soluble at pH 7.
  • prandial insulin is understood to mean a “rapid” or “regular” insulin.
  • Rapid prandial insulins are insulins which must meet the needs brought about by the ingestion of proteins and carbohydrates during a meal; they have to act in less than 30 minutes.
  • “regular” prandial insulins are chosen from the group consisting of Humulin® (human insulin) and Novolin® (human insulin).
  • “Fast-acting” prandial insulins are insulins which are obtained by recombination and which are modified in order to reduce their action time.
  • “fast-acting” prandial insulins are chosen from the group consisting of insulin lispro (Humalog®), insulin glulisine (Apidra®) and insulin aspart (NovoLog®).
  • compositions according to the invention comprise, in total, 100 IU/ml (i.e., approximately 3.6 mg/ml) of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise, in total, 40 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise, in total, 200 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise, in total, 300 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise, in total, 400 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise, in total, 500 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise, in total, 600 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise, in total, 700 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • compositions according to the invention comprise, in total, 800 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • the proportions between the basal insulin whose isoelectric point is between 5.8 and 8.5 and the prandial insulin, expressed as percentage with respect to the total amount of insulin, are, for example, 25/75, 30/70, 40/60, 50/50, 60/40, 70/30, 80/20 and 90/10 for the formulations as described above from 40 to 800 IU/ml. However, any other proportion can be produced.
  • the proportions between the basal insulin whose isoelectric point is between 5.8 and 8.5 and the prandial insulin are, for example, in IU/ml, 25/75, 30/70, 40/60, 50/50, 60/40, 70/30, 80/20 or 90/10. However, any other proportion can be produced.
  • the composition according to the invention additionally comprises a GLP-1, a GLP-1 analogue or a GLP-1 derivative.
  • the GLP-1 analogues or derivatives are chosen from the group consisting of exenatide or Byetta®, developed by Eli Lilly & Co and Amylin Pharmaceuticals, liraglutide or Victoza® developed by Novo Nordisk, or lixisenatide or Lyxumia® developed by Sanofi, their analogues or derivatives and their pharmaceutically acceptable salts.
  • the GLP-1 analogue or derivative is exenatide or Byetta®, its analogues or derivatives and their pharmaceutically acceptable salts.
  • the GLP-1 analogue or derivative is liraglutide or Victoza®, its analogues or derivatives and their pharmaceutically acceptable salts.
  • the GLP-1 analogue or derivative is lixisenatide or Lyxumia®, its analogues or derivatives and their pharmaceutically acceptable salts.
  • analogue is understood to mean, when it is used with reference to a peptide or a protein, a peptide or a protein in which one or more constituent amino acid residues have been replaced by other amino acid residues and/or from which one or more constituent amino acid residues have been deleted and/or to which one or more constituent amino acid residues have been added.
  • the percentage of homology accepted for the present definition of an analogue is 50%.
  • derivative is understood to mean, when it is used with reference to a peptide or protein, a peptide or a protein or an analogue chemically modified by a substituent which is not present in the reference peptide or protein or analogue, that is to stay a peptide or a protein which has been modified by creation of covalent bonds, in order to introduce substituents.
  • the concentration of GLP-1, of GLP-1 analogue or of GLP-1 derivative is within a range from 0.01 to 10 mg/ml.
  • the concentration of exenatide, its analogues or derivatives and their pharmaceutically acceptable salts is within a range from 0.05 to 0.5 mg/ml.
  • the concentration of liraglutide, its analogues or derivatives and their pharmaceutically acceptable salts is within a range from 1 to 10 mg/ml.
  • the concentration of lixisenatide, its analogues or derivatives and their pharmaceutically acceptable salts is within a range from 0.01 to 1 mg/ml.
  • compositions according to the invention are produced by mixing commercial solutions of basal insulin whose isoelectric point is between 5.8 and 8.5 and commercial solutions of GLP-1, of GLP-1 analogue or of GLP-1 derivative in ratios by volume within a range from 10/90 to 90/10.
  • the composition according to the invention comprises a daily dose of basal insulin and a daily dose of GLP-1, GLP-1 analogue or GLP-1 derivative.
  • compositions according to the invention comprise 500 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of exenatide.
  • compositions according to the invention comprise 500 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 1 to 10 mg/ml of liraglutide.
  • compositions according to the invention comprise 500 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of lixisenatide.
  • compositions according to the invention comprise 100 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of exenatide.
  • compositions according to the invention comprise 100 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 1 to 10 mg/ml of liraglutide.
  • compositions according to the invention comprise 100 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of lixisenatide.
  • compositions according to the invention comprise 40 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 à 0.5 mg/ml of exenatide.
  • compositions according to the invention comprise 40 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 1 to 10 mg/ml of liraglutide.
  • compositions according to the invention comprise 40 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 à 0.5 mg/ml of lixisenatide.
  • compositions according to the invention comprise 200 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of exenatide.
  • compositions according to the invention comprise 200 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 1 to 10 mg/ml of liraglutide.
  • compositions according to the invention comprise 200 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of lixisenatide.
  • compositions according to the invention additionally comprise zinc salts at a concentration of between 0 and 5000 ⁇ M.
  • compositions according to the invention additionally comprise zinc salts at a concentration of between 50 and 4000 ⁇ M.
  • compositions according to the invention additionally comprise zinc salts at a concentration of between 200 and 3000 ⁇ M.
  • compositions according to the invention additionally comprise zinc salts at a concentration of between 0 and 1000 ⁇ M.
  • compositions according to the invention additionally comprise zinc salts at a concentration of between 20 and 600 ⁇ M.
  • compositions according to the invention additionally comprise zinc salts at a concentration of between 50 and 500 ⁇ M.
  • compositions according to the invention comprise buffers chosen from the group consisting of Tris, citrates and phosphates at concentrations of between 0 and 100 mM, preferably between 0 and 50 mM or between 15 and 50 mM.
  • compositions according to the invention additionally comprise preservatives.
  • the preservatives are chosen from the group consisting of m-cresol and phenol, alone or as a mixture.
  • the concentration of the preservatives is between 10 and 50 mM.
  • the concentration of the preservatives is between 10 and 40 mM.
  • compositions according to the invention can additionally comprise additives, such as tonicity agents, such as glycerol, NaCl, mannitol and glycine.
  • additives such as tonicity agents, such as glycerol, NaCl, mannitol and glycine.
  • compositions according to the invention can additionally comprise additives in accordance with the pharmacopoeias, such as surfactants, for example polysorbate.
  • surfactants for example polysorbate.
  • compositions according to the invention can additionally comprise all the excipients in accordance with the pharmacopoeias which are compatible with the insulins used at the concentrations of use.
  • 0.7 ⁇ n ⁇ 1.5 In one embodiment, 0.7 ⁇ n ⁇ 1.5.
  • the -(f-[A]-COOH) n radical is chosen from the group consisting of the following sequences, f having the meaning given above:
  • the -(g-[B]-k-[D]) m radical is chosen from the group consisting of the following sequences, g, k and D having the meanings given above:
  • D is such that the X radical is an at least divalent radical resulting from an amino acid.
  • D is such that the X radical is an at least divalent radical resulting from an amino acid chosen from the group consisting of glycine, leucine, phenylalanine, lysine, isoleucine, alanine, valine, aspartic acid and glutamic acid.
  • radicals resulting from amino acids can be either laevorotatory or dextrorotatory.
  • D is such that the X radical is an at least divalent radical resulting from a mono- or polyethylene glycol.
  • D is such that the X radical is an at least divalent radical resulting from ethylene glycol.
  • D is such that the X radical is an at least divalent radical resulting from a polyethylene glycol chosen from the group consisting of diethylene glycol and triethylene glycol.
  • D is such that the X radical is an at least divalent radical resulting from a mono- or polyethylene glycol amine.
  • D is such that the X radical is an at least divalent radical resulting from a mono- or polyethylene glycol amine chosen from the group consisting of ethanolamine, diethylene glycol amine and triethylene glycol amine.
  • D is such that the X radical is an at least divalent radical resulting from a mono- or polyethylene glycol diamine.
  • D is such that the X radical is an at least divalent radical resulting from ethylenediamine.
  • D is such that the X radical is an at least divalent radical resulting from a mono- or polyethylene glycol diamine chosen from the group consisting of diethylene glycol diamine and triethylene glycol diamine.
  • D is such that the Y group is an alkyl group resulting from a hydrophobic alcohol.
  • D is such that the Y group is an alkyl group resulting from a hydrophobic alcohol chosen from the group consisting of octanol (capryl alcohol), 3,7-dimethyloctan-1-ol, decanol (decyl alcohol), dodecanol (lauryl alcohol), tetradecanol (myristyl alcohol) and hexadecanol (cetyl alcohol).
  • a hydrophobic alcohol chosen from the group consisting of octanol (capryl alcohol), 3,7-dimethyloctan-1-ol, decanol (decyl alcohol), dodecanol (lauryl alcohol), tetradecanol (myristyl alcohol) and hexadecanol (cetyl alcohol).
  • D is such that the Y group is an alkyl group resulting from a hydrophobic acid.
  • D is such that the Y group is an alkyl group resulting from a hydrophobic acid chosen from the group consisting of decanoic acid, dodecanoic acid, tetradecanoic acid and hexadecanoic acid.
  • D is such that the Y group is a group resulting from a sterol.
  • D is such that the Y group is a group resulting from a sterol chosen from the group consisting of cholesterol and its derivatives.
  • D is such that the Y group is a group resulting from a tocopherol.
  • D is such that the Y group is a group resulting from a tocopherol derivative chosen from the racemate, the L isomer or the D isomer of ⁇ -tocopherol.
  • D is such that the X radical results from ethylenediamine, the Y group results from dodecanoic acid and the functional group l is an amide functional group.
  • the E radical is an at least divalent radical resulting from an amino acid chosen from the group consisting of glycine, leucine, phenylalanine, lysine, isoleucine, alanine, valine, serine, threonine, aspartic acid and glutamic acid.
  • radicals resulting from amino acids can be either laevorotatory or dextrorotatory.
  • the E radical is an at least divalent radical resulting from a mono- or polyethylene glycol amine.
  • the E radical is an at least divalent radical resulting from a mono- or polyethylene glycol amine chosen from the group consisting of ethanolamine, diethylene glycol amine and triethylene glycol amine.
  • the E radical is an at least divalent radical resulting from a mono- or polyethylene glycol diamine.
  • the E radical is an at least divalent radical resulting from ethylenediamine.
  • the E radical is an at least divalent radical resulting from a mono- or polyethylene glycol diamine chosen from the group consisting of diethylene glycol diamine and triethylene glycol diamine.
  • the F group is an alkyl group resulting from a hydrophobic alcohol.
  • the F group is a group resulting from a hydrophobic alcohol chosen from the group consisting of dodecanol (lauryl alcohol), tetradecanol (myristyl alcohol) and hexadecanol (cetyl alcohol).
  • the F group is a group resulting from a hydrophobic acid.
  • the F group is a group resulting from a hydrophobic acid chosen from the group consisting of dodecanoic acid, tetradecanoic acid and hexadecanoic acid.
  • the F group is a group resulting from a sterol.
  • the F group is a group resulting from a sterol chosen from the group consisting of cholesterol and its derivatives.
  • the F group is a group resulting from a tocopherol.
  • the F group is a group resulting from a tocopherol derivative chosen from the racemate, the L isomer or the D isomer of ⁇ -tocopherol.
  • compositions according to the invention comprise a dextran chosen from the group consisting of the following dextrans of formula I, III or IV:
  • compositions according to the invention comprise a dextran chosen from the group consisting of the dextran of the following formula II:
  • the invention also relates to single-dose formulations at a pH of between 6.6 and 7.8 comprising a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.
  • the invention also relates to single-dose formulations at a pH of between 7 and 7.8 comprising a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.
  • the basal insulin whose isoelectric point is between 5.8 and 8.5 is insulin glargine.
  • the prandial insulin is chosen from the group consisting of Humulin® (human insulin) and Novolin® (human insulin).
  • the prandial insulin is chosen from the group consisting of insulin lispro (Humalog®), insulin glulisine (Apidra®) and insulin aspart (NovoLog®).
  • the dissolution at a pH of between 7 and 7.8 of the basal insulins whose isoelectric point is between 5.8 and 8.5 by the polysaccharides of formula I, II, III or IV can be observed and controlled in a simple way, with the naked eye, by virtue of a change in appearance of the solution.
  • the preparation of a composition according to the invention exhibits the advantage of being able to be carried out by simple mixing of an aqueous solution of basal insulin whose isoelectric point is between 5.8 and 8.5, of a solution of prandial insulin and of a polysaccharide of formula I, II, III or IV in aqueous solution or in the lyophilized form. If necessary, the pH of the preparation is adjusted to pH 7.
  • composition according to the invention exhibits the advantage of being able to be carried out by simple mixing of an aqueous solution of basal insulin whose isoelectric point is between 5.8 and 8.5, of a polysaccharide of formula I, II, III or IV in aqueous solution or in the lyophilized form, and of a prandial insulin in aqueous solution or in the lyophilized form.
  • the mixture of basal insulin and polysaccharide is concentrated by ultrafiltration before mixing with the prandial insulin in aqueous solution or in the lyophilized form.
  • composition of the mixture is adjusted in excipients, such as glycerol, m-cresol, zinc chloride and tween, by addition of concentrated solutions of these excipients to the mixture. If necessary, the pH of the preparation is adjusted to 7.
  • excipients such as glycerol, m-cresol, zinc chloride and tween
  • FIGS. 1 to 6 present the results obtained in the form of pharmacodynamic curves for glucose.
  • the axis of the ordinates represents the Dglucose (expressed in mM) as a function of the post-injection time (expressed in minutes).
  • FIG. 1 Mean+standard deviation of the mean curves for the sequential administrations of Apidra® and Lantus® ( ⁇ ) in comparison with a composition according to the invention Polysaccharide 4/Lantus®/Apidra® (75/25) ( ⁇ ).
  • FIG. 2 Apidra® Lantus® individual curves (tested on six pigs).
  • FIG. 3 Polysaccharide 4/Apidra®/Lantus® individual curves (tested on six pigs).
  • FIG. 4 Mean+standard deviation of the mean curves for the sequential administration of Humalog® and Lantus® ( ⁇ ) in comparison with the administration of a composition according to the invention Polysaccharide 4/Humalog®/Lantus® ( ⁇ ).
  • FIG. 5 Humalog® Lantus® individual curves (tested on six pigs).
  • FIG. 6 Polysaccharide 4/Humalog®/Lantus® individual curves (tested on five pigs).
  • FIGS. 7 to 12 present the results obtained in the form of pharmacodynamic curves for glucose.
  • the axis of the ordinates represents the Dglucose (expressed in mM) as a function of the post-injection time (expressed in hours).
  • FIG. 7 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) ( ), in comparison with a composition according to the invention described in Example B28 (0.53 IU/kg) ( ).
  • FIG. 8 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) ( ), in comparison with a composition according to the invention described in Example B27 (0.47 IU/kg) ( ).
  • FIG. 9 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) ( ), in comparison with a composition according to the invention described in Example B29 (0.53 IU/kg) ( ).
  • FIG. 10 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) ( ), in comparison with a composition according to the invention described in Example B31 (0.48 IU/kg) ( ).
  • FIG. 11 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.24 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) ( ), in comparison with a composition according to the invention described in Example B30 (0.64 IU/kg) ( ).
  • FIG. 12 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) ( ), in comparison with a composition according to the invention described in Example B32 (0.53 IU/kg) ( ).
  • Table 1 presents, in a nonlimiting way, examples of polysaccharides which can be used in the compositions according to the invention.
  • 30 ml of 10N NaOH (296 mmol) are added to the solution.
  • the mixture is brought to 35° C. and then 46 g (396 mmol) of sodium chloroacetate are added.
  • the temperature of the reaction mixture is brought to 60° C. at 0.5° C./min and then maintained at 60° C. for 100 minutes.
  • the reaction medium is diluted with 200 ml of water, neutralized with acetic acid and purified by ultrafiltration through a 5 kDa PES membrane against 6 volumes of water.
  • the final solution is assayed by dry extract, to determine the concentration of polysaccharide, and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of methylcarboxylate units per glucoside unit.
  • the mean number of methylcarboxylate units per glucoside unit is 1.1.
  • the sodium dextranmethylcarboxylate solution is passed through a Purolite resin (anionic) in order to obtain dextranmethylcarboxylic acid, which is subsequently lyophilized for 18 hours.
  • a Purolite resin anionic
  • Octyl glycinate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • the octyl glycinate suspension is added.
  • the medium is subsequently maintained at 10° C. for 45 minutes.
  • the medium is subsequently heated to 30° C.
  • a solution of imidazole (10.38 g in 17 ml of water) and 52 ml of water are added to the reaction medium.
  • the polysaccharide solution is ultrafiltered through a 10 kDa PES membrane against 15 volumes of 0.9% NaCl solution and 5 volumes of water.
  • the concentration of the polysaccharide solution is determined by dry extract.
  • a fraction of solution is lyophilized and analyzed by 1 H NMR in D 2 O in order to determine the degree of substitution of the methylcarboxylates to give octyl glycinate per glucoside unit.
  • Cetyl glycinate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • a sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 5 kg/mol (q 19, Pharmacosmos), modified by cetyl glycinate, is obtained by a process similar to that described in Example A1.
  • Octyl phenylalaninate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • a sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 5 kg/mol (q 19, Pharmacosmos), modified by octyl phenylalaninate, is obtained by a process similar to that described in Example A3.
  • a sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q 38, Pharmacosmos), modified by 3,7-dimethyl-1-octyl phenylalaninate, is obtained by a process similar to that described in Example A1.
  • Dioctyl aspartate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • a sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q 38, Pharmacosmos), modified by dioctyl aspartate, is obtained by a process similar to that described in Example A1.
  • Dilauryl aspartate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • N-(2-aminoethyl)dodecanamide is obtained according to the process described in U.S. Pat. No. 2,387,201, from the methyl ester of dodecanoic acid (Sigma) and ethylenediamine (Roth).
  • Lauryl glycinate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • a sodium dextransuccinate modified by lauryl glycinate is obtained by a process similar to that described in Example A1.
  • Dioctyl aspartate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • the final solution is assayed by dry extract, to determine the concentration of polysaccharide; and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number de N-methylcarboxylate carbamate units per glucoside unit.
  • the mean number of N-methylcarboxylate carbamate units per glucoside unit is 1.4.
  • N-(sodium methylcarboxylate) dextran carbamate modified by dioctyl aspartate is obtained by a process similar to that described in Example A1.
  • Dilauryl aspartate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • a sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 1 kg/mol (q 4, Pharmacosmos), modified by dilauryl aspartate, is obtained by a process similar to that described in Example A1.
  • 2-(2-aminoethoxy)ethyl dodecanoate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • 2-(2- ⁇ 2-[dodecanoylamino]ethoxy ⁇ ethoxy)ethylamine is obtained according to the process described in U.S. Pat. No. 2,387,201, from the methyl ester of dodecanoic acid (Sigma) and triethylene glycol diamine (Huntsman).
  • a sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q 38, Pharmacosmos), modified by 2-(2- ⁇ 2-[dodecanoylamino]ethoxy ⁇ ethoxy)ethylamine, is obtained by a process similar to that described in Example A1.
  • 2-(2- ⁇ 2-[hexadecanoylamino]ethoxy ⁇ ethoxy)ethylamine is obtained, according to the process described in U.S. Pat. No. 2,387,201, from the methyl ester of palmitic acid (Sigma) and triethylene glycol diamine (Huntsman).
  • Cetyl glycinate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • the final solution is assayed by dry extract, to determine the polysaccharide concentration, and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of methylcarboxylate units per glucoside unit.
  • the mean number of methylcarboxylate units per glucoside unit is 0.42.
  • the sodium dextranmethylcarboxylate solution is passed through a Purolite resin (anionic) in order to obtain dextranmethylcarboxylic acid, which is subsequently lyophilized for 18 hours.
  • a Purolite resin anionic
  • Cetyl glycinate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • a sodium dextranmethylcarboxylate modified by cetyl glycinate is obtained by a process similar to that described in Example A1.
  • the final solution is assayed by dry extract, to determine the polysaccharide concentration, and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of methylcarboxylate units per glucoside unit.
  • the mean number of methylcarboxylate units per glucoside unit is 1.65.
  • the sodium dextranmethylcarboxylate solution is passed through a Purolite resin (anionic) in order to obtain dextranmethylcarboxylic acid, which is subsequently lyophilized for 18 hours.
  • a Purolite resin anionic
  • Cholesteryl leucinate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • a sodium dextranmethylcarboxylate modified by cholesteryl leucinate is obtained by a process similar to that described in Example A1.
  • a sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 5 kg/mol (q 19, Pharmacosmos), modified by cholesteryl leucinate, is obtained by a process similar to that described in Example A1.
  • the final solution is assayed by dry extract, to determine the polysaccharide concentration, and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of methylcarboxylate units per glucoside unit.
  • the mean number of methylcarboxylate units per glucoside unit is 0.70.
  • the sodium dextranmethylcarboxylate solution is passed through a Purolite resin (anionic) in order to obtain dextranmethylcarboxylic acid, which is subsequently lyophilized for 18 hours.
  • a Purolite resin anionic
  • a sodium dextranmethylcarboxylate modified by cholesteryl leucinate is obtained by a process similar to that described in Example A1.
  • 30 ml of 10N NaOH (296 mmol) are added to this solution.
  • the mixture is brought to 35° C. and then 18 g (158 mmol) of sodium chloroacetate are added.
  • the temperature of the reaction medium is gradually brought to 60° C. and then maintained at 60° C. for 100 minutes.
  • the reaction medium is diluted with water, neutralized with acetic acid and purified by ultrafiltration through a 1 kDa PES membrane against water.
  • the final solution is assayed by dry extract, to determine the polysaccharide concentration, and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of methylcarboxylate units per glucoside unit.
  • the mean number of methylcarboxylate units per glucoside unit is 0.50.
  • the sodium dextranmethylcarboxylate solution is passed through a Purolite resin (anionic) in order to obtain dextranmethylcarboxylic acid, which is subsequently lyophilized for 18 hours.
  • a Purolite resin anionic
  • a sodium dextranmethylcarboxylate modified by cholesteryl leucinate is obtained by a process similar to that described in Example A1.
  • Cholesteryl 1-ethylenediaminecarboxylate hydrochloride is obtained according to the process described in the patent (Akiyoshi, K et al., WO 2010/053140).
  • a sodium dextranmethylcarboxylate, synthesized according to the process described in Example A18 using a dextran with a weight-average molecular weight of approximately 5 kg/mol (q 19, Pharmacosmos), modified by cholesteryl 1-ethylenediaminecarboxylate, is obtained by a process similar to that described in Example A18.
  • the final solution is assayed by dry extract, to determine the concentration of polysaccharide; and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of N-methylcarboxylate carbamate units per glucoside unit.
  • the mean number of N-methylcarboxylate carbamate units per glucoside unit is 2.0.
  • N-(sodium methylcarboxylate) dextran carbamate modified by cholesteryl leucinate is obtained by a process similar to that described in Example A1.
  • Cholesteryl 1-ethylenediaminecarboxylate hydrochlorate is obtained according to the process described in the patent (Akiyoshi, K et al., WO 2010/053140).
  • a dextran modified at the chain end by cholesteryl 1-ethylenediaminecarboxylate is obtained.
  • a sodium dextranmethylcarboxylate characterized by a degree of substitution as methylcarboxylate of 1.65 per glucoside unit and modified at the chain end by cholesteryl 1-ethylenediaminecarboxylate was synthesized by a process similar to that described in Example A18 using the dextran modified at the chain end by cholesteryl 1-ethylenediaminecarboxylate.
  • each polymer chain carries a cholesteryl 1-ethylenediaminecarboxylate group grafted to the reducing chain end.
  • Cholesterol leucinate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • Dilauryl aspartate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • Dilauryl aspartate, para-toluenesulphonic acid salt is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • Part B Demonstration of the Properties of the Compositions According to the Invention
  • Example B1 Solution of Rapid-Acting Insulin Analogue (NovoLog®) at 100 IU/ml
  • This solution is a commercial solution of insulin aspart, sold by the company Novo Nordisk under the name of NovoLog® in the USA and Novorapid® in Europe. This product is a rapid-acting insulin analogue.
  • Example B2 Solution of Rapid-Acting Insulin Analogue (Humalog®) at 100 IU/ml
  • This solution is a commercial solution of insulin lispro, sold by the company Eli Lilly under the name of Humalog®. This product is a rapid-acting insulin analogue.
  • Example B3 Solution of Rapid-Acting Insulin Analogue (Apidra®) at 100 IU/ml
  • This solution is a commercial solution of insulin glulisine, sold by the company Sanofi-Aventis under the name of Apidra®. This product is a rapid-acting insulin analogue.
  • Example B4 Solution of Slow-Acting Insulin Analogue (Lantus®) at 100 IU/ml
  • This solution is a commercial solution of insulin glargine, sold by the company Sanofi-Aventis under the name of Lantus®. This product is a slow-acting insulin analogue.
  • Example B5 Solution of Human Insulin (ActRapid®) at 100 IU/ml
  • This solution is a commercial solution from Novo Nordisk, sold under the name of Actrapid®. This product is a human insulin.
  • Example B6 Dissolution of Lantus® at 100 IU/ml and at pH 7 Using a Substituted Dextran
  • Example B7 Preparation of a Substituted Dextran/Lantus®/Apidra® 75/25 Composition at pH 7
  • Example B8 Preparation of a Substituted Dextran/Lantus®/Humalog® 75/25 Composition at pH 7
  • Humalog® in its commercial formulation
  • 0.25 ml of Humalog® is added to 0.75 ml of the Polysaccharide 4/Lantus® solution prepared in Example B6, in order to form 1 ml of a composition at pH 7.
  • the composition is clear, testifying to the good solubility of Lantus® and Humalog® under these formulation conditions. This clear solution is filtered through a 0.22 ⁇ m filter and is then placed at +4° C.
  • Example B9 Preparation of a Substituted Dextran/Lantus®/NovoLog® 75/25 Composition at pH 7
  • Example B10 Preparation of a Substituted Dextran/Lantus®/ActRapid® 75/25 Composition at pH 7
  • Example B11 Preparation of a Substituted Dextran/Lantus®/Apidra® 60/40 Composition at pH 7
  • Example B12 Preparation of a Substituted Dextran/Lantus®/Apidra® 40/60 Composition at pH 7
  • Lantus® 1 ml of Lantus® is added to 2 ml of a PBS solution containing 20 mg/ml of BSA (bovine serum albumin).
  • BSA bovine serum albumin
  • the PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears, which is in good agreement with the mechanism of operation of Lantus® (precipitation on injection due to the increase in the pH).
  • Example B14 Precipitation of a Substituted Dextran/Lantus® Composition
  • Polysaccharide 4/Lantus® solution prepared in Example B6 1 ml of Polysaccharide 4/Lantus® solution prepared in Example B6 is added to 2 ml of a PBS solution containing 20 mg/ml of BSA (bovine serum albumin).
  • BSA bovine serum albumin
  • the PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.
  • Dissolution and precipitation tests identical to those described in Examples B6 and B14 were carried out with other substituted dextrans at the same concentration of 10 mg/ml of polysaccharide per 100 IU/ml of Lantus®. 20 mg of polysaccharide in the lyophilisate form are weighed out accurately. This lyophilisate is taken up in 2 ml of Lantus® in its commercial formulation. A transient precipitate appears but the solution becomes clear after approximately 30 minutes to a few hours (depending on the nature of the polysaccharide). The pH of this solution is 6.3. The pH is adjusted to 7 with a 0.1N sodium hydroxide solution. This clear solution is filtered through a 0.22 ⁇ m filter and is then placed at +4° C. The results are collated in Table 2.
  • Example B15 Precipitation of a Substituted Dextran/Lantus®/Apidra® 75/25 Composition at pH 7
  • Example B7 1 ml of the substituted dextran/Lantus®/Apidra® 75/25 composition (containing 7.5 mg/ml of polysaccharide, 75 IU/ml of Lantus® and 25 IU/ml of Apidra®) prepared in Example B7 is added to 2 ml of a PBS solution containing 20 mg/ml of BSA (bovine serum albumin).
  • BSA bovine serum albumin
  • Example B16 Precipitation of Various Compositions, the Nature of the Substituted Dextran being Varied
  • Example B17 Precipitation of Various Compositions, the Nature of the Prandial Insulin being Varied
  • Compositions are prepared by mixing 0.75 ml of the Polysaccharide 4/Lantus® solution prepared in Example B6 with 0.25 ml of a prandial insulin in order to form 1 ml of substituted dextran/Lantus®/prandial insulin composition (containing 7.5 mg/mil of polysaccharide, 75 IU/ml of Lantus® and 25 IU/ml of prandial insulin).
  • This composition is added to 2 ml of PBS solution containing 20 mg/ml of BSA (bovine serum albumin).
  • BSA bovine serum albumin
  • Example B18 Preparation of a Concentrated Solution of Slow-Acting Insulin Analogue (Glargine)
  • a commercial solution of insulin glargine sold by the company Sanofi-Aventis under the name of Lantus®, is concentrated by ultrafiltration through a 3 kDa membrane made of regenerated cellulose (Amicon® Ultra-15, sold by the company Millipore). On conclusion of this ultrafiltration stage, the concentration of insulin glargine is assayed in the retentate by reverse phase liquid chromatography (RP-HPLC). The final concentration of insulin glargine is subsequently adjusted by the addition of commercial 100 IU/ml glargine solution in order to obtain the desired final concentration.
  • RP-HPLC reverse phase liquid chromatography
  • the concentrated solutions are filtered through a 0.22 ⁇ m filter and then stored at +4° C.
  • Example B19 Dialysis of a Commercial Solution of Rapid-Acting Insulin Analogue (Lispro)
  • a commercial solution of insulin lispro, sold by the company Lilly under the name of Humalog® is dialyzed by ultrafiltration through a 3 kDa membrane made of regenerated cellulose (Amicon® Ultra-15, sold by the company Millipore). The dialysis is carried out in a 1 mM phosphate buffer at pH 7. On conclusion of this dialysis stage, the concentration C dialyzed Humalog of lispro in the retentate is determined by reverse phase liquid chromatography (RP-HPLC). The dialyzed solution is stored in a freezer at ⁇ 80° C.
  • RP-HPLC reverse phase liquid chromatography
  • Example B20 Lyophilization of a Solution of Rapid-Acting Insulin Analogue (Lispro) in its Commercial Form
  • a volume V Humalog of a solution of rapid-acting insulin lispro at a concentration of 100 IU/ml in its commercial form is placed in a Lyoguard® sterilized beforehand in an autoclave.
  • the Lyoguard® is placed in a freezer at ⁇ 80° C. for approximately 1 h before being subjected to lyophilization overnight at a temperature of 20° C. and a pressure of 0.31 mbar.
  • the sterile lyophilisate thus obtained is stored at ambient temperature.
  • Example B21 Lyophilization of a Dialyzed Commercial Solution of Rapid-Acting Insulin Analogue (Lispro)
  • a volume V dialyzed Humalog of a solution of rapid-acting insulin lispro obtained according to Example B19 at a concentration of C dialyzed Humalog is placed in a Lyoguard® sterilized beforehand in an autoclave.
  • the Lyoguard® is placed in a freezer at ⁇ 80° C. for approximately 1 h before being subjected to lyophilization overnight at a temperature of 20° C. and a pressure of 0.31 mbar.
  • the sterile lyophilisate thus obtained is stored at ambient temperature.
  • Example B22 Preparation of a Substituted Dextran/Glargine Composition at pH 7 Using a Substituted Dextran, according to a Process Using Glargine in the Liquid Form (in Solution) and a Polysaccharide in the Solid Form (Lyophilized)
  • the solution is opalescent.
  • the pH of this solution is approximately 6.3. The pH is adjusted to 7 by addition of concentrated NaOH and then the solution is placed under static conditions in an oven at 37° C. for approximately 1 hour.
  • a volume V polys./glargine of this visually clear solution is placed at +4° C.
  • Example B23 Preparation of a Substituted Dextran/Glargine Composition at pH 7 Using a Substituted Dextran, according to a Process Using Glargine in the Liquid Form (in Solution) and a Polysaccharide in the Liquid Form (in Solution)
  • Concentrated solutions of m-cresol, glycerol and tween 20 are added to a mother solution of polysaccharide 20 at pH 7 exhibiting a concentration C polys. mother , so as to obtain a polysaccharide solution having the concentration C polys. mother/excipients (mg/ml) in the presence of these excipients at contents equivalent to those described in the Lantus® commercial solution in a 10 ml bottle.
  • the pH is adjusted to pH 7 by addition of 1M NaOH and the solution is placed under static conditions in an oven at 37° C. for approximately 1 h. This visually clear solution is placed at +4° C.
  • a dilute Polysaccharide 20/glargine composition at pH 7 described in Example B23 is concentrated by ultrafiltration through a 3 kDa membrane made of regenerated cellulose (Amicon® Ultra-15, sold by the company Millipore). On conclusion of this ultrafiltration stage, the retentate is clear and the concentration of insulin glargine in the composition is assayed by reverse phase chromatography (RP-HPLC). If necessary, the concentration of insulin glargine in the composition is subsequently adjusted to the desired value by diluting in a solution of m-cresol/glycerol/tween 20 excipients exhibiting, for each entity, a concentration equivalent to that described in the Lantus® commercial solution (in a 10 ml bottle). This solution at pH 7, which is visually clear, exhibiting a glargine concentration C glargine (IU/ml) and a polysaccharide concentration C polys. (mg/ml), is placed at +4° C.
  • Example B25 Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7, Starting from a Rapid-Acting Insulin Lispro in its Commercial Form
  • a volume V polysach./glargine of polysaccharide/glargine solution, pH 7, exhibiting a concentration of glargine C glargine (IU/ml) and a concentration of Polysaccharide 18 C polys. (mg/ml), prepared according to Example B22, is added to an insulin lispro lyophilisate obtained by lyophilization of a volume V lispro , the preparation of which is described in Example B19, so that the ratio V polysach./glargine /V lispro 100/C lispro , where C lispro is the concentration of lispro (IU/ml) targeted in the composition.
  • the solution is clear.
  • the zinc content of the formulation is adjusted to the desired concentration C zinc ( ⁇ M) by addition of a concentrated zinc chloride solution.
  • the final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • the formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 ⁇ m filter and is placed at +4° C.
  • Example B26 Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7, Starting from a Rapid-Acting Insulin Lispro Obtained by Dialysis of a Commercial Solution
  • a volume V polysach./glargine of polysaccharide/glargine solution, pH 7, exhibiting a concentration of glargine C glargine (IU/ml) and a concentration of Polysaccharide 20 C polys.
  • the solution is clear.
  • the zinc content of the formulation is adjusted to the desired concentration C zinc ( ⁇ M) by addition of a concentrated zinc chloride solution.
  • the final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • the formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 ⁇ m filter and is placed at +4° C.
  • Example B27 Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 200 IU/ml and a Concentration of Lispro of 33 IU/ml (Proportion as Percentage of Insulin: 85/15 as Glargine/Lispro)
  • a concentrated 200 IU/ml glargine solution is prepared according to Example B18.
  • a Polysaccharide 18 (13 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 18 according to the method of preparation described in Example B22.
  • This Polysaccharide 18/glargine 200 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue in its commercial form, according to the method of preparation described in Example B25.
  • the solution is clear.
  • the final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • Example B28 Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 200 IU/ml and a Concentration of Lispro of 66 IU/ml (Proportion as Percentage of Insulin: 75/25 as Glargine/Lispro)
  • a concentrated 200 IU/ml glargine solution is prepared according to Example B18.
  • a Polysaccharide 18 (13 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 18 according to the method of preparation described in Example B22.
  • This Polysaccharide 18/glargine 200 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue in its commercial form, according to the method of preparation described in Example B25.
  • the solution is clear.
  • the final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • the formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 ⁇ m filter and is placed at +4° C.
  • Example B29 Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 300 IU/ml and a Concentration of Lispro of 100 IU/ml (Proportion as Percentage of Insulin: 75/25 as Glargine/Lispro)
  • a concentrated 300 IU/ml glargine solution is prepared according to Example B18.
  • a Polysaccharide 18 (23 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 18 according to the method of preparation described in Example B22.
  • This Polysaccharide 18/glargine 300 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue in its commercial form, according to the method of preparation described in Example B25.
  • the solution is clear.
  • the final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • the formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 ⁇ m filter and is placed at +4° C.
  • Example B30 Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 250 IU/ml and a Concentration of Lispro of 150 IU/ml (Proportion as Percentage of Insulin: 63/37 as Glargine/Lispro)
  • a concentrated 300 IU/ml glargine solution is prepared according to Example B18.
  • a Polysaccharide 18 (19 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 18 according to the method of preparation described in Example B22.
  • This Polysaccharide 18/glargine 250 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue in its commercial form, according to the method of preparation described in Example B25.
  • the solution is clear.
  • the final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • the formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 ⁇ m filter and is placed at +4° C.
  • Example B31 Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 333 IU/ml and a Concentration of Lispro of 67 IU/ml (Proportion as Percentage of Insulin: 83/17 as Glargine/Lispro)
  • a concentrated 333 IU/ml glargine solution is prepared according to Example B18.
  • a Polysaccharide 18 (20 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 18 according to the method of preparation described in Example B22.
  • This Polysaccharide 18/glargine 333 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue in its commercial form, according to the method of preparation described in Example B25.
  • the solution is clear.
  • the final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • the formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 ⁇ m filter and is placed at +4° C.
  • Example B32 Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 300 IU/ml and a Concentration of Lispro of 100 IU/ml (Proportion as Percentage of Insulin: 75/25 as Glargine/Lispro)
  • a concentrated 300 IU/ml glargine solution is prepared according to Example B18.
  • a Polysaccharide 19 (23 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 19 according to the method of preparation described in Example B22.
  • This Polysaccharide 19/glargine 300 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue under its dialyzed form, according to the method of preparation described in Example B26.
  • the solution is clear.
  • the final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • the formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 ⁇ m filter and is placed at +4° C.
  • Example B33 Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 300 IU/ml and a Concentration of Lispro of 100 IU/ml (Proportion as Percentage of Insulin: 75/25 as Glargine/Lispro)
  • a Polysaccharide 20 (23 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 20 according to the method of preparation described in Example B23.
  • This Polysaccharide 20/glargine 300 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue resulting from the dialysis of a commercial solution, according to the method of preparation described in Example B26.
  • the solution is clear.
  • the final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • the formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 ⁇ m filter and is placed at +4° C.
  • Example B34 Precipitation of Various Substituted Dextran/Glargine/Lispro Compositions at pH 7 Exhibiting Different Concentrations of Insulin Glargine and Insulin Lispro and Different Relative Proportions of the Two Insulins
  • compositions prepared can be injected with the normal systems for the injection of insulin.
  • the solutions described in Examples B7 to B12 and the compositions described in Examples B27 à B33 are injected without any difficulty, both with insulin syringes equipped with 31-gauge needles and with insulin pens from Novo Nordisk, sold under the name of Novopen®, equipped with 31-gauge needles.
  • Lantus®/Apidra® (75/25), formulated with Polysaccharide 4 (6 mg/ml), described in Example B7, and
  • Lantus®/Humalog® (75/25), formulated with Polysaccharide 4 (6 mg/ml), described in Example B8.
  • hypoglycaemic effects of these compositions were compared with respect to injections carried out with simultaneous but separate injections of Lantus® (pH 4) and then of a prandial insulin Apidra® or Humalog®.
  • Injection of insulin at a dose of 0.4 IU/kg is carried out by subcutaneous injection into the neck, under the ear of the animal, using the Novopen® insulin pen equipped with at 31 G needle.
  • Blood samples are subsequently taken after 4, 8, 12, 16, 20, 30, 40, 50, 60, 90, 120, 240, 360, 480, 600, 660 and 720 minutes. After each sample has been taken, the catheter is rinsed with a dilute heparin solution.
  • a drop of blood is taken in order to determine the glycaemia using a glucose meter.
  • the pharmacodynamic curves of glucose are subsequently plotted.
  • Lantus®/Apidra® (75/25), formulated with Polysaccharide 4 (6 mg/ml).
  • FIG. 1 Mean+standard deviation of the mean curves for the sequential administrations of Apidra® and Lantus®, in comparison with a composition according to the invention Polysaccharide 4/Lantus®/Apidra® (75/25).
  • FIG. 2 Apidra® Lantus® individual curves.
  • FIG. 3 Polysaccharide 4/Apidra®/Lantus® individual curves.
  • FIG. 1 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the pigs tested for each formulation.
  • the drop in glycaemia in the first 30 minutes is similar for the two formulations, indicating that the presence of a polysaccharide does not interfere with the rapid-acting nature of Apidra®.
  • Lantus®/Humalog® (75/25), formulated with Polysaccharide 4 (6 mg/ml).
  • FIG. 4 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® and Lantus® in comparison with the administration of a composition according to the invention Polysaccharide 4/Humalog®/Lantus®.
  • FIG. 5 Humalog® Lantus® individual curves.
  • FIG. 6 Polysaccharide 4/Humalog®/Lantus® individual curves.
  • FIG. 4 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the pigs tested with regard to each formulation.
  • the drop in glycaemia in the first 30 minutes is similar for the two formulations, indicating that the presence of Polysaccharide 4 does not interfere with the rapid-acting nature of Humalog®.
  • the sequential administration of Humalog® and Lantus® brings about a heterogeneous drop in glucose with a homogeneous plateau response with regard to four pigs and a heterogeneous response with regard to the other two pigs ( FIG. 5 ).
  • hypoglycaemic effects of these compositions were compared with respect to injections carried out with simultaneous but separate injections of 100 IU/ml Lantus® (pH 4) and then of a prandial insulin 100 IU/ml Humalog®.
  • the injection of insulin at a dose of 0.53 IU/kg is carried out by subcutaneous injection into the neck of the animal using the Novopen® insulin pen equipped with a 31 G needle.
  • Blood samples are subsequently taken after 10, 20, 30, 40, 50, 60, 90, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720, 780, 840, 900 and 960 minutes.
  • the first samples are taken with a catheter (up to 180 min) and then directly from the jugular vein. After each sample has been taken, the catheter is rinsed with a dilute heparin solution.
  • a drop of blood is taken in order to determine the glycaemia by means of a glucose meter.
  • the pharmacodynamic curves for glucose are subsequently plotted.
  • FIG. 7 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg), in comparison with a composition according to the invention described in Example B28 (0.53 IU/kg).
  • FIG. 7 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation.
  • the two curves are similar up to 12 hours with a rapid drop in glycaemia, indicating that the polysaccharide does not influence the rapid-acting effect of Humalog®, a marked return between the peak due to Humalog® and the plateau due to glargine, and then a plateau of the glargine up to 12 h, indicating that the basal effect of glargine is well retained.
  • FIG. 8 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) in comparison with a composition according to the invention described in Example B27 (0.47 IU/kg).
  • FIG. 8 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation.
  • the dose of basal insulin (Lantus®) is identical whereas the dose of Humalog® is half for the composition, with respect to the control.
  • the drop in glucose is greater in the case of the formulation B27 in comparison with the control, whereas this control contains twice as much Humalog®.
  • the duration of the plateau is shorter in the case of the combination, with respect to the control. This indicates that, in this composition, a portion of Lantus® is not precipitated on injection and acts with Humalog®.
  • FIG. 9 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) in comparison with a composition according to the invention described in Example B29 (0.53 IU/kg).
  • FIG. 9 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation.
  • the two curves are similar, with a rapid drop in glycaemia, indicating that the polysaccharide does not influence the rapid-acting effect of Humalog®, a marked return between the peak due to Humalog® and the plateau due to Lantus®, and then a plateau of the Lantus® up to 13 h, indicating that the basal effect of glargine is well retained.
  • FIG. 10 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg), in comparison with a composition according to the invention described in Example B31 (0.48 IU/kg).
  • FIG. 10 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation.
  • the dose of basal insulin (Lantus®) is identical, whereas the dose of Humalog® is half, for the composition, with respect to the control.
  • the drop in glucose is greater in the case of the control, with respect to the combination corresponding to Example B31.
  • This response was expected, in view of the concentration of Humalog® in the combination, which was half that of the control.
  • the duration of the Lantus® plateau is identical in the case of the combination, with respect to the control. This indicates that, in this composition and by comparison with the composition described in Example B29 ( FIG. 9 ), it is possible to adjust the amount of Humalog® in the combination without modifying the Lantus® basal effect.
  • FIG. 11 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.24 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) in comparison with a composition according to the invention described in Example B30 (0.64 IU/kg).
  • FIG. 11 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation.
  • the two curves are similar, with a rapid drop in glycaemia, indicating that the polysaccharide does not influence the rapid-acting effect of Humalog®, a marked return between the peak due to Humalog® and the plateau due to Lantus®, and then a plateau of the Lantus® up to 10 h, indicating that the glargine basal effect is well retained.
  • FIG. 12 Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) in comparison with a composition according to the invention described in Example B32 (0.53 IU/kg).
  • FIG. 12 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation.
  • the two curves are similar up to 10 hours, with a rapid drop in glycaemia, indicating that the polysaccharide does not influence the rapid-acting effect of Humalog®, a marked return between the peak due to Humalog® and the plateau due to Lantus®, and then a glargine plateau, indicating that the glargine basal effect is retained up to 10 h.
  • FIGS. 7 to 12 show that, by adjusting the composition of the polysaccharide and the concentrations of lispro and glargine, it is possible to obtain profiles identical to a double injection with different proportions of rapid-acting insulin and basal insulin. It is also possible to adjust the duration of the basal insulin without impacting the rapid-acting insulin or to adjust the amount of rapid-acting insulin without impacting the effect of the basal insulin.
  • Example C1 0.25 mg/ml Solution of GLP-1 Analogue Exenatide (Byetta®)
  • This solution is an exenatide solution marketed by the company Eli Lilly and Company under the name of Byetta®.
  • Example C2 6 mg/ml Solution of GLP-1 Derivative Liraglutide (Victoza®)
  • This solution is a liraglutide solution marketed by the company Novo Nordisk under the name of Victoza®.
  • Example C3 Dissolution of Lantus® at 100 IU/Ml and at pH 7 Using a Substituted Dextran at a Concentration of 10 mg/ml
  • Example C4 Preparation of a Lantus®/Byetta® 70/30 Composition at pH 7.5
  • Example C1 0.09 ml of the exenatide solution of Example C1 is added to 0.21 ml of the insulin glargine solution of Example B4, in order to obtain 0.3 ml of composition whose pH is 4.5 on mixing.
  • the composition which contains 70 IU/ml of Lantus® and 0.075 mg/ml of Byetta®, is clear, testifying to the good solubility of Lantus® and Byetta® under these formulation conditions (pH 4.5).
  • the pH is subsequently adjusted to 7.5 with a 0.1N sodium hydroxide solution.
  • the composition then becomes cloudy, testifying to the poor solubility of the Lantus®/Byetta® composition at pH 7.5.
  • Example 70/30 Lantus®/Byetta® compositions were also prepared at pH 4.5, 5.5, 6.5, 8.5 and 9.5 by following a protocol similar to that described in Example C4.
  • 0.09 ml of the exenatide solution of Example C1 is added to 0.21 ml of the insulin glargine solution of Example B4, in order to obtain 0.3 ml of a composition whose pH is 4.5 on mixing.
  • the composition is clear, testifying to the good solubility of Lantus® and Byetta® under these formulation conditions (pH 4.5).
  • the pH is adjusted to 5.5 or 6.5 or 8.5 or 9.5 with a 0.1N sodium hydroxide solution.
  • composition at 5.5 is slightly cloudy
  • the compositions at 6.5-7.5 and 8.5 are very cloudy
  • the composition at pH 9.5 is clear.
  • These compositions are placed at +4° C. for 48 h. After 48 h at +4° C., only the composition at pH 4.5 remains clear.
  • the visual appearance after 48 h of the 70/30 Lantus®/Byetta® compositions at different pH values is summarized in Table 9.
  • Example C5 Preparation of the 70/30 Lantus®/Victoza® Composition at pH 7.5
  • Example C2 0.09 ml of the liraglutide solution of Example C2 is added to 0.21 ml of the insulin glargine solution of Example B4, in order to obtain 0.3 ml of a composition whose pH is 7 on mixing.
  • the composition which contains 70 IU/ml of glargine and 1.8 mg/ml of liraglutide, is cloudy, testifying to the poor solubility of the Lantus®/Victoza® composition under these formulation conditions.
  • the pH is adjusted to 7.5 with a 0.1N sodium hydroxide solution. After adjusting the pH, the composition remains cloudy. This composition is placed at +4° C. for 48 h.
  • Example 70/30 Lantus®/Victoza® compositions were also prepared at pH 4.5-5.5-6.5-8.5 and 9.5 by following a protocol similar to that described in Example C5.
  • 0.09 ml of the liraglutide solution of Example C1 is added to 0.21 ml of the insulin glargine solution of Example B4, in order to obtain 0.3 ml of a composition whose pH is 7.
  • the composition is cloudy, testifying to the poor solubility of the Lantus®/Victoza® composition under these formulation conditions (pH 7).
  • the pH is adjusted to 4.5 or 5.5 or 6.5 with a 0.1N hydrochloric acid solution or to pH 9.5 with a 0.1N sodium hydroxide solution.
  • compositions at pH 4.5-5.5 and 6.5 are cloudy, testifying to the poor solubility of the Lantus®/Victoza® composition under these formulation conditions. These compositions are placed at +4° C. for 48 h. After 48 h at 4° C., only the composition at pH 9.5 is clear. The visual appearance after 48 h of the 70/30 Lantus®/Victoza® compositions of different pH values is summarized in Table 10.
  • Example C6 Preparation of a Substituted Dextran-70/30 Lantus®/Byetta® Composition at pH 7
  • Example C1 0.09 ml of the exenatide solution of Example C1 is added to 0.21 ml of the substituted dextran/Lantus® solution prepared in Example C3, in order to obtain 0.3 ml of a composition at pH 5.3.
  • the pH is adjusted to 7 with a 0.1N sodium hydroxide solution.
  • the composition which contains 7 mg/ml of polysaccharide, 70 IU/ml of Lantus® and 0.075 mg/ml of Byetta® is clear, testifying to the good solubility of Lantus® and Byetta® in the presence of the substituted dextran at pH 7. This clear solution is placed at +4° C.
  • Substituted dextran-Lantus®/Byetta® compositions at pH 7 were also prepared at ratios by volume V Lantus /V Byetta of 90/10, 50/50, 30/70 and 10/90 by following the same protocol as that described in Example C6.
  • a volume V Byetta of the exenatide solution of Example C1 is added to a volume V Lantus of the substituted dextran/Lantus® solution prepared in Example C3, in order to obtain a composition whose pH is adjusted at 7 with a 0.1N sodium hydroxide solution.
  • the compositions obtained are clear, testifying to the good solubility of Lantus® and Byetta® in the presence of a substituted dextran at pH 7. These clear solutions are placed at +4° C.
  • Example C7 Preparation of a Substituted Dextran-100/50 Lantus®/Byetta® Composition at pH 7
  • Example C1 0.150 ml of the exenatide solution of Example C1 is lyophilized and then 0.3 ml of a substituted dextran/Lantus® solution prepared in Example C3 are added to the lyophilisate in order to obtain a composition whose pH is adjusted to 7 with a 0.1N sodium hydroxide solution.
  • the composition which contains 10 mg/ml of polysaccharide, 100 IU/ml of Lantus® and 0.125 mg/ml of Byetta®, is clear, testifying to the good solubility of Lantus® and Byetta® in the presence of the substituted dextran at pH 7. This clear solution is placed at +4° C.
  • Example C8 Preparation of a Substituted Dextran-70/30 Lantus®/Victoza® Composition at pH 7
  • Example C2 0.09 ml of the liraglutide solution of Example C2 is added to 0.21 ml of the substituted dextran/Lantus® solution prepared in Example C3, in order to obtain 0.3 ml of a composition at pH 7.6.
  • the pH is adjusted to 7 with a 0.1N hydrochloric acid solution.
  • the composition which contains 7 mg/ml of polysaccharide, 70 IU/ml of Lantus® and 1.8 mg/ml of Victoza®, is clear, testifying to the good solubility of Lantus® and Victoza® in the presence of the substituted dextran at pH 7. This clear solution is placed at +4° C.
  • Substituted dextran-Lantus®/Victoza® compositions at pH 7 have also been prepared at V Lantus /V Victoza ratios by volume of 90/10, 50/50, 30/70, and 90/10 by following the same protocol as that described in Example C6.
  • a volume V Victoza of the liraglutide solution of Example C2 is added to a volume V Lantus of the substituted dextran/Lantus® solution prepared in Example B3, in order to obtain a composition whose pH is adjusted to 7 with a 0.1N hydrochloric acid solution.
  • compositions obtained are clear, testifying to the good solubility of Lantus® and Victoza® in the presence of a substituted dextran at pH 7. These clear solutions are placed at +4° C.
  • Example C9 Preparation of a Substituted Dextran-100/50 Lantus®/Victoza® Composition at pH 7
  • Example C2 0.150 ml of the liraglutide solution of Example C2 is lyophilized and then 0.3 ml of a substituted dextran/Lantus® solution prepared in Example C3 is added to the lyophilisate, in order to obtain a composition whose pH is adjusted to 7 with a 0.1N sodium hydroxide solution.
  • the composition which contains 10 mg/ml of polysaccharide, 100 IU/ml of Lantus® and 3 mg/ml of Victoza®, is clear, testifying to the good solubility of Lantus® and Victoza® in the presence of the substituted dextran at pH 7. This clear solution is placed at +4° C.
  • Example C10 Preparation of a Substituted Dextran-60/20/20 Lantus®/Apidra®/Byetta® Composition at pH 7
  • Example A3 20 mg of lyophilized Polysaccharide 4 described in Example A3 are weighed out accurately. This lyophilisate is taken up in 2 ml of the insulin glargine solution of Example B4. After mechanical stirring on rolls at ambient temperature, the solution becomes clear. The pH of this solution is 6.3. The pH is adjusted to 7 with a 0.1N sodium hydroxide solution. 0.2 ml of the exenatide solution of Example C1 and 0.2 ml of the insulin glulisine solution of Example B3 are added to 0.6 ml of the substituted dextran/Lantus® solution prepared above, in order to obtain 1 ml of a composition at pH 7.
  • composition which contains 6 mg/ml of polysaccharide, 60 IU/ml of Lantus®, 20 IU/ml Apidra® and 0.05 mg/ml of Byetta®, is clear, testifying to the good solubility of Lantus®, Apidra® and Byetta® in the presence of substituted dextran at pH 7. This clear solution is filtered through a membrane (0.22 ⁇ m) and is then placed at +4° C.
  • PBS Phosphate Buffer Solution
  • BSA Bovine Serum Albumin
  • Example C12 Precipitation of a Substituted Dextran/Lantus® Composition
  • Example C3 0.250 ml of substituted dextran/Lantus® solution prepared in Example C3 is added to 0.5 ml of a PBS solution containing 20 mg/ml of BSA.
  • the PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.
  • Example C13 Precipitation of a Substituted Dextran-Lantus®/Byetta® Composition
  • Example C6 0.250 ml of the substituted dextran-Lantus®/Byetta® composition prepared in Example C6 is added to 0.5 ml of a PBS solution containing 20 mg/ml of BSA.
  • the PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.
  • Example C14 Precipitation of a Substituted Dextran-70/30 Lantus®/Victoza® Composition
  • Example C8 0.250 ml of the substituted dextran-Lantus®/Victoza® composition prepared in Example C8 is added to 0.5 ml of a PBS solution containing 20 mg/ml of BSA (bovine serum albumin).
  • BSA bovine serum albumin
  • the PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears. Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® and Victoza® are assayed in the supernatent. The percentage of precipitation of Lantus® is similar to the control described in Example C11.
  • Example C15 Precipitation of Different Compositions, the Nature of the Substituted Dextran being Varied
  • Example C16 Precipitation of a Substituted Dextran-60/20/20 Lantus®/Apidra®/Byetta® Composition at pH 7
  • Example C10 0.250 ml of the substituted dextran-Lantus®/Apidra®/Byetta® composition prepared in Example C10 is added to 0.5 ml of a PBS solution containing 20 mg/ml of BSA.
  • the PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.

Description

  • This application is a continuation of U.S. patent application Ser. No. 14/721,889 filed May 26, 2015, which in turn is a continuation of U.S. patent application Ser. No. 13/571,026 filed Aug. 9, 2012, which in turn claims benefit of U.S. Provisional Patent Application No. 61/579,966 filed Dec. 23, 2011 and U.S. Provisional Patent Application No. 61/522,031 filed Aug. 10, 2011 and claims priority to French Patent Application No. 11/62445 filed Dec. 23, 2011 and French Patent Application No. 11/57291 filed Aug. 10, 2011.
  • The invention relates to therapies by injection of insulin(s) for treating diabetes.
  • Insulin therapy, or diabetes therapy by injecting insulin, has made remarkable progress in recent years by virtue especially of the development of novel insulins that offer correction of patients' glycaemia, which enables better simulation of the physiological activity of the pancreas.
  • To cover his daily insulin needs, a diabetic patient currently has available, schematically, two types of insulin with complementary actions: prandial insulins (or rapid-acting insulins) and basal insulins (or slow-acting insulins).
  • Prandial insulins allow rapid management (metabolization and/or storage) of the glucose provided by meals and snacks. The patient must inject a prandial insulin before each food intake, i.e. about 2 to 3 injections per day. The prandial insulins most commonly used are: the recombinant human insulin, NovoLog® (aspart insulin from Novo Nordisk), Humalog® (lispro insulin from Eli Lilly) and Apidra® (glulisine insulin from Sanofi-Aventis).
  • Basal insulins maintain the patient's glycaemic homeostasis, outside periods of food intake. They act essentially by blocking the endogenous production of glucose (hepatic glucose). The daily dose of basal insulin generally corresponds to 40-50% of the total daily insulin needs. Depending on the basal insulin used, this dose is dispensed in 1 or 2 injections, regularly distributed throughout the day. The basal insulins most commonly used are Levemir® (detemir insulin from Novo Nordisk) and Lantus® (glargine insulin from Sanofi-Aventis).
  • It will be noted, for the sake of completeness, that NPH (NPH insulin, for Neutral Protamine Hagedorn; Humuline NPH®, Insulatard®) is the oldest basal insulin. This formulation is the result of a precipitation of human insulin (anionic at neutral pH) with a cationic protein, protamine. These microcrystals are dispersed in an aqueous suspension and dissolve slowly after subcutaneous injection. This slow dissolution ensures sustained release of the insulin. However, this release does not ensure a constant concentration of insulin over time. The release profile is bell-shaped and lasts only between 12 and 16 hours. It is thus injected twice a day. This NPH basal insulin is much less efficient than the modern basal insulins Levemir® and Lantus®. NPH is an intermediate-acting basal insulin.
  • The principle of NPH changed with the appearance of rapid insulin analogues to give “Premix” products that afford both rapid action and intermediate action. NovoLog Mix® (Novo Nordisk) and Humalog Mix® (Eli Lilly) are formulations comprising a rapid insulin analogue, Novolog® and Humalog®, partially complexed with protamine. These formulations thus contain microcrystals of insulin whose action is said to be intermediate, and a proportion of insulin which has remained soluble, whose action is rapid. These formulations do indeed offer the advantage of a rapid insulin, but they also have the defect of NPH, i.e. a duration of action limited to between 12 and 16 hours and a bell-shaped release of insulin. However, these products enable the patient to carry out a single injection of an intermediate-acting basal insulin with a rapid-acting prandial insulin. In point of fact, many patients are desirous to reduce their number of injections.
  • The basal insulins currently marketed and currently under clinical development may be categorized as a function of the technical solution for obtaining sustained action, and two approaches are used at the present time.
  • The first, that of insulin detemir, is the binding to albumin in vivo. It is an analogue, soluble at pH 7, which comprises a fatty acid (tetradecanoyl) side chain attached to position B29 which, in vivo, enables this insulin to combine with albumin. Its sustained action is mainly due to this affinity for albumin after subcutaneous injection.
  • However, its pharmacokinetic profile does not make it possible to cover a whole day, which means that it is usually used in two injections per day.
  • Other basal insulins which are soluble at pH 7, such as Degludec®, are currently under development. Degludec® also comprises a fatty acid side chain attached to insulin (hexadecandioyl-γ-L-Glu).
  • The second, that of insulin glargine, is the precipitation at physiological pH. This is an analogue of human insulin obtained by elongation of the C-terminal part of the B chain of human insulin with two arginine residues, and by substitution of the asparagine residue A21 with a glycine residue (U.S. Pat. No. 5,656,722). The addition of the two arginine residues was conceived to adjust the pI (isoelectric point) of insulin glargine at physiological pH, and thus make this insulin analogue insoluble in physiological medium.
  • The substitution of A21 was conceived in order to make insulin glargine stable at acidic pH and thus to be able to formulate it in the form of an injectable solution at acidic pH. During subcutaneous injection, the passage of insulin glargine from an acidic pH (pH 4-4.5) to a physiological pH (neutral pH) brings about its precipitation under the skin. The slow redissolution of the insulin glargine microparticles ensures a slow and sustained action.
  • The hypoglycaemic effect of insulin glargine is virtually constant over a period of 24 hours, which allows the majority of patients to limit themselves to a single injection per day.
  • Insulin glargine is nowadays considered as the best basal insulin marketed.
  • However, the acidic pH of the formulations of basal insulins, the isoelectric point of which is between 5.8 and 8.5, of insulin glargine type, prevents any pharmaceutical combination with other proteins and in particular prandial insulins, since the latter are unstable at acidic pH.
  • However, no one has hitherto sought to dissolve these basal insulins, the isoelectric point of which is between 5.8 and 8.5, of insulin glargine type, at neutral pH, while maintaining a difference in solubility between the in vitro medium (containing it) and the in vivo medium (under the skin), independently of the pH.
  • Specifically, the operating principle of basal insulins, of insulin glargine type, outlined above, namely that they are soluble at acidic pH and precipitate at physiological pH, dissuades a person skilled in the art from any solution in which insulin of insulin glargine type would be dissolved at pH 6-8 while maintaining its essential property, which is that of precipitating in subcutaneous medium.
  • Furthermore, the impossibility of formulating a prandial insulin, at acidic pH, arises from the fact that a prandial insulin undergoes, under these conditions, a deamidation side reaction in position A21; this does not make it possible to satisfy the requirement of the US Pharmacopeia, namely less than 5% of by-product after 4 weeks at 30° C.
  • Furthermore, this acidic pH of formulations of basal insulins, the isoelectric point of which is between 5.8 and 8.5, of insulin glargine type, even prevents any extemporaneous combination with prandial insulins at neutral pH.
  • A recent clinical study, presented at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, La., 5-9 Jun. 2009, verified this limitation of use of insulin glargine. A dose of insulin glargine and a dose of prandial insulin (in the case in point, insulin lispro) were mixed together just before injection (E. Cengiz et al., 2010, Diabetes Care, 33(5), 1009-12). This experiment made it possible to demonstrate a significant delay in the pharmacokinetic and pharmacodynamic profiles of prandial insulin, which may give rise to postprandial hyperglycaemia and to nocturnal hypoglycaemia. This study indeed confirms the incompatibility of insulin glargine with the currently marketed rapid-acting insulins.
  • Moreover, the instructions for use for Lantus®, the commercial product based on insulin glargine from the company Sanofi-Aventis, explicitly indicates to users that they should not mix it with a solution of prandial insulin, whichever it may be, on account of the serious risk of modifying the pharmacokinetics and pharmacodynamics of the insulin glargine and/or of the mixed prandial insulin.
  • However, from a therapeutic point of view, clinical studies made public during the 70th annual scientific sessions of the American Diabetes Association (ADA) of 2010, abstract 2163-PO and abstract number 0001-LB, in particular those conducted by the company Sanofi-Aventis, showed that treatments which combine Lantus®, insulin glargine, and a prandial insulin are much more efficient than treatments based on products of the “Premix”, Novolog Mix® or Humalog Mix® type.
  • As regards combinations of insulin glargine and rapid insulin, the company Biodel has notably described, in patent application U.S. Pat. No. 7,718,609, compositions comprising a basal insulin and a prandial insulin at a pH of between 3.0 and 4.2 in the presence of a chelating agent and polyacids. This patent teaches how to make a prandial insulin compatible at acidic pH in the presence of an insulin of insulin glargine type. It does not teach how to prepare a combination of insulin of insulin glargine type and of a prandial insulin at neutral pH.
  • From the analysis of the compositions described in the literature and the patents, it appears that the insolubility at pH 7 of basal insulins of the insulin glargine type is a prerequisite for having its slow action. As a result, all the solutions proposed for combining them with other products, such as prandial insulins, are based on tests of dissolution or stabilization of prandial insulins at acidic pH; see, for example, WO 2007/121256 and WO 2009/021955.
  • Surprisingly, the compositions according to the invention make it possible to dissolve, at pH 7, a basal insulin whose isoelectric point is between 5.8 and 8.5.
  • Surprisingly, the compositions according to the invention allow maintenance of the duration of the hypoglycaemic activity of the basal insulin whose isoelectric point is between 5.8 and 8.5, despite its dissolution at pH 7 before injection. This noteworthy property arises from the fact that the insulin of insulin glargine type dissolved at pH 7 in the composition of the invention precipitates in subcutaneous medium by means of a change of composition of the medium. The factor triggering the precipitation of the insulin of insulin glargine type is no longer the pH modification, but a modification of composition of the environment during the passage of the pharmaceutical composition into the physiological medium.
  • By solving this problem of solubility at pH 7, the present invention makes it possible:
      • to propose an injectable composition, intended for treating diabetes, comprising a basal insulin whose isoelectric point is between 5.8 and 8.5, in the form of a homogeneous solution at pH 7, while retaining its biological activity and its action profile;
      • to propose a composition in the form of a formulation comprising a combination of a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin without modification of the activity profile of the prandial insulin which is soluble at pH 6-8 and unstable at acidic pH, while maintaining the basal action profile intrinsic to the basal insulin;
      • to propose an injectable composition, intended for treating diabetes, additionally comprising a combination of a basal insulin whose isoelectric point is between 5.8 and 8.5 and a derivative or an analogue of a gastrointestinal hormone such as GLP-1 or “glucagon-like peptide-1”;
      • for patients to reduce their number of injections;
      • for the said compositions to satisfy the requirements of the American Pharmacopeia and European Pharmacopoeia.
  • Surprisingly, in insulin combinations of insulin glargine type with a prandial insulin, which are subject-matters of the invention, the rapid action of the prandial insulin is preserved despite the precipitation of the insulin of insulin glargine type in subcutaneous medium.
  • The invention relates to a composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, comprising at least:
      • a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5;
      • b) a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals of formula I or of formula II:
  • Figure US20180311316A1-20181101-C00001
      • in which:
        • R is —OH or chosen from the group consisting of the radicals:
          • -(f-[A]-COOH)n;
          • -(g-[B]-k-[D])m, D comprising at least one alkyl chain comprising at least 8 carbon atoms;
        • n represents the degree of substitution of the glucoside units by -f-[A]-COOH and 0.1≤n≤2;
        • m represents the degree of substitution of the glucoside units by -g-[B]-k-[D] and 0<m≤0.5;
        • q represents the degree of polymerization as glucoside units, that is to say the mean number of glucoside units per polysaccharide chain, and 3≤q≤50;
        • -(f-[A]-COOH)n:
          • -A- is a linear or branched radical comprising from 1 to 4 carbon atoms; the said -A- radical:
          • being bonded to a glucoside unit via a functional group f chosen from the group consisting of ether, ester and carbamate functional groups;
        • -(g-[B]-k-[D])m:
          • -B- is a linear or branched, at least divalent, radical comprising from 1 to 4 carbon atoms; the said -B- radical:
          • being bonded to a glucoside unit via a functional group g chosen from the group consisting of ether, ester and carbamate functional groups;
          • being bonded to a -D radical via a functional group k; k chosen from the group consisting of ester, amide and carbamate functional groups; the said -D radical:
            • being an -X(-l-Y)p radical, X being an at least divalent radical comprising from 1 to 12 atoms chosen from the group consisting of C, N and O atoms, optionally carrying carboxyl or amine functional groups and/or resulting from an amino acid, a dialcohol, a diamine or a mono- or polyethylene glycol mono- or diamine; Y being a linear or cyclic alkyl group, an alkylaryl or an arylalkyl, of 8 to 30 carbon atoms, optionally substituted by one or more C1 to C3 alkyl groups; p≥1 and l a functional group chosen from the group consisting of ester, amide and carbamate functional groups;
        • f, g and k being identical or different;
        • the free acid functional groups being in the form of salts of alkali metal cations chosen from the group consisting of Na+ and K+;
        • and, when p=1, if Y is a C8 to C14 alkyl, then q*m≥2, if Y is a C15 alkyl, then q*m≥2; and if Y is a C16 to C20 alkyl, then q*m≥1;
        • and, when p≥2, if Y is a C8 to C9 alkyl, then q*m≥2 and, if Y is a C10 to C16 alkyl, then q*m≥0.2;
  • Figure US20180311316A1-20181101-C00002
      • in which:
        • R is —OH or a -(f-[A]-COOH)n radical:
          • -A- is a linear or branched radical comprising from 1 to 4 carbon atoms; the said radical -A-:
          • being bonded to a glucoside unit via a functional group f chosen from the group consisting of ether, ester or carbamate functional groups;
          • n represents the degree of substitution of the glucoside units by -f-[A]-COOH and 0.1≤n≤2;
        • R′ is chosen from the group consisting of the radicals:
          • —C(O)NH-[E]-(o-[F])t;
          • —CH2N(L)z-[E]-(o-[F])t;
        • in which:
          • z is a positive integer equal to 1 or 2,
          • L is chosen from the group consisting of:
            • —H and z is equal to 1, and/or
            • -[A]-COOH and z is equal to 1 or 2, if f is an ether functional group,
            • —CO-[A]-COOH and z is equal to 1 if f is an ester functional group, and
            • —CO—NH-[A]-COOH and z is equal to 1 if f is a carbamate functional group;
          • -[E]-(o-[F])t:
            • -E- is a linear or branched, at least divalent, radical comprising from 1 to 8 carbon atoms and optionally comprising heteroatoms, such as O, N or S;
            • -F- is a linear or cyclic alkyl group, an alkylaryl or an arylalkyl, of 12 to 30 carbon atoms, optionally substituted by one or more C1 to C3 alkyl groups;
            • o is a functional group chosen from the group consisting of ether, ester, amide or carbamate functional groups;
            • t is a positive integer equal to 1 or 2;
        • q represents the degree of polymerization as glucoside units, that is to say the mean number of glucoside units per polysaccharide chain, and 3≤q≤50;
        • the free acid functional groups being in the form of salts of alkali metal cations chosen from the group consisting of Na+ and K+
        • when z=2, the nitrogen atom is in the form of a quaternary ammonium.
  • In one embodiment, when p=1, if Y is a C21 to C30 group, then q*m≥1.
  • In one embodiment, when p=1, if Y is a C21 to C30 group, then q*m≥0.1.
  • In one embodiment, the -(f-[A]-COOH)n radical is such that:
      • -A- is a radical comprising one carbon atom; the said -A- radical being bonded to a glucoside unit via a ether functional group f.
  • In one embodiment, the -(g-[B]-k-[D])m radical is such that:
      • -B- is a radical comprising one carbon atom; the said -B- radical being bonded to a glucoside unit via an ether functional group g, and
      • X is a radical resulting from an amino acid.
  • In one embodiment, the -(f-[A]-COOH)n radical is such that:
      • -A- is a radical comprising one carbon atom; the said -A- radical being bonded to a glucoside unit via an ether functional group f, and
      • the -(g-[B]-k-[D])m radical is such that:
      • -B- is a radical comprising one carbon atom; the said -B- radical being bonded to a glucoside unit via an ether functional group g, and
      • X is a radical resulting from an amino acid,
      • k is an amide functional group.
  • In one embodiment, the dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals is of formula III:
  • Figure US20180311316A1-20181101-C00003
      • in which:
        • R is —OH or chosen from the group consisting of the radicals:
          • -(f-[A]-COOH)n;
          • -(g-[B]-k-[D])m, D comprising at least one alkyl chain comprising at least 8 carbon atoms;
        • n represents the degree of substitution of the glucoside units by -f-[A]-COOH and 0.1≤n≤2;
        • m represents the degree of substitution of the glucoside units by -g-[B]-k-[D] and 0<m≤0.5;
        • q represents the degree of polymerization as glucoside units, that is to say the mean number of glucoside units per polysaccharide chain, and 3≤q≤50;
        • -(f-[A]-COOH)n:
          • -A- is a linear or branched radical comprising from 1 to 4 carbon atoms; the said -A- radical:
          • being bonded to a glucoside unit via a functional group f chosen from the group consisting of ether, ester and carbamate functional groups;
        • -(g-[B]-k-[D])m:
          • -B- is a linear or branched, at least divalent, radical comprising from 1 to 4 carbon atoms; the said -B- radical:
          • being bonded to a glucoside unit via a functional group g chosen from the group consisting of ether, ester and carbamate functional groups;
          • being bonded to a -D radical via a functional group k; k chosen from the group consisting of ester, amide and carbamate functional groups; the said -D radical:
            • being an -X(-l-Y)p radical, X being an at least divalent radical comprising from 1 to 12 atoms chosen from the group consisting of C, N and O atoms, optionally carrying carboxyl or amine functional groups and/or resulting from an amino acid, a dialcohol, a diamine or a mono- or polyethylene glycol mono- or diamine; Y being a linear or cyclic alkyl group, an alkylaryl or an arylalkyl, of 8 to 20 carbon atoms, optionally substituted by one or more C1 to C3 alkyl groups; p≥1 and l a functional group chosen from the group consisting of ester, amide and carbamate functional groups;
        • f, g and k being identical or different;
        • the free acid functional groups being in the form of salts of alkali metal cations chosen from the group consisting of Na+ and K+;
        • and, when p=1, if Y is a C8 to C14 alkyl, then q*m≥2, if Y is a C15 alkyl, then q*m≥2; and if Y is a C16 to C20 alkyl, then q*m≥1;
        • and, when p≥2, if Y is a C8 to C11 alkyl, then q*m≥2 and, if Y is a C12 to C16 alkyl, then q*m≥0.3.
  • In one embodiment, the dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals is of formula IV:
  • Figure US20180311316A1-20181101-C00004
      • in which:
        • R is —OH or chosen from the group consisting of the radicals:
          • -(f-[A]-COOH)n;
          • -(g-[B]-k-[D])m, D comprising at least one alkyl chain comprising at least 8 carbon atoms;
        • n represents the degree of substitution of the hydroxyl —OH functional groups by -f-[A]-COOH per glucoside unit; and 0.1≤n≤2;
        • m represents the degree of substitution of the hydroxyl —OH functional groups by -g-[B]-k-[D] per glucoside unit; and 0<m≤0.5;
        • q represents the degree of polymerization as glucoside units, that is to say the mean number of glucoside units per polysaccharide chain, and 3≤q≤50;
        • -(f-[A]-COOH)n:
          • -A- is a linear or branched radical comprising from 1 to 4 carbon atoms; the said -A- radical:
          • being bonded to a glucoside unit via a functional group f chosen from the group consisting of ether, ester and carbamate functional groups;
        • -(g-[B]-k-[D])m:
          • -B- is a linear or branched, at least divalent, radical comprising from 1 to 4 carbon atoms; the said -B- radical:
          • being bonded to a glucoside unit via a functional group g chosen from the group consisting of ether, ester and carbamate functional groups;
          • being bonded to a -D radical via a functional group k; k chosen from the group consisting of ester, amide and carbamate functional groups; the said -D radical:
            • being an -X(-l-Y)p radical, X being an at least divalent radical comprising from 1 to 12 atoms chosen from the group consisting of C, N and O atoms, optionally carrying carboxyl or amine functional groups and/or resulting from an amino acid, a dialcohol, a diamine or a mono- or polyethylene glycol mono- or diamine; Y being a linear or cyclic alkyl group, an alkylaryl or an arylalkyl, of 8 to 30 carbon atoms, optionally substituted by one or more C1 to C3 alkyl groups; p≥1 and l a functional group chosen from the group consisting of ester, amide and carbamate functional groups;
        • f, g and k being identical or different;
        • the free acid functional groups being in the form of salts of alkali metal cations chosen from the group consisting of Na+ and K+;
        • and, when p=1, if Y is a C8 to C14 alkyl, then q*m≥2, if Y is a C15 alkyl, then q*m≥2; and if Y is a C16 to C30 alkyl, then q*m≥1;
        • and, when p≥2, if Y is a C8 to C9 alkyl, then q*m≥2 and, if Y is a C10 to C16 alkyl, then q*m≥0.2.
  • The structure drawn corresponds to the representation commonly used to represent dextran, which is a polysaccharide predominantly composed of (1,6) linkages between glucoside units, which is the representation adopted. Dextran also comprises (1,3) linkages at approximately 5% in general, which are deliberately not represented but which are, of course, included within the scope of the invention.
  • The term “basal insulin” whose isoelectric point is between 5.8 and 8.5 is understood to mean an insulin which is insoluble at pH 7 and which has a duration of action of between 8 and 24 hours or more in the standard models of diabetes.
  • These basal insulins whose isoelectric point is between 5.8 and 8.5 are recombinant insulins, the primary structure of which has been modified mainly by introduction of basic amino acids, such as arginine or lysine. They are described, for example, in the following patents, patent applications or publications: WO 2003/053339, WO 2004/096854, U.S. Pat. No. 5,656,722 and U.S. Pat. No. 6,100,376.
  • In one embodiment, the basal insulin whose isoelectric point is between 5.8 and 8.5 is insulin glargine.
  • In one embodiment, the compositions according to the invention comprise 100 IU/ml (i.e., approximately 3.6 mg/ml) of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise 40 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise 200 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise 300 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise 400 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise 500 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 0.2 and 5.
  • In one embodiment, the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 0.2 and 4.
  • In one embodiment, the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 0.2 and 3.
  • In one embodiment, the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 0.5 and 3.
  • In one embodiment, the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 0.8 and 3.
  • In one embodiment, the ratio by weight of the basal insulin whose isoelectric point is between 5.8 and 8.5 to the substituted dextran, i.e. substituted dextran/basal insulin, is between 1 and 3.
  • In one embodiment, the concentration of substituted dextran is between 1 and 100 mg/ml.
  • In one embodiment, the concentration of substituted dextran is between 1 and 80 mg/ml.
  • In one embodiment, the concentration of substituted dextran is between 1 and 60 mg/ml.
  • In one embodiment, the concentration of substituted dextran is between 1 and 50 mg/ml.
  • In one embodiment, the concentration of substituted dextran is between 1 and 30 mg/ml.
  • In one embodiment, the concentration of substituted dextran is between 1 and 20 mg/ml.
  • In one embodiment, the concentration of substituted dextran is between 1 and 10 mg/ml.
  • In one embodiment, the concentration of polysaccharide is between 5 and 20 mg/ml.
  • In one embodiment, the concentration of polysaccharide is between 5 and 10 mg/ml.
  • In one embodiment, the compositions according to the invention additionally comprise a prandial insulin. Prandial insulins are soluble at pH 7.
  • The term “prandial insulin” is understood to mean a “rapid” or “regular” insulin.
  • “Rapid” prandial insulins are insulins which must meet the needs brought about by the ingestion of proteins and carbohydrates during a meal; they have to act in less than 30 minutes.
  • In one embodiment, “regular” prandial insulins are chosen from the group consisting of Humulin® (human insulin) and Novolin® (human insulin).
  • “Fast-acting” prandial insulins are insulins which are obtained by recombination and which are modified in order to reduce their action time.
  • In one embodiment, “fast-acting” prandial insulins are chosen from the group consisting of insulin lispro (Humalog®), insulin glulisine (Apidra®) and insulin aspart (NovoLog®).
  • In one embodiment, the compositions according to the invention comprise, in total, 100 IU/ml (i.e., approximately 3.6 mg/ml) of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise, in total, 40 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise, in total, 200 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise, in total, 300 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise, in total, 400 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise, in total, 500 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise, in total, 600 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise, in total, 700 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • In one embodiment, the compositions according to the invention comprise, in total, 800 IU/ml of insulin with a combination of prandial insulin and basal insulin whose isoelectric point is between 5.8 and 8.5.
  • The proportions between the basal insulin whose isoelectric point is between 5.8 and 8.5 and the prandial insulin, expressed as percentage with respect to the total amount of insulin, are, for example, 25/75, 30/70, 40/60, 50/50, 60/40, 70/30, 80/20 and 90/10 for the formulations as described above from 40 to 800 IU/ml. However, any other proportion can be produced.
  • For a formulation comprising 100 IU/ml as total insulin, the proportions between the basal insulin whose isoelectric point is between 5.8 and 8.5 and the prandial insulin are, for example, in IU/ml, 25/75, 30/70, 40/60, 50/50, 60/40, 70/30, 80/20 or 90/10. However, any other proportion can be produced.
  • In one embodiment, the composition according to the invention additionally comprises a GLP-1, a GLP-1 analogue or a GLP-1 derivative.
  • In one embodiment, the GLP-1 analogues or derivatives are chosen from the group consisting of exenatide or Byetta®, developed by Eli Lilly & Co and Amylin Pharmaceuticals, liraglutide or Victoza® developed by Novo Nordisk, or lixisenatide or Lyxumia® developed by Sanofi, their analogues or derivatives and their pharmaceutically acceptable salts.
  • In one embodiment, the GLP-1 analogue or derivative is exenatide or Byetta®, its analogues or derivatives and their pharmaceutically acceptable salts.
  • In one embodiment, the GLP-1 analogue or derivative is liraglutide or Victoza®, its analogues or derivatives and their pharmaceutically acceptable salts.
  • In one embodiment, the GLP-1 analogue or derivative is lixisenatide or Lyxumia®, its analogues or derivatives and their pharmaceutically acceptable salts.
  • The term “analogue” is understood to mean, when it is used with reference to a peptide or a protein, a peptide or a protein in which one or more constituent amino acid residues have been replaced by other amino acid residues and/or from which one or more constituent amino acid residues have been deleted and/or to which one or more constituent amino acid residues have been added. The percentage of homology accepted for the present definition of an analogue is 50%.
  • The term “derivative” is understood to mean, when it is used with reference to a peptide or protein, a peptide or a protein or an analogue chemically modified by a substituent which is not present in the reference peptide or protein or analogue, that is to stay a peptide or a protein which has been modified by creation of covalent bonds, in order to introduce substituents.
  • In one embodiment, the concentration of GLP-1, of GLP-1 analogue or of GLP-1 derivative is within a range from 0.01 to 10 mg/ml.
  • In one embodiment, the concentration of exenatide, its analogues or derivatives and their pharmaceutically acceptable salts is within a range from 0.05 to 0.5 mg/ml.
  • In one embodiment, the concentration of liraglutide, its analogues or derivatives and their pharmaceutically acceptable salts is within a range from 1 to 10 mg/ml.
  • In one embodiment, the concentration of lixisenatide, its analogues or derivatives and their pharmaceutically acceptable salts is within a range from 0.01 to 1 mg/ml.
  • In one embodiment, the compositions according to the invention are produced by mixing commercial solutions of basal insulin whose isoelectric point is between 5.8 and 8.5 and commercial solutions of GLP-1, of GLP-1 analogue or of GLP-1 derivative in ratios by volume within a range from 10/90 to 90/10.
  • In one embodiment, the composition according to the invention comprises a daily dose of basal insulin and a daily dose of GLP-1, GLP-1 analogue or GLP-1 derivative.
  • In one embodiment, the compositions according to the invention comprise 500 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of exenatide.
  • In one embodiment, the compositions according to the invention comprise 500 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 1 to 10 mg/ml of liraglutide.
  • In one embodiment, the compositions according to the invention comprise 500 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of lixisenatide.
  • In one embodiment, the compositions according to the invention comprise 100 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of exenatide.
  • In one embodiment, the compositions according to the invention comprise 100 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 1 to 10 mg/ml of liraglutide.
  • In one embodiment, the compositions according to the invention comprise 100 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of lixisenatide.
  • In one embodiment, the compositions according to the invention comprise 40 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 à 0.5 mg/ml of exenatide.
  • In one embodiment, the compositions according to the invention comprise 40 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 1 to 10 mg/ml of liraglutide.
  • In one embodiment, the compositions according to the invention comprise 40 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 à 0.5 mg/ml of lixisenatide.
  • In one embodiment, the compositions according to the invention comprise 200 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of exenatide.
  • In one embodiment, the compositions according to the invention comprise 200 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 1 to 10 mg/ml of liraglutide.
  • In one embodiment, the compositions according to the invention comprise 200 IU/ml of basal insulin whose isoelectric point is between 5.8 and 8.5 and from 0.05 to 0.5 mg/ml of lixisenatide.
  • In one embodiment, the compositions according to the invention additionally comprise zinc salts at a concentration of between 0 and 5000 μM.
  • In one embodiment, the compositions according to the invention additionally comprise zinc salts at a concentration of between 50 and 4000 μM.
  • In one embodiment, the compositions according to the invention additionally comprise zinc salts at a concentration of between 200 and 3000 μM.
  • In one embodiment, the compositions according to the invention additionally comprise zinc salts at a concentration of between 0 and 1000 μM.
  • In one embodiment, the compositions according to the invention additionally comprise zinc salts at a concentration of between 20 and 600 μM.
  • In one embodiment, the compositions according to the invention additionally comprise zinc salts at a concentration of between 50 and 500 μM.
  • In one embodiment, the compositions according to the invention comprise buffers chosen from the group consisting of Tris, citrates and phosphates at concentrations of between 0 and 100 mM, preferably between 0 and 50 mM or between 15 and 50 mM.
  • In one embodiment, the compositions according to the invention additionally comprise preservatives.
  • In one embodiment, the preservatives are chosen from the group consisting of m-cresol and phenol, alone or as a mixture.
  • In one embodiment, the concentration of the preservatives is between 10 and 50 mM.
  • In one embodiment, the concentration of the preservatives is between 10 and 40 mM.
  • The compositions according to the invention can additionally comprise additives, such as tonicity agents, such as glycerol, NaCl, mannitol and glycine.
  • The compositions according to the invention can additionally comprise additives in accordance with the pharmacopoeias, such as surfactants, for example polysorbate.
  • The compositions according to the invention can additionally comprise all the excipients in accordance with the pharmacopoeias which are compatible with the insulins used at the concentrations of use.
  • In one embodiment, 0.3≤n≤1.7.
  • In one embodiment, 0.7≤n≤1.5.
  • In one embodiment, 0.9≤n≤1.2.
  • In one embodiment, 0.01≤m≤0.5.
  • In one embodiment, 0.02≤m≤0.4.
  • In one embodiment, 0.03≤m≤0.3.
  • In one embodiment, 0.05≤m≤0.2.
  • In one embodiment, 3≤q≤50.
  • In one embodiment, 3≤q≤40.
  • In one embodiment, 3≤q≤30.
  • In one embodiment, 3≤q≤20.
  • In one embodiment, 3≤q≤10.
  • In one embodiment, the -(f-[A]-COOH)n radical is chosen from the group consisting of the following sequences, f having the meaning given above:
  • Figure US20180311316A1-20181101-C00005
  • In one embodiment, the -(g-[B]-k-[D])m radical is chosen from the group consisting of the following sequences, g, k and D having the meanings given above:
  • Figure US20180311316A1-20181101-C00006
  • In one embodiment, D is such that the X radical is an at least divalent radical resulting from an amino acid.
  • In one embodiment, D is such that the X radical is an at least divalent radical resulting from an amino acid chosen from the group consisting of glycine, leucine, phenylalanine, lysine, isoleucine, alanine, valine, aspartic acid and glutamic acid.
  • The radicals resulting from amino acids can be either laevorotatory or dextrorotatory.
  • In one embodiment, D is such that the X radical is an at least divalent radical resulting from a mono- or polyethylene glycol.
  • In one embodiment, D is such that the X radical is an at least divalent radical resulting from ethylene glycol.
  • In one embodiment, D is such that the X radical is an at least divalent radical resulting from a polyethylene glycol chosen from the group consisting of diethylene glycol and triethylene glycol.
  • In one embodiment, D is such that the X radical is an at least divalent radical resulting from a mono- or polyethylene glycol amine.
  • In one embodiment, D is such that the X radical is an at least divalent radical resulting from a mono- or polyethylene glycol amine chosen from the group consisting of ethanolamine, diethylene glycol amine and triethylene glycol amine.
  • In one embodiment, D is such that the X radical is an at least divalent radical resulting from a mono- or polyethylene glycol diamine.
  • In one embodiment, D is such that the X radical is an at least divalent radical resulting from ethylenediamine.
  • In one embodiment, D is such that the X radical is an at least divalent radical resulting from a mono- or polyethylene glycol diamine chosen from the group consisting of diethylene glycol diamine and triethylene glycol diamine.
  • In one embodiment, D is such that the Y group is an alkyl group resulting from a hydrophobic alcohol.
  • In one embodiment, D is such that the Y group is an alkyl group resulting from a hydrophobic alcohol chosen from the group consisting of octanol (capryl alcohol), 3,7-dimethyloctan-1-ol, decanol (decyl alcohol), dodecanol (lauryl alcohol), tetradecanol (myristyl alcohol) and hexadecanol (cetyl alcohol).
  • In one embodiment, D is such that the Y group is an alkyl group resulting from a hydrophobic acid.
  • In one embodiment, D is such that the Y group is an alkyl group resulting from a hydrophobic acid chosen from the group consisting of decanoic acid, dodecanoic acid, tetradecanoic acid and hexadecanoic acid.
  • In one embodiment, D is such that the Y group is a group resulting from a sterol.
  • In one embodiment, D is such that the Y group is a group resulting from a sterol chosen from the group consisting of cholesterol and its derivatives.
  • In one embodiment, D is such that the Y group is a group resulting from a tocopherol.
  • In one embodiment, D is such that the Y group is a group resulting from a tocopherol derivative chosen from the racemate, the L isomer or the D isomer of α-tocopherol.
  • In one embodiment, D is such that the X radical results from glycine, p=1, the Y group results from octanol and the functional group l is an ester functional group.
  • In one embodiment, D is such that the X radical results from glycine, p=1, the Y group results from dodecanol and the functional group l is an ester functional group.
  • In one embodiment, D is such that the X radical results from glycine, p=1, the Y group results from hexadecanol and the functional group l is an ester functional group.
  • In one embodiment, D is such that the X radical results from phenylalanine, p=1, the Y group results from octanol and the functional group l is an ester functional group.
  • In one embodiment, D is such that the X radical results from phenylalanine, p=1, the Y group results from 3,7-dimethyloctan-1-ol and the functional group l is an ester functional group.
  • In one embodiment, D is such that the X radical results from aspartic acid, p=2, the Y groups result from octanol and the functional groups l are ester functional groups.
  • In one embodiment, D is such that the X radical results from aspartic acid, p=2, the Y groups result from decanol and the functional groups l are ester functional groups.
  • In one embodiment, D is such that the X radical results from aspartic acid, p=2, the Y groups result from dodecanol and the functional groups l are ester functional groups.
  • In one embodiment, D is such that the X radical results from ethylenediamine, the Y group results from dodecanoic acid and the functional group l is an amide functional group.
  • In one embodiment, D is such that the X radical results from diethylene glycol amine, p=1, the Y group results from dodecanoic acid and the functional group l is an ester functional group.
  • In one embodiment, D is such that the X radical results from triethylene glycol diamine, p=1, the Y group results from dodecanoic acid and the functional group l is an amide functional group.
  • In one embodiment, D is such that the X radical results from triethylene glycol diamine, p=1, the Y group results from hexadecanoic acid and the functional group l is an amide functional group.
  • In one embodiment, D is such that the X radical results from leucine, p=1, the Y group results from cholesterol and the functional group l is an ester functional group.
  • In one embodiment, D is such that X results from ethylenediamine, p=1, the Y group results from cholesterol and the functional group l is a carbamate functional group.
  • In one embodiment, the E radical is an at least divalent radical resulting from an amino acid chosen from the group consisting of glycine, leucine, phenylalanine, lysine, isoleucine, alanine, valine, serine, threonine, aspartic acid and glutamic acid.
  • The radicals resulting from amino acids can be either laevorotatory or dextrorotatory.
  • In one embodiment, the E radical is an at least divalent radical resulting from a mono- or polyethylene glycol amine.
  • In one embodiment, the E radical is an at least divalent radical resulting from a mono- or polyethylene glycol amine chosen from the group consisting of ethanolamine, diethylene glycol amine and triethylene glycol amine.
  • In one embodiment, the E radical is an at least divalent radical resulting from a mono- or polyethylene glycol diamine.
  • In one embodiment, the E radical is an at least divalent radical resulting from ethylenediamine.
  • In one embodiment, the E radical is an at least divalent radical resulting from a mono- or polyethylene glycol diamine chosen from the group consisting of diethylene glycol diamine and triethylene glycol diamine.
  • In one embodiment, the F group is an alkyl group resulting from a hydrophobic alcohol.
  • In one embodiment, the F group is a group resulting from a hydrophobic alcohol chosen from the group consisting of dodecanol (lauryl alcohol), tetradecanol (myristyl alcohol) and hexadecanol (cetyl alcohol).
  • In one embodiment, the F group is a group resulting from a hydrophobic acid.
  • In one embodiment, the F group is a group resulting from a hydrophobic acid chosen from the group consisting of dodecanoic acid, tetradecanoic acid and hexadecanoic acid.
  • In one embodiment, the F group is a group resulting from a sterol.
  • In one embodiment, the F group is a group resulting from a sterol chosen from the group consisting of cholesterol and its derivatives.
  • In one embodiment, the F group is a group resulting from a tocopherol.
  • In one embodiment, the F group is a group resulting from a tocopherol derivative chosen from the racemate, the L isomer or the D isomer of α-tocopherol.
  • In one embodiment, the E radical results from ethylenediamine, t=1, o is a carbamate functional group and the F group results from cholesterol.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from glycine, l is an ester functional group and Y results from octanol;
      • q=38, n=0.9 and m=0.2.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from glycine, p=1, l is an ester functional group and Y results from hexadecanol;
      • q=19, n=1.0 and m=0.1.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from phenylalanine, p=1, l is an ester functional group and Y results from octanol;
      • q=38, n=1.0 and m=0.1.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from phenylalanine, p=1, l is an ester functional group and Y results from octanol;
      • q=19, n=1.0 and m=0.2.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from phenylalanine, p=1, l is an ester functional group and Y results from 3,7-dimethyloctan-1-ol;
      • q=38, n=1.0 and m=0.1.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from aspartic acid, p=2, l are ester functional groups and Y result from octanol;
      • q=38, n=1.05 and m=0.05.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from aspartic acid, p=2, l are ester functional groups and Y result from decanol;
      • q=38, n=1.05 and m=0.05.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from aspartic acid, p=2, l are ester functional groups and Y result from dodecanol;
      • q=19, n=1.05 and m=0.05.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from ethylenediamine, p=1, l is an amide functional group and Y results from dodecanoic acid;
      • q=38, n=1.0 and m=0.1.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2—CH2— radical and f is an ester functional group;
      • -(g-[B]-k-[D])m is such that g is an ester functional group, B is the —CH2—CH2— radical, k is an amide functional group and D is such that X results from glycine, p=1, l is an ester functional group and Y results from dodecanol;
      • q=38, n=1.3 and m=0.1.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is a carbamate functional group;
      • -(g-[B]-k-[D])m is such that g is a carbamate functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from aspartic acid, p=2, l are ester functional groups and Y result from octanol;
      • q=38, n=1.3 and m=0.1.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from aspartic acid, p=2, l are ester functional groups and Y result from dodecanol;
      • q=4, n=0.96 and m=0.07.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from diethylene glycol amine, p=1, l is an ester functional group and Y results from dodecanoic acid;
      • q=38, n=1.0 and m=0.1.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from triethylene glycol diamine, p=1, l is an amide functional group and Y results from dodecanoic acid;
      • q=38, n=1.0 and m=0.1.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from triethylene glycol diamine, p=1, l is an amide functional group and Y results from hexadecanoic acid;
      • q=38, n=1.05 and m=0.05.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from glycine, p=1, l is an ester functional group and Y results from hexadecanol;
      • q=19, n=1.05 and m=0.05.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from glycine, p=1, l is an ester functional group and Y results from hexadecanol;
      • q=38, n=0.37 and m=0.05.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from leucine, p=1, l is an ester functional group and Y results from cholesterol;
      • q=19, n=1.61 and m=0.04.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from leucine, p=1, l is an ester functional group and Y results from cholesterol;
      • q=19, n=1.06 and m=0.04.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from leucine, p=1, l is an ester functional group and Y results from cholesterol;
      • q=19, n=0.66 and m=0.04.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from leucine, p=1, l is an ester functional group and Y results from cholesterol;
      • q=19, n=0.46 and m=0.04.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from leucine, p=1, l is an ester functional group and Y results from cholesterol;
      • q=4, n=1.61 and m=0.05.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from ethylenediamine, p=1, l is a carbamate functional group and Y results from cholesterol;
      • q=19, n=1.61 and m=0.04.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is a carbamate functional group;
      • -(g-[B]-k-[D])m is such that g is a carbamate functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from leucine, p=1, l is an ester functional group and Y results from cholesterol;
      • q=19, n=1.96 and m=0.04.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -[E]-(o-[F])t is such that E results from ethylenediamine, o is a carbamate functional group and F results from cholesterol;
      • q=19 and n=1.65.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from leucine, p=1, l is an ester functional group and Y results from cholesterol;
      • q=38, n=0.99 and m=0.05.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from aspartic acid, p=2, l are ester functional groups and Y result from dodecanol;
      • q=4, n=1.41 and m=0.16.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from aspartic acid, p=2, l are ester functional groups and Y result from dodecanol;
      • q=4, n=1.50 and m=0.07.
  • In one embodiment:
      • -(f-[A]-COOH)n is such that A is the —CH2— radical and f is an ether functional group;
      • -(g-[B]-k-[D])m is such that g is an ether functional group, B is the —CH2— radical, k is an amide functional group and D is such that X results from aspartic acid, p=2, l are ester functional groups and Y result from decanol;
      • q=4, n=1.05 and m=0.05.
  • In one embodiment, the compositions according to the invention comprise a dextran chosen from the group consisting of the following dextrans of formula I, III or IV:
    • Sodium dextranmethylcarboxylate modified by octyl glycinate,
    • Sodium dextranmethylcarboxylate modified by cetyl glycinate,
    • Sodium dextranmethylcarboxylate modified by octyl phenylalaninate,
    • Sodium dextranmethylcarboxylate modified by 3,7-dimethyl-1-octyl phenylalaninate,
    • Sodium dextranmethylcarboxylate modified by dioctyl aspartate,
    • Sodium dextranmethylcarboxylate modified by didecyl aspartate,
    • Sodium dextranmethylcarboxylate modified by dilauryl aspartate,
    • Sodium dextranmethylcarboxylate modified by N-(2-aminoethyl)dodecanamide,
    • Sodium dextransuccinate modified by lauryl glycinate,
    • N-(sodium methylcarboxylate) dextran carbamate modified by dioctyl aspartate,
    • Sodium dextranmethylcarboxylate modified by 2-(2-aminoethoxy)ethyl dodecanoate,
    • Sodium dextranmethylcarboxylate modified by 2-(2-{2-[dodecanoylamino]ethoxy}ethoxy)ethylamine,
    • Sodium dextranmethylcarboxylate modified by 2-(2-{2-[hexadecanoylamino]ethoxy}ethoxy)ethylamine,
    • Sodium dextranmethylcarboxylate modified by cholesteryl leucinate,
    • Sodium dextranmethylcarboxylate modified by cholesteryl 1-ethylenediaminecarboxylate,
    • N-(sodium methylcarboxylate) dextran carbamate modified by cholesteryl leucinate.
  • In one embodiment, the compositions according to the invention comprise a dextran chosen from the group consisting of the dextran of the following formula II:
    • Sodium dextranmethylcarboxylate modified by cholesteryl 1-ethylenediaminecarboxylate grafted by reductive amination to the reducing chain end.
  • The invention also relates to single-dose formulations at a pH of between 6.6 and 7.8 comprising a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.
  • The invention also relates to single-dose formulations at a pH of between 7 and 7.8 comprising a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.
  • In one embodiment, the basal insulin whose isoelectric point is between 5.8 and 8.5 is insulin glargine.
  • In one embodiment, the prandial insulin is chosen from the group consisting of Humulin® (human insulin) and Novolin® (human insulin).
  • In one embodiment, the prandial insulin is chosen from the group consisting of insulin lispro (Humalog®), insulin glulisine (Apidra®) and insulin aspart (NovoLog®).
  • The dissolution at a pH of between 6.6 and 7.8 of the basal insulins whose isoelectric point is between 5.8 and 8.5 by the polysaccharides of formula I, II, III or IV can be observed and controlled in a simple way, with the naked eye, by virtue of a change in appearance of the solution
  • The dissolution at a pH of between 7 and 7.8 of the basal insulins whose isoelectric point is between 5.8 and 8.5 by the polysaccharides of formula I, II, III or IV can be observed and controlled in a simple way, with the naked eye, by virtue of a change in appearance of the solution.
  • Furthermore and just as importantly, the Applicant Company has been able to confirm that a basal insulin whose isoelectric point is between 5.8 and 8.5, dissolved in the presence of a polysaccharide of formula I, II, III or IV, had lost none of its slow insulin action.
  • The preparation of a composition according to the invention exhibits the advantage of being able to be carried out by simple mixing of an aqueous solution of basal insulin whose isoelectric point is between 5.8 and 8.5, of a solution of prandial insulin and of a polysaccharide of formula I, II, III or IV in aqueous solution or in the lyophilized form. If necessary, the pH of the preparation is adjusted to pH 7.
  • The preparation of a composition according to the invention exhibits the advantage of being able to be carried out by simple mixing of an aqueous solution of basal insulin whose isoelectric point is between 5.8 and 8.5, of a polysaccharide of formula I, II, III or IV in aqueous solution or in the lyophilized form, and of a prandial insulin in aqueous solution or in the lyophilized form.
  • In one embodiment, the mixture of basal insulin and polysaccharide is concentrated by ultrafiltration before mixing with the prandial insulin in aqueous solution or in the lyophilized form.
  • If necessary, the composition of the mixture is adjusted in excipients, such as glycerol, m-cresol, zinc chloride and tween, by addition of concentrated solutions of these excipients to the mixture. If necessary, the pH of the preparation is adjusted to 7.
    • DESCRIPTION OF THE FIGURES
  • FIGS. 1 to 6 present the results obtained in the form of pharmacodynamic curves for glucose. The axis of the ordinates represents the Dglucose (expressed in mM) as a function of the post-injection time (expressed in minutes).
  • FIG. 1: Mean+standard deviation of the mean curves for the sequential administrations of Apidra® and Lantus® (□) in comparison with a composition according to the invention Polysaccharide 4/Lantus®/Apidra® (75/25) (▪).
  • FIG. 2: Apidra® Lantus® individual curves (tested on six pigs).
  • FIG. 3: Polysaccharide 4/Apidra®/Lantus® individual curves (tested on six pigs).
  • FIG. 4: Mean+standard deviation of the mean curves for the sequential administration of Humalog® and Lantus® (□) in comparison with the administration of a composition according to the invention Polysaccharide 4/Humalog®/Lantus® (▪).
  • FIG. 5: Humalog® Lantus® individual curves (tested on six pigs).
  • FIG. 6: Polysaccharide 4/Humalog®/Lantus® individual curves (tested on five pigs).
  • FIGS. 7 to 12 present the results obtained in the form of pharmacodynamic curves for glucose. The axis of the ordinates represents the Dglucose (expressed in mM) as a function of the post-injection time (expressed in hours).
  • FIG. 7: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) (
    Figure US20180311316A1-20181101-P00001
    ), in comparison with a composition according to the invention described in Example B28 (0.53 IU/kg) (
    Figure US20180311316A1-20181101-P00002
    ).
  • FIG. 8: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) (
    Figure US20180311316A1-20181101-P00001
    ), in comparison with a composition according to the invention described in Example B27 (0.47 IU/kg) (
    Figure US20180311316A1-20181101-P00002
    ).
  • FIG. 9: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) (
    Figure US20180311316A1-20181101-P00001
    ), in comparison with a composition according to the invention described in Example B29 (0.53 IU/kg) (
    Figure US20180311316A1-20181101-P00002
    ).
  • FIG. 10: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) (
    Figure US20180311316A1-20181101-P00001
    ), in comparison with a composition according to the invention described in Example B31 (0.48 IU/kg) (
    Figure US20180311316A1-20181101-P00002
    ).
  • FIG. 11: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.24 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) (
    Figure US20180311316A1-20181101-P00001
    ), in comparison with a composition according to the invention described in Example B30 (0.64 IU/kg) (
    Figure US20180311316A1-20181101-P00002
    ).
  • FIG. 12: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) (
    Figure US20180311316A1-20181101-P00001
    ), in comparison with a composition according to the invention described in Example B32 (0.53 IU/kg) (
    Figure US20180311316A1-20181101-P00002
    ).
    •  EXAMPLES
  • Part A: Polysaccharides
  • Table 1 below presents, in a nonlimiting way, examples of polysaccharides which can be used in the compositions according to the invention.
  • TABLE 1
    SUBSTITUENTS
    —f—A—COONa
    POLYSACCHARIDES —g—B—k—D COMMON NAME
    Polysaccharide 1 q: 38 n: 0.9 m: 0.2
    Figure US20180311316A1-20181101-C00007
         		Sodium dextranmethylcarboxylate modified by octyl glycinate
    Figure US20180311316A1-20181101-C00008
    Polysaccharide 2 q: 19 n: 1.0 m: 0.1 Polysaccharide 16 q: 19 n: 1.05 m: 0.05 Polysaccharide 17 q: 38 n: 0.37 m: 0.05
    Figure US20180311316A1-20181101-C00009
      
    Figure US20180311316A1-20181101-C00010
         		Sodium dextranmethylcarboxylate modified by cetyl glycinate
    Polysaccharide 3 q: 38 n: 1.0 m: 0.1 Polysaccharide 4 q: 19 n: 1.0 m: 0.2
    Figure US20180311316A1-20181101-C00011
      
    Figure US20180311316A1-20181101-C00012
         		Sodium dextranmethylcarboxylate modified by octyl phenylalaninate
    Polysaccharide 5 q: 38 n: 1.0 m: 0.1
    Figure US20180311316A1-20181101-C00013
         		Sodium dextranmethylcarboxylate modified by 3,7-dimethyl-1- octyl phenylalaninate
    Figure US20180311316A1-20181101-C00014
    Polysaccharide 6 q: 38 n: 1.05 m: 0.05
    Figure US20180311316A1-20181101-C00015
         		Sodium dextranmethylcarboxylate modified by dioctyl aspartate
    Figure US20180311316A1-20181101-C00016
    Polysaccharide 7 q: 38 n: 1.05 m: 0.05 Polysaccharide 29 q: 4 n: 1.05 m: 0.05
    Figure US20180311316A1-20181101-C00017
      
    Figure US20180311316A1-20181101-C00018
         		Sodium dextranmethylcarboxylate modified by didecyl aspartate
    Polysaccharide 8 q: 19 n: 1.05 m: 0.05 Polysaccharide 27 q: 4 n: 1.41 m: 0.16 Polysaccharide 28 q: 4 n: 1.50 m: 0.07
    Figure US20180311316A1-20181101-C00019
      
    Figure US20180311316A1-20181101-C00020
         		Sodium dextranmethylcarboxylate modified by dilauryl aspartate
    Polysaccharide 9 q: 38 n: 1.0 m: 0.1
    Figure US20180311316A1-20181101-C00021
         		Sodium dextranmethylcarboxylate modified by N-(2- aminoethyl)dodecanamide
    Figure US20180311316A1-20181101-C00022
    Polysaccharide 10 q: 38 n: 1.3 m: 0.1
    Figure US20180311316A1-20181101-C00023
         		Sodium dextransuccinate modified by lauryl glycinate
    Figure US20180311316A1-20181101-C00024
    Polysaccharide 11 q: 38 n: 1.3 m: 0.1
    Figure US20180311316A1-20181101-C00025
         		N-(sodium methylcarboxylate) dextran carbamate modified by dioctyl aspartate
    Figure US20180311316A1-20181101-C00026
    Polysaccharide 12 q: 4 n: 0.96 m: 0.07
    Figure US20180311316A1-20181101-C00027
         		Sodium dextranmethylcarboxylate modified by dilauryl aspartate
    Figure US20180311316A1-20181101-C00028
    Polysaccharide 13 q: 38 n: 1.0 m: 0.1
    Figure US20180311316A1-20181101-C00029
      
    Figure US20180311316A1-20181101-C00030
         		Sodium dextranmethylcarboxylate modified by 2-(2- aminoethoxy)ethyl dodecanoate
    Polysaccharide 14 q: 38 n: 1.0 m: 0.1
    Figure US20180311316A1-20181101-C00031
      
    Figure US20180311316A1-20181101-C00032
         		Sodium dextranmethylcarboxylate modified by 2-(2-{2- [dodecanoylamino]ethoxy} ethoxy)ethylamine
    Polysaccharide 15 q: 38 n: 1.05 m: 0.05
    Figure US20180311316A1-20181101-C00033
      
    Figure US20180311316A1-20181101-C00034
         		Sodium dextranmethylcarboxylate modified by 2-(2-{2- [hexadecanoylamino]ethoxy} ethoxy)ethylamine
    Polysaccharide 18 q: 19 n: 1.61 m: 0.04 Polysaccharide 19 q: 19 n: 1.06 m: 0.04 Polysaccharide 20 q: 19 n: 0.66 m: 0.04 Polysaccharide 21 q: 19 n: 0.46 m: 0.04 Polysaccharide 22 q: 4 n: 1.61 m: 0.04 Polysaccharide 26 q: 38 n: 0.99 m: 0.05
    Figure US20180311316A1-20181101-C00035
      
    Figure US20180311316A1-20181101-C00036
         		Sodium dextranmethylcarboxylate modified by cholesteryl leucinate
    Polysaccharide 23 q: 19 n: 1.61 m: 0.04
    Figure US20180311316A1-20181101-C00037
         		Sodium dextranmethylcarboxylate modified by cholesteryl 1-ethylenediaminecarboxylate
    Figure US20180311316A1-20181101-C00038
    Polysaccharide 24 q: 19 n: 1.96 m: 0.04
    Figure US20180311316A1-20181101-C00039
         		N-(sodium methylcarboxylate) dextran carbamate modified by cholesteryl leucinate
    Figure US20180311316A1-20181101-C00040
    SUBSTITUENTS
    —f—A—COONa
    POLYSACCHARIDES —[E]—o—[F] COMMON NAME
    Polysaccharide 25 q: 19 n: 1.65
    Figure US20180311316A1-20181101-C00041
         		Sodium dextranmethylcarboxylate modified by cholesteryl 1-ethylenediaminecarboxylate grafted by reductive amination to the reducing chain end
    • Example A1: Preparation of Polysaccharide 1
  • 16 g (i.e., 296 mmol of hydroxyls) of dextran with a weight-average molar mass of approximately 10 kg/mol (q=38, Pharmacosmos) are dissolved in water at 420 g/l. 30 ml of 10N NaOH (296 mmol) are added to the solution. The mixture is brought to 35° C. and then 46 g (396 mmol) of sodium chloroacetate are added. The temperature of the reaction mixture is brought to 60° C. at 0.5° C./min and then maintained at 60° C. for 100 minutes. The reaction medium is diluted with 200 ml of water, neutralized with acetic acid and purified by ultrafiltration through a 5 kDa PES membrane against 6 volumes of water. The final solution is assayed by dry extract, to determine the concentration of polysaccharide, and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of methylcarboxylate units per glucoside unit.
  • According to the dry extract: [polysaccharide]=31.5 mg/g.
  • According to the acid/base titration: the mean number of methylcarboxylate units per glucoside unit is 1.1.
  • The sodium dextranmethylcarboxylate solution is passed through a Purolite resin (anionic) in order to obtain dextranmethylcarboxylic acid, which is subsequently lyophilized for 18 hours.
  • Octyl glycinate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • 10 g of dextranmethylcarboxylic acid (44.86 mmol of methylcarboxylic acid) are dissolved in DMF at 60 g/l and then cooled to 0° C. 3.23 g of octyl glycinate, para-toluenesulphonic acid salt, (8.97 mmol) are suspended in DMF at 100 g/l. 0.91 g of triethylamine (8.97 mmol) is subsequently added to the suspension. Once the polysaccharide solution is at 0° C., a solution of NMM (5.24 g, 51.8 mmol) in DMF (530 g/l) and 5.62 g (51.8 mmol) of EtOCOCl are subsequently added. After reacting for 10 minutes, the octyl glycinate suspension is added. The medium is subsequently maintained at 10° C. for 45 minutes. The medium is subsequently heated to 30° C. A solution of imidazole (10.38 g in 17 ml of water) and 52 ml of water are added to the reaction medium. The polysaccharide solution is ultrafiltered through a 10 kDa PES membrane against 15 volumes of 0.9% NaCl solution and 5 volumes of water. The concentration of the polysaccharide solution is determined by dry extract. A fraction of solution is lyophilized and analyzed by 1H NMR in D2O in order to determine the degree of substitution of the methylcarboxylates to give octyl glycinate per glucoside unit.
  • According to the dry extract: [Polysaccharide 1]=36.4 mg/g
  • According to the acid/base titration: n=0.9
  • According to the 1H NMR: m=0.2.
    • Example A2: Preparation of Polysaccharide 2
  • Cetyl glycinate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 5 kg/mol (q=19, Pharmacosmos), modified by cetyl glycinate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 2]=15.1 mg/g
  • According to the acid/base titration: n=1.05
  • According to the 1H NMR: m=0.05.
    • Example A3: Preparation of Polysaccharide 3
  • Octyl phenylalaninate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q=38, Pharmacosmos), modified by octyl phenylalaninate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 3]=27.4 mg/g
  • According to the acid/base titration: n=1.0
  • According to the 1H NMR: m=0.1.
    • Example A4: Preparation of Polysaccharide 4
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 5 kg/mol (q=19, Pharmacosmos), modified by octyl phenylalaninate, is obtained by a process similar to that described in Example A3.
  • According to the dry extract: [Polysaccharide 4]=21.8 mg/g
  • According to the acid/base titration: n=1.0
  • According to the 1H NMR: m=0.2.
    • Example A5: Preparation of Polysaccharide 5
  • 3,7-dimethyl-1-octyl phenylalaninate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q=38, Pharmacosmos), modified by 3,7-dimethyl-1-octyl phenylalaninate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 5]=24.3 mg/g
  • According to the acid/base titration: n=1.0
  • According to the 1H NMR: m=0.1.
    • Example A6: Preparation of Polysaccharide 6
  • Dioctyl aspartate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q=38, Pharmacosmos), modified by dioctyl aspartate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 6]=22.2 mg/g
  • According to the acid/base titration: n=1.05
  • According to the 1H NMR: m=0.05.
    • Example A7: Preparation of Polysaccharide 7
  • Didecyl aspartate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q=38, Pharmacosmos), modified by didecyl aspartate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 7]=19.8 mg/g
  • According to the acid/base titration: n=1.05
  • According to the 1H NMR: m=0.05.
    • Example A8: Preparation of Polysaccharide 8
  • Dilauryl aspartate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 5 kg/mol (q=19, Pharmacosmos), modified by dilauryl aspartate is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 8]=22.8 mg/g
  • According to the acid/base titration: n=1.05
  • According to the 1H NMR: m=0.05.
    • Example A9: Preparation of Polysaccharide 9
  • N-(2-aminoethyl)dodecanamide is obtained according to the process described in U.S. Pat. No. 2,387,201, from the methyl ester of dodecanoic acid (Sigma) and ethylenediamine (Roth).
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q=38, Pharmacosmos), modified by N-(2-aminoethyl)dodecanamide, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 9]=23.8 mg/g
  • According to the acid/base titration: n=1.0
  • According to the 1H NMR: m=0.1.
    • Example A10: Preparation of Polysaccharide 10
  • Sodium dextransuccinate is obtained from a dextran with a weight-average molar mass of approximately 10 kg/mol (q=38, Pharmacosmos) according to the method described in the paper by Sanchez-Chaves et al., 1998 (Manuel et al., Polymer, 1998, 39 (13), 2751-2757). According to the 1H NMR in D2O/NaOD, the mean number of succinate groups per glucoside unit is 1.4.
  • Lauryl glycinate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextransuccinate modified by lauryl glycinate is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 10]=16.1 mg/g
  • According to the acid/base titration: n=1.3
  • According to the 1H NMR: m=0.1.
    • Example A11: Preparation of Polysaccharide 11
  • Dioctyl aspartate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • 12 g (i.e., 0.22 mol of hydroxyls) of dextran with a weight-average molar mass of approximately 10 kg/mol (q=38, Pharmacosmos) are dissolved in a DMF/DMSO mixture. The mixture is brought to 80° C. with stirring. 3.32 g (0.03 mol) of 1,4-diazabicyclo[2.2.2]octane and then 14.35 g (0.11 mol) of ethyl isocyanatoacetate are gradually introduced. After reacting for 5 h, the medium is diluted in water and purified by diafiltration through a 5 kDa PES membrane against 0.1N NaOH, 0.9% NaCl and water. The final solution is assayed by dry extract, to determine the concentration of polysaccharide; and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number de N-methylcarboxylate carbamate units per glucoside unit.
  • According to the dry extract: [polysaccharide]=30.5 mg/g
  • According to the acid/base titration: the mean number of N-methylcarboxylate carbamate units per glucoside unit is 1.4.
  • An N-(sodium methylcarboxylate) dextran carbamate modified by dioctyl aspartate is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 11]=17.8 mg/g
  • According to the acid/base titration: n=1.3
  • According to the 1H NMR: m=0.1.
    • Example A12: Preparation of Polysaccharide 12
  • Dilauryl aspartate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 1 kg/mol (q=4, Pharmacosmos), modified by dilauryl aspartate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 12]=12.3 mg/g
  • According to the acid/base titration: n=0.96
  • According to the 1H NMR: m=0.07.
    • Example A13: Preparation of Polysaccharide 13
  • 2-(2-aminoethoxy)ethyl dodecanoate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q=38, Pharmacosmos), modified by 2-(2-amino-ethoxy)ethyl dodecanoate is obtained, by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 13]=25.6 mg/g
  • According to the acid/base titration: n=1.0
  • According to the 1H NMR: m=0.1.
    • Example A14: Preparation of Polysaccharide 14
  • 2-(2-{2-[dodecanoylamino]ethoxy}ethoxy)ethylamine is obtained according to the process described in U.S. Pat. No. 2,387,201, from the methyl ester of dodecanoic acid (Sigma) and triethylene glycol diamine (Huntsman).
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q=38, Pharmacosmos), modified by 2-(2-{2-[dodecanoylamino]ethoxy}ethoxy)ethylamine, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 14]=24.9 mg/g
  • According to the acid/base titration: n=1.0
  • According to the 1H NMR: m=0.1.
    • Example A15: Preparation of Polysaccharide 15
  • 2-(2-{2-[hexadecanoylamino]ethoxy}ethoxy)ethylamine is obtained, according to the process described in U.S. Pat. No. 2,387,201, from the methyl ester of palmitic acid (Sigma) and triethylene glycol diamine (Huntsman).
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q=38, Pharmacosmos), modified by 2-(2-{2-[hexadecanoylamino]ethoxy}ethoxy)ethylamine is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 15]=22.2 mg/g
  • According to the acid/base titration: n=1.05
  • According to the 1H NMR: m=0.05.
    • Example A16: Preparation of Polysaccharide 16
  • Cetyl glycinate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 5 kg/mol (q=19, Pharmacosmos), modified by cetyl glycinate is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 16]=23 mg/g
  • According to the acid/base titration: n=1.05
  • According to the 1H NMR: m=0.05.
    • Example A17: Preparation of Polysaccharide 17
  • 10 g (i.e., 185 mmol of hydroxyls) of dextran with a weight-average molar mass of approximately 10 kg/mol (q=38, Pharmacosmos) are dissolved in water at 420 g/l. 19 ml of 10N NaOH (185 mmol) are added to the solution. The mixture is brought to 35° C. and then 8.6 g (74 mmol) of sodium chloroacetate are added. The temperature of the reaction mixture is brought to 60° C. at 0.5° C./min and is then maintained at 60° C. for 100 minutes. The reaction medium is diluted with 200 ml of water, neutralized with acetic acid and purified by ultrafiltration through a 5 kDa PES membrane against 6 volumes of water. The final solution is assayed by dry extract, to determine the polysaccharide concentration, and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of methylcarboxylate units per glucoside unit.
  • According to the dry extract: [polysaccharide]=35.1 mg/g
  • According to the acid/base titration: the mean number of methylcarboxylate units per glucoside unit is 0.42.
  • The sodium dextranmethylcarboxylate solution is passed through a Purolite resin (anionic) in order to obtain dextranmethylcarboxylic acid, which is subsequently lyophilized for 18 hours.
  • Cetyl glycinate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate modified by cetyl glycinate is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 17]=18 mg/g
  • According to the acid/base titration: n=0.37
  • According to the 1H NMR: m=0.05.
    • Example A18: Preparation of Polysaccharide 18
  • 10 g of sodium dextranmethylcarboxylate, characterized by a degree of substitution as methylcarboxylate of 1.10 per glucoside unit, are synthesized from a dextran with a weight-average molar mass of 5 kg/mol (q=19, Pharmacosmos), according to a process similar to that described for Polysaccharide 1, and then lyophilized.
  • 8 g (i.e., 64 mmol of hydroxyls) of sodium dextranmethylcarboxylate, characterized by a degree of substitution as methylcarboxylate of 1.10 per glucoside unit, are dissolved in water at 1000 g/l. 6 ml of 10N NaOH (64 mmol) are added. The mixture is heated to 35° C. and 7.6 g of sodium chloroacetate (65 mmol) are added. The mixture is gradually brought to a temperature of 60° C., and is maintained at this temperature for an additional 100 minutes. The mixture is diluted with water, neutralized with acetic acid and then purified by ultrafiltration through a 5 kDa PES membrane against water. The final solution is assayed by dry extract, to determine the polysaccharide concentration, and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of methylcarboxylate units per glucoside unit.
  • According to the dry extract: [polysaccharide]=45.8 mg/g
  • According to the acid/base titration: the mean number of methylcarboxylate units per glucoside unit is 1.65.
  • The sodium dextranmethylcarboxylate solution is passed through a Purolite resin (anionic) in order to obtain dextranmethylcarboxylic acid, which is subsequently lyophilized for 18 hours.
  • Cholesteryl leucinate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate modified by cholesteryl leucinate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 18]=21 mg/g
  • According to the acid/base titration: n=1.61
  • According to the 1H NMR: m=0.04.
    • Example A19: Preparation of Polysaccharide 19
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 5 kg/mol (q=19, Pharmacosmos), modified by cholesteryl leucinate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 19]=19.4 mg/g
  • According to the acid/base titration: n=1.06
  • According to the 1H NMR: m=0.04.
    • Example A20: Preparation of Polysaccharide 20
  • 16 g (i.e., 296 mmol of hydroxyls) of dextran with a weight-average molar mass of approximately 5 kg/mol (q=19, Pharmacosmos) are dissolved in water at 420 g/l. 30 ml of 10N NaOH (296 mmol) are added to this solution. The mixture is brought to 35° C. and then 26 g (222 mmol) of sodium chloroacetate are added. The temperature of the reaction medium is gradually brought to 60° C. and then maintained at 60° C. for 100 minutes. The reaction medium is diluted with water, neutralized with acetic acid and purified by ultrafiltration through a 5 kDa PES membrane against water. The final solution is assayed by dry extract, to determine the polysaccharide concentration, and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of methylcarboxylate units per glucoside unit.
  • According to the dry extract: [polysaccharide]=33.1 mg/g
  • According to the acid/base titration: the mean number of methylcarboxylate units per glucoside unit is 0.70.
  • The sodium dextranmethylcarboxylate solution is passed through a Purolite resin (anionic) in order to obtain dextranmethylcarboxylic acid, which is subsequently lyophilized for 18 hours.
  • A sodium dextranmethylcarboxylate modified by cholesteryl leucinate is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 20]=18.9 mg/g
  • According to the acid/base titration: n=0.66
  • According to the 1H NMR: m=0.04.
    • Example A21: Preparation of Polysaccharide 21
  • 16 g (i.e., 296 mmol of hydroxyls) of dextran with a weight-average molar mass of approximately 5 kg/mol (q=19, Pharmacosmos) are dissolved in water at 420 g/l. 30 ml of 10N NaOH (296 mmol) are added to this solution. The mixture is brought to 35° C. and then 18 g (158 mmol) of sodium chloroacetate are added. The temperature of the reaction medium is gradually brought to 60° C. and then maintained at 60° C. for 100 minutes. The reaction medium is diluted with water, neutralized with acetic acid and purified by ultrafiltration through a 1 kDa PES membrane against water. The final solution is assayed by dry extract, to determine the polysaccharide concentration, and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of methylcarboxylate units per glucoside unit.
  • According to the dry extract: [polysaccharide]=52.6 mg/g
  • According to the acid/base titration: the mean number of methylcarboxylate units per glucoside unit is 0.50.
  • The sodium dextranmethylcarboxylate solution is passed through a Purolite resin (anionic) in order to obtain dextranmethylcarboxylic acid, which is subsequently lyophilized for 18 hours.
  • A sodium dextranmethylcarboxylate modified by cholesteryl leucinate is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 21]=18.9 mg/g
  • According to the acid/base titration: n=0.46
  • According to the 1H NMR: m=0.04.
    • Example A22: Preparation of Polysaccharide 22
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A18 using a dextran with a weight-average molecular weight of approximately 1 kg/mol (q=4, Pharmacosmos), modified by cholesteryl leucinate, is obtained by a process similar to that described in Example A18.
  • According to the dry extract: [Polysaccharide 22]=20.2 mg/g
  • According to the acid/base titration: n=1.61
  • According to the 1H NMR: m=0.04.
    • Example A23: Preparation of Polysaccharide 23
  • Cholesteryl 1-ethylenediaminecarboxylate hydrochloride is obtained according to the process described in the patent (Akiyoshi, K et al., WO 2010/053140).
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A18 using a dextran with a weight-average molecular weight of approximately 5 kg/mol (q=19, Pharmacosmos), modified by cholesteryl 1-ethylenediaminecarboxylate, is obtained by a process similar to that described in Example A18.
  • According to the dry extract: [Polysaccharide 23]=20.1 mg/g
  • According to the acid/base titration: n=1.61
  • According to the 1H NMR: m=0.04.
    • Example A24: Preparation of Polysaccharide 24
  • 12 g (i.e., 0.22 mol of hydroxyls) of dextran with a weight-average molar mass of approximately 5 kg/mol (q=19, Pharmacosmos) are dissolved in a DMF/DMSO mixture. The mixture is brought to 80° C. with stirring. 3.32 g (0.03 mol) of 1,4-diazabicyclo[2.2.2]octane and then 26.8 g (0.21 mol) of ethyl isocyanatoacetate are gradually introduced. After reacting for 5 h, the medium is diluted in water and purified by diafiltration through a 5 kDa PES membrane against 0.1N NaOH, 0.9% NaCl and water. The final solution is assayed by dry extract, to determine the concentration of polysaccharide; and then assayed by acid/base titration in 50/50 (V/V) water/acetone, to determine the mean number of N-methylcarboxylate carbamate units per glucoside unit.
  • According to the dry extract: [polysaccharide]=30.1 mg/g
  • According to the acid/base titration: the mean number of N-methylcarboxylate carbamate units per glucoside unit is 2.0.
  • An N-(sodium methylcarboxylate) dextran carbamate modified by cholesteryl leucinate is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 24]=17.9 mg/g
  • According to the acid/base titration: n=1.96
  • According to the 1H NMR: m=0.04.
    • Example A25: Preparation of Polysaccharide 25
  • Cholesteryl 1-ethylenediaminecarboxylate hydrochlorate is obtained according to the process described in the patent (Akiyoshi, K et al., WO 2010/053140).
  • 10 g of dextran with a weight-average molar mass of approximately 5 kg/mol (q=19, Pharmacosmos, 3.2 mmol of chain ends) are dissolved in DMSO at 80° C. 4.8 g of cholesteryl 1-ethylenediaminecarboxylate hydrochloride (9.5 mmol), 0.96 g of triethylamine (9.5 mmol) and 2.0 g of sodium cyanoborohydride (32 mmol) are added to the reaction medium, which is stirred at 80° C. for 24 hours. After cooling, the mixture is precipitated from dichloromethane and then from acetone, and dried under vacuum. According to the 1H NMR, a dextran modified at the chain end by cholesteryl 1-ethylenediaminecarboxylate is obtained. A sodium dextranmethylcarboxylate characterized by a degree of substitution as methylcarboxylate of 1.65 per glucoside unit and modified at the chain end by cholesteryl 1-ethylenediaminecarboxylate was synthesized by a process similar to that described in Example A18 using the dextran modified at the chain end by cholesteryl 1-ethylenediaminecarboxylate.
  • According to the dry extract: [Polysaccharide 25]=13.7 mg/g
  • According to the acid/base titration: n=1.65
  • According to the 1H NMR: each polymer chain carries a cholesteryl 1-ethylenediaminecarboxylate group grafted to the reducing chain end.
    • Example A26: Preparation of Polysaccharide 26
  • Cholesterol leucinate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 10 kg/mol (q=38, Pharmacosmos), modified by cholesterol leucinate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 26]=26.6 mg/g
  • According to the acid/base titration: n=0.99
  • According to the 1H NMR: m=0.05.
    • Example A27: Preparation of Polysaccharide 27
  • Dilauryl aspartate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A18 using a dextran with a weight-average molecular weight of approximately 1 kg/mol (q=4, Pharmacosmos), modified by dilauryl aspartate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 27]=16.7 mg/g
  • According to the acid/base titration: n=1.41
  • According to the 1H NMR: m=0.16.
    • Example A28: Preparation of Polysaccharide 28
  • Dilauryl aspartate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A18 using a dextran with a weight-average molecular weight of approximately 1 kg/mol (q=4, Pharmacosmos), modified by dilauryl aspartate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 28]=25 mg/g
  • According to the acid/base titration: n=1.50
  • According to the 1H NMR: m=0.07.
    • Example A29: Preparation of Polysaccharide 29
  • Didecyl aspartate, para-toluenesulphonic acid salt, is obtained according to the process described in U.S. Pat. No. 4,826,818.
  • A sodium dextranmethylcarboxylate, synthesized according to the process described in Example A1 using a dextran with a weight-average molecular weight of approximately 1 kg/mol (q=4, Pharmacosmos), modified by didecyl aspartate, is obtained by a process similar to that described in Example A1.
  • According to the dry extract: [Polysaccharide 29]=15 mg/g
  • According to the acid/base titration: n=1.05
  • According to the 1H NMR: m=0.05.
    • EXAMPLES
  • Part B: Demonstration of the Properties of the Compositions According to the Invention
    • Example B1: Solution of Rapid-Acting Insulin Analogue (NovoLog®) at 100 IU/ml
  • This solution is a commercial solution of insulin aspart, sold by the company Novo Nordisk under the name of NovoLog® in the USA and Novorapid® in Europe. This product is a rapid-acting insulin analogue.
    • Example B2: Solution of Rapid-Acting Insulin Analogue (Humalog®) at 100 IU/ml
  • This solution is a commercial solution of insulin lispro, sold by the company Eli Lilly under the name of Humalog®. This product is a rapid-acting insulin analogue.
    • Example B3: Solution of Rapid-Acting Insulin Analogue (Apidra®) at 100 IU/ml
  • This solution is a commercial solution of insulin glulisine, sold by the company Sanofi-Aventis under the name of Apidra®. This product is a rapid-acting insulin analogue.
    • Example B4: Solution of Slow-Acting Insulin Analogue (Lantus®) at 100 IU/ml
  • This solution is a commercial solution of insulin glargine, sold by the company Sanofi-Aventis under the name of Lantus®. This product is a slow-acting insulin analogue.
    • Example B5: Solution of Human Insulin (ActRapid®) at 100 IU/ml
  • This solution is a commercial solution from Novo Nordisk, sold under the name of Actrapid®. This product is a human insulin.
    • Example B6: Dissolution of Lantus® at 100 IU/ml and at pH 7 Using a Substituted Dextran
  • 20 mg of Polysaccharide 4 described in Example A4 are weighed out accurately. This lyophilisate is taken up in 2 ml of Lantus® in its commercial formulation. A transient precipitate appears but the solution becomes clear after approximately 30 minutes. The pH of this solution is 6.3. The pH is adjusted to 7 with a 0.1N sodium hydroxide solution. This clear solution is filtered through a 0.22 μm filter and is then placed at +4° C.
    • Example B7: Preparation of a Substituted Dextran/Lantus®/Apidra® 75/25 Composition at pH 7
  • 0.25 ml of Apidra® (in its commercial formulation) is added to 0.75 ml of the Polysaccharide 4/Lantus® solution prepared in Example B6, in order to form 1 ml of a composition at pH 7. The composition is clear, testifying to the good solubility of Lantus® and Apidra® under these formulation conditions. This clear solution is filtered through a 0.22 μm filter and is then placed at +4° C.
    • Example B8: Preparation of a Substituted Dextran/Lantus®/Humalog® 75/25 Composition at pH 7
  • 0.25 ml of Humalog® (in its commercial formulation) is added to 0.75 ml of the Polysaccharide 4/Lantus® solution prepared in Example B6, in order to form 1 ml of a composition at pH 7. The composition is clear, testifying to the good solubility of Lantus® and Humalog® under these formulation conditions. This clear solution is filtered through a 0.22 μm filter and is then placed at +4° C.
    • Example B9: Preparation of a Substituted Dextran/Lantus®/NovoLog® 75/25 Composition at pH 7
  • 0.25 ml of NovoLog® (in its commercial formulation) is added to 0.75 ml of the Polysaccharide 4/Lantus® solution prepared in Example B6, in order to form 1 ml of a composition at pH 7. The composition is clear, testifying to the good solubility of Lantus® and NovoLog® under these formulation conditions. This clear solution is filtered through a 0.22 μm filter and is then placed at +4° C.
    • Example B10: Preparation of a Substituted Dextran/Lantus®/ActRapid® 75/25 Composition at pH 7
  • 0.25 ml of ActRapid® (in its commercial formulation) is added to 0.75 ml of the Polysaccharide 4/Lantus® solution prepared in Example B6, in order to form 1 ml of a composition at pH 7. The composition is clear, testifying to the good solubility of Lantus® and ActRapid® under these formulation conditions. This clear solution is filtered through a 0.22 μm filter and is then placed at +4° C.
    • Example B11: Preparation of a Substituted Dextran/Lantus®/Apidra® 60/40 Composition at pH 7
  • 0.4 ml of Apidra® (in its commercial formulation) is added to 0.6 ml of the Polysaccharide 4/Lantus® solution prepared in Example B6, in order to form 1 ml of a composition at pH 7. The composition is clear, testifying to the good solubility of Lantus® and Apidra® under these formulation conditions. This clear solution is filtered through a 0.22 μm filter and is then placed at +4° C.
    • Example B12: Preparation of a Substituted Dextran/Lantus®/Apidra® 40/60 Composition at pH 7
  • 0.6 ml of Apidra® (in its commercial formulation) is added to 0.4 ml of the Polysaccharide 4/Lantus® solution prepared in Example B6, in order to form 1 ml of a composition at pH 7. The composition is clear, testifying to the good solubility of Lantus® and Apidra® under these formulation conditions. This clear solution is filtered through a 0.22 μm filter and is then placed at +4° C.
    • Example B13: Precipitation of Lantus®
  • 1 ml of Lantus® is added to 2 ml of a PBS solution containing 20 mg/ml of BSA (bovine serum albumin). The PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears, which is in good agreement with the mechanism of operation of Lantus® (precipitation on injection due to the increase in the pH).
  • Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® is assayed in the supernatent. The result of this is that 86% of Lantus® is found in a precipitated form.
    • Example B14: Precipitation of a Substituted Dextran/Lantus® Composition
  • 1 ml of Polysaccharide 4/Lantus® solution prepared in Example B6 is added to 2 ml of a PBS solution containing 20 mg/ml of BSA (bovine serum albumin). The PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.
  • Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® is assayed in the supernatent. The result of this is that 85% of Lantus® is found in a precipitated form. This percentage of precipitation of Lantus® is identical to that obtained for the control described in Example B13.
  • Dissolution and precipitation tests identical to those described in Examples B6 and B14 were carried out with other substituted dextrans at the same concentration of 10 mg/ml of polysaccharide per 100 IU/ml of Lantus®. 20 mg of polysaccharide in the lyophilisate form are weighed out accurately. This lyophilisate is taken up in 2 ml of Lantus® in its commercial formulation. A transient precipitate appears but the solution becomes clear after approximately 30 minutes to a few hours (depending on the nature of the polysaccharide). The pH of this solution is 6.3. The pH is adjusted to 7 with a 0.1N sodium hydroxide solution. This clear solution is filtered through a 0.22 μm filter and is then placed at +4° C. The results are collated in Table 2.
  • TABLE 2
    Polysaccha- Dissolution Precipitation % of
    ride No. of Lantus ® of Lantus ® precipitation
    2 Yes Yes 85
    1 Yes Yes Not measured
    4 Yes Yes 87
    3 Yes Yes Not measured
    5 Yes Yes 94
    6 Yes Yes Not measured
    7 Yes Yes Not measured
    8 Yes Yes Not measured
    9 Yes Yes 94
    10 Yes Yes Not measured
    15 Yes Yes Not measured
    14 Yes Yes Not measured
    13 Yes Yes Not measured
    12 Yes Yes Not measured
    11 Yes Yes Not measured
    16 Yes Yes Not measured
    17 Yes Yes Not measured
    18 Yes Yes Not measured
    19 Yes Yes Not measured
    20 Yes Yes Not measured
    21 Yes Yes Not measured
    22 Yes Yes Not measured
    23 Yes Yes Not measured
    24 Yes Yes Not measured
    25 Yes Yes Not measured
    26 Yes Yes Not measured
    • Example B15: Precipitation of a Substituted Dextran/Lantus®/Apidra® 75/25 Composition at pH 7
  • 1 ml of the substituted dextran/Lantus®/Apidra® 75/25 composition (containing 7.5 mg/ml of polysaccharide, 75 IU/ml of Lantus® and 25 IU/ml of Apidra®) prepared in Example B7 is added to 2 ml of a PBS solution containing 20 mg/ml of BSA (bovine serum albumin). The PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.
  • Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® is assayed in the supernatent. The percentages of precipitation of Lantus® are similar to the control described in Example B13.
    • Example B16: Precipitation of Various Compositions, the Nature of the Substituted Dextran being Varied
  • Other tests under the same conditions as those of Example B15 were carried out in the presence of other substituted dextrans.
  • The results are combined in the following Table 3 and it is observed that the dissolution and the precipitation of Lantus® are retained.
  • TABLE 3
    Dissolution Percentage
    Polysaccha- Lantus ®/Apidra ® of precipitation
    ride No. 75/25 of Lantus ®
    2 Yes 85
    1 Yes Not measured
    4 Yes 87
    3 Yes Not measured
    5 Yes 86
    6 Yes Not measured
    7 Yes Not measured
    8 Yes Not measured
    9 Yes 86
    10 Yes 85
    15 Yes 87
    14 Yes 86
    13 Yes 88
    12 Yes 91
    18 Yes Not measured
    19 Yes Not measured
    20 Yes Not measured
    21 Yes Not measured
    22 Yes Not measured
    23 Yes Not measured
    24 Yes Not measured
    25 Yes Not measured
    26 Yes Not measured
    • Example B17: Precipitation of Various Compositions, the Nature of the Prandial Insulin being Varied
  • Compositions are prepared by mixing 0.75 ml of the Polysaccharide 4/Lantus® solution prepared in Example B6 with 0.25 ml of a prandial insulin in order to form 1 ml of substituted dextran/Lantus®/prandial insulin composition (containing 7.5 mg/mil of polysaccharide, 75 IU/ml of Lantus® and 25 IU/ml of prandial insulin).
  • This composition is added to 2 ml of PBS solution containing 20 mg/ml of BSA (bovine serum albumin). The PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.
  • Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® is assayed in the supernatent. In the presence of the four prandial insulins tested, Lantus® precipitates to approximately 90%. This percentage of precipitation of Lantus® is similar to the control described in Example B13; the results are collated in Table 4.
  • TABLE 4
    Dissolution Percentage
    Nature of the Lantus ®/prandial insulin of precipitation
    prandial insulin 75/25 of Lantus ®
    Apidra ® Yes 88
    NovoLog ® Yes 92
    Humalog ® Yes 89
    ActRapid ® Yes 90
    • Example B18: Preparation of a Concentrated Solution of Slow-Acting Insulin Analogue (Glargine)
  • A commercial solution of insulin glargine, sold by the company Sanofi-Aventis under the name of Lantus®, is concentrated by ultrafiltration through a 3 kDa membrane made of regenerated cellulose (Amicon® Ultra-15, sold by the company Millipore). On conclusion of this ultrafiltration stage, the concentration of insulin glargine is assayed in the retentate by reverse phase liquid chromatography (RP-HPLC). The final concentration of insulin glargine is subsequently adjusted by the addition of commercial 100 IU/ml glargine solution in order to obtain the desired final concentration. This process makes it possible to obtain concentrated solutions of glargine, denoted Cglargine, at various concentrations of greater than 100 IU/ml, such as Cglargine=200, 250, 300 and 333 IU/ml. The concentrated solutions are filtered through a 0.22 μm filter and then stored at +4° C.
    • Example B19: Dialysis of a Commercial Solution of Rapid-Acting Insulin Analogue (Lispro)
  • A commercial solution of insulin lispro, sold by the company Lilly under the name of Humalog® is dialyzed by ultrafiltration through a 3 kDa membrane made of regenerated cellulose (Amicon® Ultra-15, sold by the company Millipore). The dialysis is carried out in a 1 mM phosphate buffer at pH 7. On conclusion of this dialysis stage, the concentration Cdialyzed Humalog of lispro in the retentate is determined by reverse phase liquid chromatography (RP-HPLC). The dialyzed solution is stored in a freezer at −80° C.
    • Example B20: Lyophilization of a Solution of Rapid-Acting Insulin Analogue (Lispro) in its Commercial Form
  • A volume VHumalog of a solution of rapid-acting insulin lispro at a concentration of 100 IU/ml in its commercial form is placed in a Lyoguard® sterilized beforehand in an autoclave. The Lyoguard® is placed in a freezer at −80° C. for approximately 1 h before being subjected to lyophilization overnight at a temperature of 20° C. and a pressure of 0.31 mbar.
  • The sterile lyophilisate thus obtained is stored at ambient temperature.
    • Example B21: Lyophilization of a Dialyzed Commercial Solution of Rapid-Acting Insulin Analogue (Lispro)
  • A volume Vdialyzed Humalog of a solution of rapid-acting insulin lispro obtained according to Example B19 at a concentration of Cdialyzed Humalog is placed in a Lyoguard® sterilized beforehand in an autoclave. The Lyoguard® is placed in a freezer at −80° C. for approximately 1 h before being subjected to lyophilization overnight at a temperature of 20° C. and a pressure of 0.31 mbar.
  • The sterile lyophilisate thus obtained is stored at ambient temperature.
    • Example B22: Preparation of a Substituted Dextran/Glargine Composition at pH 7 Using a Substituted Dextran, According to a Process Using Glargine in the Liquid Form (in Solution) and a Polysaccharide in the Solid Form (Lyophilized)
  • A weight wpolys. of Polysaccharide 18 is weighed out accurately. This lyophilisate is taken up in a volume Vglargine of a concentrated solution of glargine prepared according to Example B18, so as to obtain a composition exhibiting a concentration of polysaccharide Cpolys. (mg/ml)=wpolys./Vglargine and a concentration of glargine Cglargine (IU/ml). The solution is opalescent. The pH of this solution is approximately 6.3. The pH is adjusted to 7 by addition of concentrated NaOH and then the solution is placed under static conditions in an oven at 37° C. for approximately 1 hour. A volume Vpolys./glargine of this visually clear solution is placed at +4° C.
    • Example B23: Preparation of a Substituted Dextran/Glargine Composition at pH 7 Using a Substituted Dextran, According to a Process Using Glargine in the Liquid Form (in Solution) and a Polysaccharide in the Liquid Form (in Solution)
  • Concentrated solutions of m-cresol, glycerol and tween 20 are added to a mother solution of polysaccharide 20 at pH 7 exhibiting a concentration Cpolys. mother, so as to obtain a polysaccharide solution having the concentration Cpolys. mother/excipients (mg/ml) in the presence of these excipients at contents equivalent to those described in the Lantus® commercial solution in a 10 ml bottle.
  • A volume VLantus of a commercial solution of slow-acting insulin glargine, sold under the name of Lantus® at a concentration de 100 IU/ml, is added to a volume Vpolys. mother/excipients of a polysaccharide solution at the concentration Cpolys. mother/excipients (mg/ml) in a sterile flask. A cloudiness appears. The pH is adjusted to pH 7 by addition of 1M NaOH and the solution is placed under static conditions in an oven at 37° C. for approximately 1 h. This visually clear solution is placed at +4° C.
    • Example B24: Preparation of a Concentrated Polysaccharide/Glargine Composition at pH=7 Using a Substituted Dextran, According to a Process for the Concentration of a Dilute Composition
  • A dilute Polysaccharide 20/glargine composition at pH 7 described in Example B23 is concentrated by ultrafiltration through a 3 kDa membrane made of regenerated cellulose (Amicon® Ultra-15, sold by the company Millipore). On conclusion of this ultrafiltration stage, the retentate is clear and the concentration of insulin glargine in the composition is assayed by reverse phase chromatography (RP-HPLC). If necessary, the concentration of insulin glargine in the composition is subsequently adjusted to the desired value by diluting in a solution of m-cresol/glycerol/tween 20 excipients exhibiting, for each entity, a concentration equivalent to that described in the Lantus® commercial solution (in a 10 ml bottle). This solution at pH 7, which is visually clear, exhibiting a glargine concentration Cglargine (IU/ml) and a polysaccharide concentration Cpolys. (mg/ml), is placed at +4° C.
    • Example B25: Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7, Starting from a Rapid-Acting Insulin Lispro in its Commercial Form
  • A volume Vpolysach./glargine of polysaccharide/glargine solution, pH 7, exhibiting a concentration of glargine Cglargine (IU/ml) and a concentration of Polysaccharide 18 Cpolys. (mg/ml), prepared according to Example B22, is added to an insulin lispro lyophilisate obtained by lyophilization of a volume Vlispro, the preparation of which is described in Example B19, so that the ratio Vpolysach./glargine/Vlispro=100/Clispro, where Clispro is the concentration of lispro (IU/ml) targeted in the composition. The solution is clear. The zinc content of the formulation is adjusted to the desired concentration Czinc (μM) by addition of a concentrated zinc chloride solution. The final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • The formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 μm filter and is placed at +4° C.
    • Example B26: Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7, Starting from a Rapid-Acting Insulin Lispro Obtained by Dialysis of a Commercial Solution
  • A volume Vpolysach./glargine of polysaccharide/glargine solution, pH 7, exhibiting a concentration of glargine Cglargine (IU/ml) and a concentration of Polysaccharide 20 Cpolys. (mg/ml), prepared according to Example B24, is added to an insulin lispro lyophilisate obtained by lyophilization of a volume Vdialyzed Humalog, the preparation of which is described in Example B21, so that the ratio Vpolysach./glargine/Vdialyzed Humalog=Cdialyzed Humalog Clispro, where Cdialyzed Humalog is the concentration of lispro (IU/ml) obtained on conclusion of the dialysis of the commercial solution, which stage is described in Example B19, and Clispro is the concentration of lispro (IU/ml) targeted in the composition. The solution is clear. The zinc content of the formulation is adjusted to the desired concentration Czinc (μM) by addition of a concentrated zinc chloride solution. The final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • The formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 μm filter and is placed at +4° C.
    • Example B27: Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 200 IU/ml and a Concentration of Lispro of 33 IU/ml (Proportion as Percentage of Insulin: 85/15 as Glargine/Lispro)
  • A concentrated 200 IU/ml glargine solution is prepared according to Example B18. A Polysaccharide 18 (13 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 18 according to the method of preparation described in Example B22. This Polysaccharide 18/glargine 200 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue in its commercial form, according to the method of preparation described in Example B25. The solution is clear. The zinc content of the formulation is adjusted to the concentration Czinc (μM)=750 μM by addition of a concentrated zinc chloride solution. The final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • This composition is described in Table 5.
    • Example B28: Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 200 IU/ml and a Concentration of Lispro of 66 IU/ml (Proportion as Percentage of Insulin: 75/25 as Glargine/Lispro)
  • A concentrated 200 IU/ml glargine solution is prepared according to Example B18. A Polysaccharide 18 (13 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 18 according to the method of preparation described in Example B22. This Polysaccharide 18/glargine 200 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue in its commercial form, according to the method of preparation described in Example B25. The solution is clear. The zinc content of the formulation is adjusted to the concentration Czinc (μM)=1500 μM by addition of a concentrated zinc chloride solution. The final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • The formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 μm filter and is placed at +4° C.
  • This composition is described in Table 5.
    • Example B29: Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 300 IU/ml and a Concentration of Lispro of 100 IU/ml (Proportion as Percentage of Insulin: 75/25 as Glargine/Lispro)
  • A concentrated 300 IU/ml glargine solution is prepared according to Example B18. A Polysaccharide 18 (23 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 18 according to the method of preparation described in Example B22. This Polysaccharide 18/glargine 300 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue in its commercial form, according to the method of preparation described in Example B25. The solution is clear. The zinc content of the formulation is adjusted to the concentration Czinc (μM)=2000 μM by addition of a concentrated zinc chloride solution. The final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • The formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 μm filter and is placed at +4° C.
  • This composition is described in Table 5.
    • Example B30: Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 250 IU/ml and a Concentration of Lispro of 150 IU/ml (Proportion as Percentage of Insulin: 63/37 as Glargine/Lispro)
  • A concentrated 300 IU/ml glargine solution is prepared according to Example B18. A Polysaccharide 18 (19 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 18 according to the method of preparation described in Example B22. This Polysaccharide 18/glargine 250 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue in its commercial form, according to the method of preparation described in Example B25. The solution is clear. The zinc content of the formulation is adjusted to the concentration Czinc (μM)=1500 μM by addition of a concentrated zinc chloride solution. The final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • The formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 μm filter and is placed at +4° C.
  • This composition is described in Table 5.
    • Example B31: Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 333 IU/ml and a Concentration of Lispro of 67 IU/ml (Proportion as Percentage of Insulin: 83/17 as Glargine/Lispro)
  • A concentrated 333 IU/ml glargine solution is prepared according to Example B18. A Polysaccharide 18 (20 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 18 according to the method of preparation described in Example B22. This Polysaccharide 18/glargine 333 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue in its commercial form, according to the method of preparation described in Example B25. The solution is clear. The zinc content of the formulation is adjusted to the concentration Czinc (μM)=2000 μM by addition of a concentrated zinc chloride solution. The final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • The formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 μm filter and is placed at +4° C.
  • This composition is described in Table 5.
    • Example B32: Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 300 IU/ml and a Concentration of Lispro of 100 IU/ml (Proportion as Percentage of Insulin: 75/25 as Glargine/Lispro)
  • A concentrated 300 IU/ml glargine solution is prepared according to Example B18. A Polysaccharide 19 (23 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 19 according to the method of preparation described in Example B22. This Polysaccharide 19/glargine 300 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue under its dialyzed form, according to the method of preparation described in Example B26. The solution is clear. The zinc content of the formulation is adjusted to the concentration Czinc (μM)=3000 μM by addition of a concentrated zinc chloride solution. The final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • The formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 μm filter and is placed at +4° C.
  • This composition is described in Table 5.
    • Example B33: Preparation of a Substituted Dextran/Glargine/Lispro Composition at pH 7 Exhibiting a Concentration of Glargine of 300 IU/ml and a Concentration of Lispro of 100 IU/ml (Proportion as Percentage of Insulin: 75/25 as Glargine/Lispro)
  • A Polysaccharide 20 (23 mg/ml)/glargine 300 IU/ml composition, pH 7, is prepared from Polysaccharide 20 according to the method of preparation described in Example B23. This Polysaccharide 20/glargine 300 IU/ml composition is added to an insulin lispro lyophilisate obtained by lyophilization of the solution of rapid-acting analogue resulting from the dialysis of a commercial solution, according to the method of preparation described in Example B26. The solution is clear. The zinc content of the formulation is adjusted to the concentration Czinc (μM)=1500 μM by addition of a concentrated zinc chloride solution. The final pH is adjusted to 7 by addition of concentrated NaOH or HCl.
  • The formulation is clear, testifying to the good solubility of glargine and lispro under these formulation conditions. This solution is filtered through a 0.22 μm filter and is placed at +4° C.
  • This composition is described in Table 5.
  • TABLE 5
    Substituted dextran/glargine/lispro compositions at pH 7
    Cglargine/
    Example Polysaccharide Cpolysach. Cglargine Clispro Clispro
    No. No. (mg/ml) (IU/ml) (IU/ml) (%/%) pH
    B27
    18 13 200 33 85/15 7
    B28 18 13 200 66 75/25 7
    B29 18 23 300 100 75/25 7
    B30 18 19 250 150 63/37 7
    B31 18 20 333 67 83/17 7
    B32 19 23 300 100 75/25 7
    B33 20 23 300 100 75/25 7
    • Example B34: Precipitation of Various Substituted Dextran/Glargine/Lispro Compositions at pH 7 Exhibiting Different Concentrations of Insulin Glargine and Insulin Lispro and Different Relative Proportions of the Two Insulins
  • 1 ml of substituted dextran/Lantus®/Humalog® composition prepared in Examples B27 to B33 is added to 2 ml of a PBS solution containing 20 mg/ml of BSA (bovine serum albumin). The PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.
  • Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® is assayed in the supernatent. The percentages of precipitation of Lantus® are similar to the control described in Example B13. The results are summarized in Table 6.
  • TABLE 6
    Dissolution
    of
    glargine
    Cglargine/ and of Precipitation
    Example Polysaccharide Cpolysach. Cglargine Clispro Clispro lispro at of %
    No. No. (mg/ml) (IU/ml) (IU/ml) (%/%) pH 7 glargine Precipitation
    B27
    18 13 200 33 85/15 YES YES 96
    B28 18 13 200 66 75/25 YES YES 86
    B29 18 23 300 100 75/25 YES YES 91
    B30 18 19 250 150 63/37 YES YES 90
    B31 18 20 333 67 83/17 YES YES 93
    B32 19 23 300 100 75/25 YES YES 98
    B33 20 23 300 100 75/25 YES YES Not
    measured
    • Example B35: Chemical Stability of the Compositions
  • The substituted dextran/Lantus®/prandial insulin compositions described in Examples B7, B27, B28 and B29 and the corresponding controls are placed at 30° C. for 4 weeks. Regulations require 95% of native (nondegraded) insulin after 4 weeks at 30° C.
  • After 4 weeks, the formulations studied meet the specifications defined by the regulations. The results are combined in Table 7.
  • TABLE 7
    Percentage of native Percentage of native
    glargine after prandial insulin after
    Compositions 4 weeks at 30° C. 4 weeks at 30° C.
    Lantus ® 97 na
    (commercial formulation)
    Apidra ® na 95
    (commercial formulation)
    Humalog ® na 98
    (commercial formulation)
    B7 96 98
    B27 97 99
    B28 95 97
    B29 98 100
  • Thus, whatever the formulation studied, a percentage of native insulin of greater than 95% is obtained, which is in accordance with regulatory requirements.
    • Example B36: Injectability of the Solutions
  • All the compositions prepared can be injected with the normal systems for the injection of insulin. The solutions described in Examples B7 to B12 and the compositions described in Examples B27 à B33 are injected without any difficulty, both with insulin syringes equipped with 31-gauge needles and with insulin pens from Novo Nordisk, sold under the name of Novopen®, equipped with 31-gauge needles.
    • Example B37: Protocol for Measuring the Pharmacodynamics of the Insulin Solutions
  • Preclinical studies were carried out on pigs for the purpose of evaluating two compositions according to the invention:
  • Lantus®/Apidra® (75/25), formulated with Polysaccharide 4 (6 mg/ml), described in Example B7, and
  • Lantus®/Humalog® (75/25), formulated with Polysaccharide 4 (6 mg/ml), described in Example B8.
  • The hypoglycaemic effects of these compositions were compared with respect to injections carried out with simultaneous but separate injections of Lantus® (pH 4) and then of a prandial insulin Apidra® or Humalog®.
  • Six domesticated pigs weighing approximately 50 kg, catheterized beforehand in the jugular vein, are deprived of food for 2 to 3 hours before the beginning of the experiment. In the hour preceding the injection of insulin, three blood samples are taken in order to determine the basal glucose level.
  • Injection of insulin at a dose of 0.4 IU/kg is carried out by subcutaneous injection into the neck, under the ear of the animal, using the Novopen® insulin pen equipped with at 31 G needle.
  • Blood samples are subsequently taken after 4, 8, 12, 16, 20, 30, 40, 50, 60, 90, 120, 240, 360, 480, 600, 660 and 720 minutes. After each sample has been taken, the catheter is rinsed with a dilute heparin solution.
  • A drop of blood is taken in order to determine the glycaemia using a glucose meter. The pharmacodynamic curves of glucose are subsequently plotted.
  • The results obtained are presented in the form of pharmacodynamic curves for glucose represented in FIGS. 1 to 6.
  • Lantus®/Apidra® (75/25), formulated with Polysaccharide 4 (6 mg/ml).
  • FIG. 1: Mean+standard deviation of the mean curves for the sequential administrations of Apidra® and Lantus®, in comparison with a composition according to the invention Polysaccharide 4/Lantus®/Apidra® (75/25).
  • FIG. 2: Apidra® Lantus® individual curves.
  • FIG. 3: Polysaccharide 4/Apidra®/Lantus® individual curves.
  • FIG. 1 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the pigs tested for each formulation. The drop in glycaemia in the first 30 minutes is similar for the two formulations, indicating that the presence of a polysaccharide does not interfere with the rapid-acting nature of Apidra®.
  • On the other hand, between 90 min and 10 h (600 minutes), the sequential administration of Apidra® and Lantus® brings about a heterogeneous drop in glucose with a homogeneous plateau response with regard to three pigs and a heterogeneous response with regard to the other three pigs (FIG. 2). In contrast, the six pigs tested with the Polysaccharide 4/Apidra®/Lantus® formulation have a homogeneous response (FIG. 3). This is reflected by the analysis of the coefficients of variation (CV) between 60 min and 10 h, which are on average 54% (between 21% and 113%) for the Apidra® Lantus® control and 12% (between 5% and 25%) for Polysaccharide 4/Apidra®/Lantus®.
  • Lantus®/Humalog® (75/25), formulated with Polysaccharide 4 (6 mg/ml).
  • FIG. 4: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® and Lantus® in comparison with the administration of a composition according to the invention Polysaccharide 4/Humalog®/Lantus®.
  • FIG. 5: Humalog® Lantus® individual curves.
  • FIG. 6: Polysaccharide 4/Humalog®/Lantus® individual curves.
  • FIG. 4 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the pigs tested with regard to each formulation. The drop in glycaemia in the first 30 minutes is similar for the two formulations, indicating that the presence of Polysaccharide 4 does not interfere with the rapid-acting nature of Humalog®. On the other hand, between 60 min and 8 h (480 minutes), the sequential administration of Humalog® and Lantus® brings about a heterogeneous drop in glucose with a homogeneous plateau response with regard to four pigs and a heterogeneous response with regard to the other two pigs (FIG. 5). In contrast, the 5 pigs tested with the Polysaccharide 4/Humalog®/Lantus® formulation have a homogeneous response (FIG. 6). This is reflected by the analysis of the coefficients of variation (CV) with regard to the data for drop in glycaemia between 60 min and 8 h, which are on average 54% (between 31% and 72%) for the Humalog® Lantus® control and 15% (between 6% and 28%) for Polysaccharide 4/Humalog®/Lantus®. The presence of Polysaccharide 4 thus greatly reduced the variability of Lantus® with regard to the drop in glycaemia.
    • Example B38: Protocol for Measuring the Pharmacodynamics of the Insulin Solutions
  • Preclinical studies were carried out on dogs for the purpose of evaluating six compositions according to the invention:
  • The hypoglycaemic effects of these compositions were compared with respect to injections carried out with simultaneous but separate injections of 100 IU/ml Lantus® (pH 4) and then of a prandial insulin 100 IU/ml Humalog®.
  • Ten domesticated dogs (beagles) weighing approximately 12 kg are deprived of food for 18 hours before the beginning of the experiment. In the hour preceding the injection of insulin, three blood samples are taken in order to determine the basal glucose level.
  • The injection of insulin at a dose of 0.53 IU/kg (unless otherwise mentioned in the examples below) is carried out by subcutaneous injection into the neck of the animal using the Novopen® insulin pen equipped with a 31 G needle.
  • Blood samples are subsequently taken after 10, 20, 30, 40, 50, 60, 90, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720, 780, 840, 900 and 960 minutes. The first samples are taken with a catheter (up to 180 min) and then directly from the jugular vein. After each sample has been taken, the catheter is rinsed with a dilute heparin solution.
  • A drop of blood is taken in order to determine the glycaemia by means of a glucose meter. The pharmacodynamic curves for glucose are subsequently plotted.
  • The results obtained are presented in the form of pharmacodynamic curves for glucose represented in FIGS. 7 to 12.
    • The Solution of Example B28
  • FIG. 7: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg), in comparison with a composition according to the invention described in Example B28 (0.53 IU/kg).
  • FIG. 7 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation. The two curves are similar up to 12 hours with a rapid drop in glycaemia, indicating that the polysaccharide does not influence the rapid-acting effect of Humalog®, a marked return between the peak due to Humalog® and the plateau due to glargine, and then a plateau of the glargine up to 12 h, indicating that the basal effect of glargine is well retained.
    • The Solution of Example B27
  • FIG. 8: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) in comparison with a composition according to the invention described in Example B27 (0.47 IU/kg).
  • FIG. 8 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation. In this comparison, the dose of basal insulin (Lantus®) is identical whereas the dose of Humalog® is half for the composition, with respect to the control. The drop in glucose is greater in the case of the formulation B27 in comparison with the control, whereas this control contains twice as much Humalog®. On the other hand, the duration of the plateau is shorter in the case of the combination, with respect to the control. This indicates that, in this composition, a portion of Lantus® is not precipitated on injection and acts with Humalog®.
    • The Solution of Example B29
  • FIG. 9: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) in comparison with a composition according to the invention described in Example B29 (0.53 IU/kg).
  • FIG. 9 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation. The two curves are similar, with a rapid drop in glycaemia, indicating that the polysaccharide does not influence the rapid-acting effect of Humalog®, a marked return between the peak due to Humalog® and the plateau due to Lantus®, and then a plateau of the Lantus® up to 13 h, indicating that the basal effect of glargine is well retained.
    • The Solution of Example B31
  • FIG. 10: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg), in comparison with a composition according to the invention described in Example B31 (0.48 IU/kg).
  • FIG. 10 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation. In this comparison, the dose of basal insulin (Lantus®) is identical, whereas the dose of Humalog® is half, for the composition, with respect to the control. The drop in glucose is greater in the case of the control, with respect to the combination corresponding to Example B31. This response was expected, in view of the concentration of Humalog® in the combination, which was half that of the control. Furthermore, the duration of the Lantus® plateau is identical in the case of the combination, with respect to the control. This indicates that, in this composition and by comparison with the composition described in Example B29 (FIG. 9), it is possible to adjust the amount of Humalog® in the combination without modifying the Lantus® basal effect.
    • The Solution of Example B30
  • FIG. 11: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.24 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) in comparison with a composition according to the invention described in Example B30 (0.64 IU/kg).
  • FIG. 11 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation. The two curves are similar, with a rapid drop in glycaemia, indicating that the polysaccharide does not influence the rapid-acting effect of Humalog®, a marked return between the peak due to Humalog® and the plateau due to Lantus®, and then a plateau of the Lantus® up to 10 h, indicating that the glargine basal effect is well retained.
    • The Solution of Example B32
  • FIG. 12: Mean+standard deviation of the mean curves for the sequential administrations of Humalog® (100 IU/ml, 0.13 IU/kg) and Lantus® (100 IU/ml, 0.4 IU/kg) in comparison with a composition according to the invention described in Example B32 (0.53 IU/kg).
  • FIG. 12 presents the mean curves for drop in glycaemia and the standard deviations of the mean for the dogs tested for each formulation. The two curves are similar up to 10 hours, with a rapid drop in glycaemia, indicating that the polysaccharide does not influence the rapid-acting effect of Humalog®, a marked return between the peak due to Humalog® and the plateau due to Lantus®, and then a glargine plateau, indicating that the glargine basal effect is retained up to 10 h.
  • In conclusion, FIGS. 7 to 12 show that, by adjusting the composition of the polysaccharide and the concentrations of lispro and glargine, it is possible to obtain profiles identical to a double injection with different proportions of rapid-acting insulin and basal insulin. It is also possible to adjust the duration of the basal insulin without impacting the rapid-acting insulin or to adjust the amount of rapid-acting insulin without impacting the effect of the basal insulin.
    • EXAMPLES
  • Part C: Demonstration of the Properties of the Compositions Comprising a GLP-1 Analogue or Derivative According to the Invention
    • Example C1: 0.25 mg/ml Solution of GLP-1 Analogue Exenatide (Byetta®)
  • This solution is an exenatide solution marketed by the company Eli Lilly and Company under the name of Byetta®.
    • Example C2: 6 mg/ml Solution of GLP-1 Derivative Liraglutide (Victoza®)
  • This solution is a liraglutide solution marketed by the company Novo Nordisk under the name of Victoza®.
    • Example C3: Dissolution of Lantus® at 100 IU/Ml and at pH 7 Using a Substituted Dextran at a Concentration of 10 mg/ml
  • 20 mg of a substituted dextran chosen from those described in Table 1 are weighed out accurately. This lyophilisate is taken up in 2 ml of the insulin glargine solution of Example B4 in order to obtain a solution whose polysaccharide concentration is equal to 10 mg/ml. After mechanically stirring on rolls at ambient temperature, the solution becomes clear. The pH of this solution is 6.3. The pH is adjusted to 7 with a 0.1N sodium hydroxide solution. This clear solution is filtered through a membrane (0.22 μm) filter and is then placed at +4° C.
  • Generalization: Clear solutions of Lantus at 100 IU/ml and at pH 7 were also obtained with concentrations of substituted dextrans at 20 and 40 mg/ml by following the same protocol as that described in Example C3. Thus, a weight of lyophilized polysaccharide among those described in Table 1 is weighed out accurately. This lyophilisate is taken up in the insulin glargine solution of Example B4, so as to obtain a solution whose concentration of substituted dextran is 20 or 40 mg/ml, as described in Table 8. After mechanical stirring on rolls at ambient temperature, the solution becomes clear. The pH of this solution is less than 7. The pH is subsequently adjusted to 7 with a 0.1N sodium hydroxide solution. This clear final solution is filtered through a membrane (0.22 μm) and is then placed at +4° C.
  • TABLE 8
    Preparation of a solution of Lantus ® at 100 IU/ml and at pH 7 using
    a substituted dextran at a concentration of 10, 20 or 40 mg/ml
    Volume of the insulin
    Final concentration of Weight of substituted glargine solution of
    substituted dextran dextran weighed out Example B4 added
    (mg/ml) (mg) (ml)
    10 20 2
    20 40 2
    40 80 2
    • Example C4: Preparation of a Lantus®/Byetta® 70/30 Composition at pH 7.5
  • 0.09 ml of the exenatide solution of Example C1 is added to 0.21 ml of the insulin glargine solution of Example B4, in order to obtain 0.3 ml of composition whose pH is 4.5 on mixing. The composition, which contains 70 IU/ml of Lantus® and 0.075 mg/ml of Byetta®, is clear, testifying to the good solubility of Lantus® and Byetta® under these formulation conditions (pH 4.5). The pH is subsequently adjusted to 7.5 with a 0.1N sodium hydroxide solution. The composition then becomes cloudy, testifying to the poor solubility of the Lantus®/Byetta® composition at pH 7.5.
  • 70/30 Lantus®/Byetta® compositions were also prepared at pH 4.5, 5.5, 6.5, 8.5 and 9.5 by following a protocol similar to that described in Example C4. For each of these compositions, 0.09 ml of the exenatide solution of Example C1 is added to 0.21 ml of the insulin glargine solution of Example B4, in order to obtain 0.3 ml of a composition whose pH is 4.5 on mixing. The composition is clear, testifying to the good solubility of Lantus® and Byetta® under these formulation conditions (pH 4.5). The pH is adjusted to 5.5 or 6.5 or 8.5 or 9.5 with a 0.1N sodium hydroxide solution. After adjusting the pH, the composition at 5.5 is slightly cloudy, the compositions at 6.5-7.5 and 8.5 are very cloudy and the composition at pH 9.5 is clear. These compositions are placed at +4° C. for 48 h. After 48 h at +4° C., only the composition at pH 4.5 remains clear. The visual appearance after 48 h of the 70/30 Lantus®/Byetta® compositions at different pH values is summarized in Table 9.
  • TABLE 9
    Visual appearance after 48 h of the 70/30
    Lantus ®/Byetta ® compositions at different pH values
    70/30 Lantus ®/Byetta ® compositions at different pH values
    pH Visual appearance at t = 48 h
    4.5 Clear
    5.5 Presence of a precipitate
    6.5 Presence of a precipitate
    7.5 Presence of a precipitate
    8.5 Presence of a precipitate
    9.5 Presence of a precipitate
    • Example C5: Preparation of the 70/30 Lantus®/Victoza® Composition at pH 7.5
  • 0.09 ml of the liraglutide solution of Example C2 is added to 0.21 ml of the insulin glargine solution of Example B4, in order to obtain 0.3 ml of a composition whose pH is 7 on mixing. The composition, which contains 70 IU/ml of glargine and 1.8 mg/ml of liraglutide, is cloudy, testifying to the poor solubility of the Lantus®/Victoza® composition under these formulation conditions. The pH is adjusted to 7.5 with a 0.1N sodium hydroxide solution. After adjusting the pH, the composition remains cloudy. This composition is placed at +4° C. for 48 h.
  • 70/30 Lantus®/Victoza® compositions were also prepared at pH 4.5-5.5-6.5-8.5 and 9.5 by following a protocol similar to that described in Example C5. For each of these compositions, 0.09 ml of the liraglutide solution of Example C1 is added to 0.21 ml of the insulin glargine solution of Example B4, in order to obtain 0.3 ml of a composition whose pH is 7. The composition is cloudy, testifying to the poor solubility of the Lantus®/Victoza® composition under these formulation conditions (pH 7). The pH is adjusted to 4.5 or 5.5 or 6.5 with a 0.1N hydrochloric acid solution or to pH 9.5 with a 0.1N sodium hydroxide solution. After adjusting the pH, the compositions at pH 4.5-5.5 and 6.5 are cloudy, testifying to the poor solubility of the Lantus®/Victoza® composition under these formulation conditions. These compositions are placed at +4° C. for 48 h. After 48 h at 4° C., only the composition at pH 9.5 is clear. The visual appearance after 48 h of the 70/30 Lantus®/Victoza® compositions of different pH values is summarized in Table 10.
  • TABLE 10
    Visual appearance after 48 h of the 70/30
    Lantus ®/Victoza ® compositions at different pH values
    70/30 Lantus ®/Victoza ® compositions at different pH values
    pH Visual appearance at t = 48 h
    4.5 Presence of a precipitate
    5.5 Presence of a precipitate
    6.5 Presence of a precipitate
    7.5 Presence of a precipitate
    8.5 Presence of a precipitate
    9.5 Clear
    • Example C6: Preparation of a Substituted Dextran-70/30 Lantus®/Byetta® Composition at pH 7
  • 0.09 ml of the exenatide solution of Example C1 is added to 0.21 ml of the substituted dextran/Lantus® solution prepared in Example C3, in order to obtain 0.3 ml of a composition at pH 5.3. The pH is adjusted to 7 with a 0.1N sodium hydroxide solution. The composition, which contains 7 mg/ml of polysaccharide, 70 IU/ml of Lantus® and 0.075 mg/ml of Byetta® is clear, testifying to the good solubility of Lantus® and Byetta® in the presence of the substituted dextran at pH 7. This clear solution is placed at +4° C.
  • Generalization: Substituted dextran-Lantus®/Byetta® compositions at pH 7 were also prepared at ratios by volume VLantus/VByetta of 90/10, 50/50, 30/70 and 10/90 by following the same protocol as that described in Example C6. Thus, a volume VByetta of the exenatide solution of Example C1 is added to a volume VLantus of the substituted dextran/Lantus® solution prepared in Example C3, in order to obtain a composition whose pH is adjusted at 7 with a 0.1N sodium hydroxide solution. The compositions obtained (see Table 11) are clear, testifying to the good solubility of Lantus® and Byetta® in the presence of a substituted dextran at pH 7. These clear solutions are placed at +4° C.
    • Example C7: Preparation of a Substituted Dextran-100/50 Lantus®/Byetta® Composition at pH 7
  • 0.150 ml of the exenatide solution of Example C1 is lyophilized and then 0.3 ml of a substituted dextran/Lantus® solution prepared in Example C3 are added to the lyophilisate in order to obtain a composition whose pH is adjusted to 7 with a 0.1N sodium hydroxide solution. The composition, which contains 10 mg/ml of polysaccharide, 100 IU/ml of Lantus® and 0.125 mg/ml of Byetta®, is clear, testifying to the good solubility of Lantus® and Byetta® in the presence of the substituted dextran at pH 7. This clear solution is placed at +4° C.
  • TABLE 11
    Final concentrations of Lantus ®, substituted dextran and Byetta ® of
    the compositions obtained in Examples C6 and C7
    Lantus ® [Polysaccharide No.] Byetta ®
    IU/ml mg/ml (mg/ml) (mg/ml)
    100/50  100 3.5 10 0.125
    90/10 90 3.15 9 0.025
    70/30 70 2.45 7 0.075
    50/50 50 1.75 5 0.125
    30/70 30 1.05 3 0.175
    • Example C8: Preparation of a Substituted Dextran-70/30 Lantus®/Victoza® Composition at pH 7
  • 0.09 ml of the liraglutide solution of Example C2 is added to 0.21 ml of the substituted dextran/Lantus® solution prepared in Example C3, in order to obtain 0.3 ml of a composition at pH 7.6. The pH is adjusted to 7 with a 0.1N hydrochloric acid solution. The composition, which contains 7 mg/ml of polysaccharide, 70 IU/ml of Lantus® and 1.8 mg/ml of Victoza®, is clear, testifying to the good solubility of Lantus® and Victoza® in the presence of the substituted dextran at pH 7. This clear solution is placed at +4° C.
  • Generalization: Substituted dextran-Lantus®/Victoza® compositions at pH 7 have also been prepared at VLantus/VVictoza ratios by volume of 90/10, 50/50, 30/70, and 90/10 by following the same protocol as that described in Example C6. Thus, a volume VVictoza of the liraglutide solution of Example C2 is added to a volume VLantus of the substituted dextran/Lantus® solution prepared in Example B3, in order to obtain a composition whose pH is adjusted to 7 with a 0.1N hydrochloric acid solution.
  • The compositions obtained (see Table 12) are clear, testifying to the good solubility of Lantus® and Victoza® in the presence of a substituted dextran at pH 7. These clear solutions are placed at +4° C.
    • Example C9: Preparation of a Substituted Dextran-100/50 Lantus®/Victoza® Composition at pH 7
  • 0.150 ml of the liraglutide solution of Example C2 is lyophilized and then 0.3 ml of a substituted dextran/Lantus® solution prepared in Example C3 is added to the lyophilisate, in order to obtain a composition whose pH is adjusted to 7 with a 0.1N sodium hydroxide solution. The composition, which contains 10 mg/ml of polysaccharide, 100 IU/ml of Lantus® and 3 mg/ml of Victoza®, is clear, testifying to the good solubility of Lantus® and Victoza® in the presence of the substituted dextran at pH 7. This clear solution is placed at +4° C.
  • TABLE 12
    Final concentrations of Lantus ®, substituted dextran and Victoza ® of
    the compositions obtained in Examples C8 and C9
    Lantus ® [Polysaccharide No.] Victoza ®
    IU/ml mg/ml (mg/ml) (mg/ml)
    100/50  100 3.5 10 3
    90/10 90 3.15 9 0.6
    70/30 70 2.45 7 1.8
    50/50 50 1.75 5 3
    30/70 30 1.05 3 4.2
    • Example C10: Preparation of a Substituted Dextran-60/20/20 Lantus®/Apidra®/Byetta® Composition at pH 7
  • 20 mg of lyophilized Polysaccharide 4 described in Example A3 are weighed out accurately. This lyophilisate is taken up in 2 ml of the insulin glargine solution of Example B4. After mechanical stirring on rolls at ambient temperature, the solution becomes clear. The pH of this solution is 6.3. The pH is adjusted to 7 with a 0.1N sodium hydroxide solution. 0.2 ml of the exenatide solution of Example C1 and 0.2 ml of the insulin glulisine solution of Example B3 are added to 0.6 ml of the substituted dextran/Lantus® solution prepared above, in order to obtain 1 ml of a composition at pH 7. The composition, which contains 6 mg/ml of polysaccharide, 60 IU/ml of Lantus®, 20 IU/ml Apidra® and 0.05 mg/ml of Byetta®, is clear, testifying to the good solubility of Lantus®, Apidra® and Byetta® in the presence of substituted dextran at pH 7. This clear solution is filtered through a membrane (0.22 μm) and is then placed at +4° C.
    • Example C11: Precipitation of Lantus®
  • 0.250 ml of Lantus® is added to 0.5 ml of a PBS (Phosphate Buffer Solution) solution containing 20 mg/ml of BSA (Bovine Serum Albumin). The PBS/BSA mixture simulates the composition of the subcutaneous medium.
  • A precipitate appears, which is in good agreement with the mechanism of operation of Lantus® (precipitation on injection due to the increase in the pH).
  • Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® is assayed in the supernatent. The result of this is that 90% of Lantus® is found in a precipitated form.
    • Example C12: Precipitation of a Substituted Dextran/Lantus® Composition
  • 0.250 ml of substituted dextran/Lantus® solution prepared in Example C3 is added to 0.5 ml of a PBS solution containing 20 mg/ml of BSA. The PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.
  • Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® is assayed in the supernatent. The result of this is that 90% of Lantus® is found in a precipitated form. This percentage of precipitation of Lantus® is identical to that obtained for the control described in Example C11.
    • Example C13: Precipitation of a Substituted Dextran-Lantus®/Byetta® Composition
  • 0.250 ml of the substituted dextran-Lantus®/Byetta® composition prepared in Example C6 is added to 0.5 ml of a PBS solution containing 20 mg/ml of BSA. The PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.
  • Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® and Byetta® are assayed in the supernatent. The percentage of precipitation of Lantus® is similar to the control described in Example C11.
    • Example C14: Precipitation of a Substituted Dextran-70/30 Lantus®/Victoza® Composition
  • 0.250 ml of the substituted dextran-Lantus®/Victoza® composition prepared in Example C8 is added to 0.5 ml of a PBS solution containing 20 mg/ml of BSA (bovine serum albumin). The PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears. Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® and Victoza® are assayed in the supernatent. The percentage of precipitation of Lantus® is similar to the control described in Example C11.
    • Example C15: Precipitation of Different Compositions, the Nature of the Substituted Dextran being Varied
  • Other tests under the same conditions as those of Examples C13 and C14 were carried out in the presence of other dextrans.
  • Results with at most 20 mg/ml of substituted dextran and a 70/30 Lantus®/Byetta® composition are combined in the following Table 13. It is observed that the dissolution and the precipitation of Lantus® are retained.
  • TABLE 13
    Results of the dissolution and precipitation tests
    obtained with at most 20 mg/ml of substituted dextran
    and a 70/30 Lantus ®/Byetta ® composition
    Dissolution Percentage
    Polysaccha- 70/30 of precipitation
    ride No. Lantus ®/Byetta ® of Lantus ®
    1 Yes 94
    2 Yes 96
    5 Yes 88
    7 Yes 95
    10 Yes Not measured
    11 Yes 81
    14 Yes Not measured
    16 Yes 96
    26 Yes 81
    27 Yes 96
    28 Yes 96
    29 Yes 95
  • Results with at most 20 mg/ml of substituted dextran and various Lantus®/Byetta® compositions are combined in the following Table 14. It is observed that the dissolution and the precipitation of Lantus® are retained.
  • TABLE 14
    Results of the dissolution and precipitation tests
    obtained with at most 20 mg/ml of substituted dextran
    and various Lantus ®/Byetta ® compositions
    Ratio Dissolution Percentage
    Polysaccha- Lantus ®/ Lantus ®/ of precipitation
    ride No. Byetta ® Byetta ® of Lantus ®
    4 100/50  Yes 95
    4 90/10 Yes 94
    4 70/30 Yes 95
    4 50/50 Yes 90
    4 30/70 Yes 82
    8 100/50  Yes 96
    8 90/10 Yes 94
    8 70/30 Yes 96
    8 50/50 Yes 90
    8 30/70 Yes 81
  • Results with at most 40 mg/ml of substituted dextran and a 70/30 Lantus®/Victoza® composition are combined in the following Table 15. It is observed that the dissolution and the precipitation of Lantus® are retained.
  • TABLE 15
    Results of the dissolution and precipitation tests
    obtained with at most 40 mg/ml of substituted dextran
    and a 70/30 Lantus ®/Victoza ® composition
    Dissolution Percentage
    Polysaccha- 70/30 of precipitation
    ride No. Lantus ®/Victoza ® of Lantus ®
    1 Yes 95
    2 Yes 97
    5 Yes Not measured
    7 Yes 97
    10 Yes Not measured
    11 Yes Not measured
    14 Yes 90
    16 Yes 97
    26 Yes 74
    27 Yes 96
    28 Yes 95
    29 Yes 94
  • Results with at most 20 mg/ml of substituted dextran and various Lantus®/Victoza® compositions are combined in the following Table 16. It is observed that the dissolution and the precipitation of Lantus® are retained.
  • TABLE 16
    Results of the dissolution and precipitation tests
    obtained with at most 20 mg/ml of substituted dextran
    and various Lantus ®/Victoza ® compositions
    Ratio Dissolution Percentage
    Polysaccha- Lantus ®/ Lantus ®/ of precipitation
    ride No. Victoza ® Victoza ® of Lantus ®
    4 90/10 Yes 94
    4 70/30 Yes Not measured
    4 50/50 Yes 90
    4 30/70 Yes 86
    8 100/50  Yes 93
    8 90/10 Yes 95
    8 70/30 Yes 98
    8 50/50 Yes 89
    8 30/70 Yes 85
    • Example C16: Precipitation of a Substituted Dextran-60/20/20 Lantus®/Apidra®/Byetta® Composition at pH 7
  • 0.250 ml of the substituted dextran-Lantus®/Apidra®/Byetta® composition prepared in Example C10 is added to 0.5 ml of a PBS solution containing 20 mg/ml of BSA. The PBS/BSA mixture simulates the composition of the subcutaneous medium. A precipitate appears.
  • Centrifuging at 4000 rev/min is carried out in order to separate the precipitate from the supernatent. Subsequently, Lantus® is assayed in the supernatent. The percentage of precipitation of Lantus® is similar to the control described in Example C11.

Claims (26)

1. A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, comprising at least:
a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and
b) dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals of formula I or of formula II:
Figure US20180311316A1-20181101-C00042
in which:
R is —OH or chosen from the group consisting of the radicals:
-(f-[A]-COOH)n; and
-(g-[B]-k-[D])m, D comprising at least one alkyl chain comprising at least 8 carbon atoms; wherein:
n represents the degree of substitution of the glucoside units by -f-[A]-COOH and 0.3≤n≤2;
m represents the degree of substitution of the glucoside units by -g-[B]-k-[D] and 0.02<m≤0.2;
q represents the degree of polymerization as glucoside units, that is to say the mean number of glucoside units per polysaccharide chain, and 3≤q≤40;
-A- is a linear or branched radical comprising from 1 to 4 carbon atoms; the said -A- radical:
being bonded to a glucoside unit via a functional group f chosen from the group consisting of ether, ester and carbamate functional groups;
-B- is a linear or branched, at least divalent, radical comprising from 1 to 4 carbon atoms; the said -B- radical:
being bonded to a glucoside unit via a functional group g chosen from the group consisting of ether, ester and carbamate functional groups;
being bonded to a -D radical via a functional group k; k chosen from the group consisting of ester, amide and carbamate functional groups; the said -D radical:
being an -X(-l-Y)p radical, X being an at least divalent radical comprising from 1 to 12 atoms chosen from the group consisting of C, N and O atoms, optionally carrying carboxyl or amine functional groups; Y being a linear or cyclic alkyl group, an alkylaryl or an arylalkyl, of 8 to 30 carbon atoms, optionally substituted by one or several C1 to C3 alkyl groups; p≥1 and 1 a functional group chosen from the group consisting of ester, amide and carbamate functional groups;
f, g and k being identical or different;
the free acid functional groups being in the form of salts of alkali metal cations chosen from the group consisting of Na+ and K+;
and, when p=1, if Y is a C8 to C14 alkyl, then q*m≥2, if Y is a C15 alkyl, then q*m≥2; if Y is a C16 to C20 alkyl, then q*m≥1; and if Y is a C21 to C30 group, then q*m≥1;
and, when p≥2, if Y is a C8 to C9 alkyl, then q*m≥2 and, if Y is a C10 to C16 alkyl, then q*m≥0.2;
Figure US20180311316A1-20181101-C00043
in which:
R is —OH or a -(f-[A]-COOH)n radical:
-A- is a linear or branched radical comprising from 1 to 4 carbon atoms; the said radical -A-:
being bonded to a glucoside unit via a functional group f chosen from the group consisting of ether, ester or carbamate functional groups;
n represents the degree of substitution of the glucoside units by -f-[A]-COOH and 0.3≤n≤2;
R′ is chosen from the group consisting of the radicals:
—C(O)NH-[E]-(o-[F])t; and
—CH2N(L)z-[E]-(o-[F])t;
in which:
z is a positive integer equal to 1 or 2,
L is chosen from the group consisting of:
—H and z is equal to 1, and/or
-[A]-COOH and z is equal to 1 or 2, if f is an ether functional group,
—CO-[A]-COOH and z is equal to 1 if f is an ester functional group, and
—CO—NH-[A]-COOH and z is equal to 1 if f is a carbamate functional group;
-[E]-(o-[F])t:
-E- is a linear or branched, at least divalent, radical comprising from 1 to 8 carbon atoms and optionally comprising heteroatoms, such as O, N or S;
-F- is a linear or cyclic alkyl group, an alkylaryl or an arylalkyl, of 12 to 30 carbon atoms, optionally substituted by one or several C1 to C3 alkyl groups;
o is a functional group chosen from the group consisting of ether, ester, amide or carbamate functional groups;
t is a positive integer equal to 1 or 2;
q represents the degree of polymerization as glucoside units, that is to say the mean number of glucoside units per polysaccharide chain, and 3≤q≤40;
the free acid functional groups being in the form of salts of alkali metal cations chosen from the group consisting of Na+ and K+; and
when z=2, the nitrogen atom is in the form of a quaternary ammonium.
2. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the dextran polymers of formula I.
3. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the dextran polymers of formula II.
4. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the dextran polymers of formula I in which the -(f-[A]-COOH)n radical is chosen from the group consisting of the following sequences, f having the meaning given above:
Figure US20180311316A1-20181101-C00044
5. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the dextran polymers of formula I in which the -(g-[B]-k-[D])m radical is chosen from the group consisting of the following sequences, g, k and D having the meanings given above:
Figure US20180311316A1-20181101-C00045
6. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the dextran polymers of formula I in which the -(g-[B]-k-[D])m radical is such that:
-B- is a radical comprising one carbon atom; the said -B- radical being bonded to a glucoside unit via an ether functional group g, and X is a radical resulting from an amino acid.
7. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the dextran polymers of formula I in which the X radical is an at least divalent radical resulting from an amino acid chosen from the group consisting of glycine, leucine, phenylalanine, lysine, isoleucine, alanine, valine, aspartic acid and glutamic acid.
8. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the dextran polymers of formula I in which the Y group is chosen from the group consisting of a hydrophobic alcohol, a hydrophobic acid, a sterol or a tocopherol.
9. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the dextran polymers of formula I in which the Y group is a sterol chosen from cholesterol derivatives.
10. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the dextran polymers of formula II in which the R′ group is such that the -E- radical results from a diamine.
11. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the dextran polymers of formula II in which the R′ group is such that the -F- group results from a cholesterol derivative.
12. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the group consisting of the following dextran polymers of formula I:
Sodium dextranmethylcarboxylate modified by octyl glycinate,
Sodium dextranmethylcarboxylate modified by cetyl glycinate,
Sodium dextranmethylcarboxylate modified by octyl phenylalaninate,
Sodium dextranmethylcarboxylate modified by 3,7-dimethyl-1-octyl phenylalaninate,
Sodium dextranmethylcarboxylate modified by dioctyl aspartate,
Sodium dextranmethylcarboxylate modified by didecyl aspartate,
Sodium dextranmethylcarboxylate modified by dilauryl aspartate,
Sodium dextranmethylcarboxylate modified by N-(2-aminoethyl)dodecanamide,
Sodium dextransuccinate modified by lauryl glycinate,
N-(sodium methylcarboxylate) dextran carbamate modified by dioctyl aspartate,
Sodium dextranmethylcarboxylate modified by 2-(2-aminoethoxy)ethyl dodecanoate,
Sodium dextranmethylcarboxylate modified by 2-(2-{2-[dodecanoylamino]ethoxy}ethoxy)ethylamine,
Sodium dextranmethylcarboxylate modified by 2-(2-{2-[hexadecanoylamino]ethoxy}ethoxy)ethylamine,
Sodium dextranmethylcarboxylate modified by cholesteryl leucinate,
Sodium dextranmethylcarboxylate modified by cholesteryl 1-ethylenediaminecarboxylate, and
N-(sodium methylcarboxylate) dextran carbamate modified by cholesteryl leucinate.
13. The composition according to claim 1, wherein the dextran polymers substituted by radicals carrying carboxylate charges and hydrophobic radicals is chosen from the group consisting of the dextran polymers of formula II and is:
Sodium dextranmethylcarboxylate modified by cholesteryl 1-ethylenediaminecarboxylate grafted by reductive amination to the reducing chain end.
14. The composition according to claim 1, wherein the basal insulin whose isoelectric point is between 5.8 and 8.5 is insulin glargine.
15. The composition according to claim 1, wherein the composition comprises between 40 IU/ml and 500 IU/ml of the basal insulin whose isoelectric point is between 5.8 and 8.5.
16. The composition according to claim 1, wherein the composition additionally comprises a prandial insulin.
17. The composition according to claim 1, wherein the composition comprises between 40 and 800 IU/ml of total insulin.
18. The composition according to claim 16, wherein the composition comprises proportions, expressed as percentage, between the basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin of 25/75, 30/70, 40/60, 50/50, 60/40, 70/30, 80/20 and 90/10.
19. The composition according to claim 1, wherein the composition additionally comprises a GLP-1, a GLP-1 analogue or a GLP-1 derivative.
20. The composition according to claim 1, wherein the composition additionally comprises zinc salts at a concentration of between 0 and 5000 μM.
21. The composition according to claim 1, wherein the composition comprises buffers chosen from the group consisting of Tris, citrates and phosphates at concentrations of between 0 and 100 mM, preferably between 0 and 50 mM.
22. The composition according to claim 16, wherein the prandial insulin is chosen from the group formed by human insulin, insulin glulisine, insulin lispro and insulin aspart.
23. A single-dose formulation comprising a composition according to claim 1, at a pH of between 6.6 and 7.8, and a prandial insulin.
24. A single-dose formulation comprising a composition according to claim 1, at a pH of between 6.6 and 7.8, and a GLP-1, a GLP-1 derivative or a GLP-1 analogue.
25. A single-dose formulation according to claim 23, wherein the prandial insulin is chosen from the group comprising of human insulin.
26. A single-dose formulation according to claim 23, wherein the prandial insulin is chosen from the group consisting of insulin lispro, insulin glulisine and insulin aspart.
US16/025,832 2011-08-10 2018-07-02 Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5 Abandoned US20180311316A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/025,832 US20180311316A1 (en) 2011-08-10 2018-07-02 Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161522031P 2011-08-10 2011-08-10
FR11/57291 2011-08-10
FR1157291A FR2978918B1 (en) 2011-08-10 2011-08-10 PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH AN IP BETWEEN 5.8 AND 8.5
US201161579966P 2011-12-23 2011-12-23
FR1162445A FR2984749A1 (en) 2011-12-23 2011-12-23 Composition, useful for treating diabetes, comprises basal insulin, and a dextran substituted by carboxylate charge carrier radicals and hydrophobic radicals
FR11/62445 2011-12-23
US13/571,026 US9089476B2 (en) 2011-08-10 2012-08-09 Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5
US14/721,889 US20170182131A9 (en) 2011-08-10 2015-05-26 Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5
US16/025,832 US20180311316A1 (en) 2011-08-10 2018-07-02 Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/721,889 Continuation US20170182131A9 (en) 2011-08-10 2015-05-26 Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5

Publications (1)

Publication Number Publication Date
US20180311316A1 true US20180311316A1 (en) 2018-11-01

Family

ID=47667929

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/571,026 Expired - Fee Related US9089476B2 (en) 2011-08-10 2012-08-09 Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5
US14/721,889 Abandoned US20170182131A9 (en) 2011-08-10 2015-05-26 Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5
US16/025,832 Abandoned US20180311316A1 (en) 2011-08-10 2018-07-02 Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US13/571,026 Expired - Fee Related US9089476B2 (en) 2011-08-10 2012-08-09 Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5
US14/721,889 Abandoned US20170182131A9 (en) 2011-08-10 2015-05-26 Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5

Country Status (14)

Country Link
US (3) US9089476B2 (en)
EP (2) EP3053590A1 (en)
JP (1) JP5950477B2 (en)
KR (1) KR101810055B1 (en)
CN (1) CN103889442B (en)
AU (1) AU2012293463B2 (en)
BR (1) BR112014002986A2 (en)
CA (1) CA2843586A1 (en)
DK (1) DK2741765T3 (en)
IL (1) IL230611A (en)
MX (1) MX2014001190A (en)
RU (1) RU2578460C2 (en)
WO (1) WO2013021143A1 (en)
ZA (1) ZA201400773B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014002986A2 (en) 2011-08-10 2017-06-13 Adocia composition in the form of a solution for injection, and single dose formulation
CN113730555A (en) 2012-01-09 2021-12-03 阿道恰公司 Injectable solution of basal insulin and substituted copoly (amino acid) having pH7 and at least PI 5.8 to 8.5
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
EP2919804B1 (en) 2012-11-13 2018-01-31 Adocia Quick-acting insulin formulation including a substituted anionic compound
FR3001895B1 (en) * 2013-02-12 2015-07-03 Adocia PH7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISOELECTRIC POINT IS INCLUDED IN 5.8 AND 8.5 AND AN ANIONIC COMPOUND CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
EP2934566B1 (en) 2012-12-21 2017-06-21 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
US20160271226A1 (en) 2013-09-30 2016-09-22 Wockhardt Limited Pharmaceutical composition
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
US9795678B2 (en) * 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020952B1 (en) * 2014-05-14 2017-09-08 Adocia FAST-ACTING INSULIN FORMULATION COMPRISING SUBSTITUTED ANIONIC COMPOUND AND POLYANIONIC COMPOUND
FR3020947B1 (en) 2014-05-14 2018-08-31 Adocia AQUEOUS COMPOSITION COMPRISING AT LEAST ONE PROTEIN AND A SOLUBILIZING AGENT, ITS PREPARATION AND ITS USES
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
CN107949374B (en) * 2015-09-04 2022-04-08 莱迪杜德制药公司 Stabilized glucagon solutions
FR3043557B1 (en) 2015-11-16 2019-05-31 Adocia RAPID ACID COMPOSITION OF INSULIN COMPRISING A SUBSTITUTED CITRATE
EP3377038A1 (en) * 2015-11-16 2018-09-26 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
US20210187078A1 (en) * 2016-02-25 2021-06-24 Wockhardt Limited Pharmaceutical composition of insulin glargine and amino acids
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
FR3052072A1 (en) * 2016-06-07 2017-12-08 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACIDE CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
WO2018122278A1 (en) * 2016-12-27 2018-07-05 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a copolyamino acid
FR3070264A1 (en) 2017-08-24 2019-03-01 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN INCLUDING AN INHIBIT OF 5.8 TO 8.5 AND A CO-POLYAMINOACIDE CARBOXYLATE AND HYDROPHOBIC RADICAL CARRIERS
EP3720472A1 (en) 2017-12-06 2020-10-14 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
FR3083089A1 (en) 2018-06-29 2020-01-03 Adocia PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS
FR3083088B1 (en) 2018-06-29 2020-10-02 Adocia SOLUTION FOR INJECTION AT PH 7 INCLUDING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS
IL275148B2 (en) 2017-12-07 2025-02-01 Adocia Injectable solution with a ph of 7 comprising at least one basal insulin with a pi of between 5.8 and 8.5 and a co-polyaminoacid bearing carboxylate charges and hydrophobic radicals
EP3740229B1 (en) 2017-12-07 2025-04-09 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
MX2020005913A (en) 2017-12-07 2020-10-19 Adocia INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A COPOLYAMINO ACID WITH CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS.
EP3773472A1 (en) * 2018-04-04 2021-02-17 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CA3094308A1 (en) * 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
CN111989088A (en) * 2018-04-04 2020-11-24 艾瑞克有限公司 Medical infusion pump system for delivering insulin compounds
EP3814321A1 (en) * 2018-06-29 2021-05-05 Basf Se Esteramine salts
FR3083700B1 (en) * 2018-07-13 2021-03-12 Adocia THERMOSTABLE FORMULATION OF HUMAN INSULIN A21G
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2387201A (en) 1942-01-12 1945-10-16 Bonneville Ltd Mono-acyl ethylene diamines
US4826818A (en) 1983-10-26 1989-05-02 Kanebo Ltd. Proteinaceous emulsifier, process for preparing same and emulsion type cosmetic compositions containing same
DE3837825A1 (en) 1988-11-08 1990-05-10 Hoechst Ag NEW INSULIN DERIVATIVES, THEIR USE AND A PHARMACEUTICAL PREPARATION CONTAINING THEM
ATE446108T1 (en) 1999-04-09 2009-11-15 Amag Pharmaceuticals Inc HEAT RESISTANT COATED COLLOIDAL IRON OXIDES
FR2801226B1 (en) 1999-11-23 2002-01-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND METHOD OF PREPARATION
IL140844A0 (en) 2001-01-10 2002-02-10 Polygene Ltd Cationic polysaccharide compositions
MXPA04006084A (en) 2001-12-20 2005-03-31 Lilly Co Eli Insulin molecule having protracted time action.
FR2840614B1 (en) 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
DE10227232A1 (en) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
JP4970731B2 (en) 2002-12-04 2012-07-11 フラメル・テクノロジー Polyamino acids functionalized by at least one (oligo) amino acid group and their applications, in particular medical applications
WO2004096854A2 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
EP1687019B1 (en) * 2003-11-20 2017-11-22 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
FR2862536B1 (en) 2003-11-21 2007-11-23 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR THE PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2873040B1 (en) 2004-07-19 2007-11-30 Flamel Technologies Sa COLLOIDAL FORMULATION OF LONG-ACTING INSULIN AND ITS PREPARATION
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
JP2008528509A (en) 2005-01-21 2008-07-31 アルザ コーポレイション Therapeutic peptide formulation for coating microneedles with improved stability comprising at least one counter ion
KR20090013179A (en) 2006-04-07 2009-02-04 아도시아 Difunctional polysaccharides
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
FR2902007B1 (en) 2006-06-09 2012-01-13 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
PT2057165E (en) 2006-09-07 2011-05-12 Einstein Coll Med Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
FR2915683B1 (en) 2007-05-03 2009-08-07 Flamel Technologies Sa SELF-PRECIPITANT PHARMACEUTICAL FORMULATIONS FOR MODIFIED RELEASE OF ACTIVE INGREDIENTS
FR2919188B1 (en) * 2007-07-27 2010-02-26 Proteins & Peptides Man COMPLEXES BETWEEN AN AMPHIPHILIC POLYMER AND A OSTEOGENIC PROTEIN BELONGING TO THE BMPS FAMILY
EP2178909B1 (en) 2007-08-13 2015-10-21 Novo Nordisk A/S Rapid acting insulin analogues
BRPI0820535B8 (en) * 2007-11-16 2021-05-25 Novo Nordisk As pharmaceutical compositions containing insulin and an insulinotropic peptide
TWI394580B (en) * 2008-04-28 2013-05-01 Halozyme Inc Super fast-acting insulin compositions
TWI451876B (en) * 2008-06-13 2014-09-11 Lilly Co Eli Pegylated insulin lispro compounds
US20100069292A1 (en) * 2008-09-02 2010-03-18 Biodel, Inc. Insulin with a basal release profile
FR2940802A1 (en) 2008-10-10 2010-07-09 Adocia COMPLEXITY BETWEEN HUMAN INSULIN AND AN AMPHIPHILIC POLYMER AND USE OF THIS COMPLEX FOR PREPARING RAPID HUMAN INSULIN FORMULATION
US20100167984A1 (en) 2008-09-26 2010-07-01 Adocia Complex between human insulin and an amphiphilic polymer and use of this complex in the preparation of a fast-acting human insulin formulation
US8426382B2 (en) * 2008-10-06 2013-04-23 Adocia Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative
FR2936800B1 (en) * 2008-10-06 2010-12-31 Adocia POLYSACCHARIDE COMPRISING FUNCTIONAL CARBOXYL GROUPS SUBSTITUTED WITH A HYDROPHOBIC ALCOHOL DERIVATIVE
EP2360188B1 (en) 2008-11-05 2014-09-17 National University Corporation Tokyo Medical and Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
EP2350296A4 (en) 2008-11-17 2013-04-03 Enzon Pharmaceuticals Inc Branched cationic lipids for nucleic acids delivery system
FR2948573B1 (en) * 2009-07-31 2011-11-18 Adocia NEW FORM OF ADMINISTRATION OF OSTEOGENIC PROTEIN COMPLEXES
FR2944448B1 (en) * 2008-12-23 2012-01-13 Adocia STABLE PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE MONODONAL ANTIBODY AND AT LEAST ONE AMPHIPHILIC POLYSACHARIDE COMPRISING SUBSTITUENTS DERIVED FROM HYDROFOB ALCOHOLS OR HYDROPHOBIC AMINES.
WO2010082894A1 (en) * 2009-01-13 2010-07-22 Ge Healthcare Bio-Sciences Ab Precipitation of biomolecules with negatively charged polymers
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
FR2943538B1 (en) * 2009-03-27 2011-05-20 Adocia QUICK ACTION FORMULATION OF RECOMBINANT HUMAN INSULIN
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2956116A1 (en) 2010-02-09 2011-08-12 Adocia SOLUBLE POLYSACCHARIDE / BMP-7 COMPLEXES WITH PH PHYSIOLOGICAL PH
FR2958646B1 (en) 2010-04-07 2012-05-18 Adocia POLYSACCHARIDES COMPRISING FUNCTIONAL CARBOXYL GROUPS SUBSTITUTED WITH A HYDROPHOBIC ACID DERIVATIVE.
FR2958647B1 (en) 2010-04-08 2013-08-23 Adocia POLYSACCHARIDES COMPRISING FUNCTIONAL CARBOXYL GROUPS SUBSTITUTED WITH A HYDROPHOBIC DERIVATIVE CARRIED BY AT LEAST TRIVALENT SPACER.
CN105218685B (en) * 2010-02-09 2018-12-25 阿道恰公司 The anion polysaccharide being functionalized by least two hydrophobic groupings as entrained by the spacer of at least trivalent
EP2388723A1 (en) 2010-05-18 2011-11-23 University College Cork-National University of Ireland, Cork Method of assessing allergic status in a subject
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
WO2012153070A1 (en) 2011-05-10 2012-11-15 Adocia Functionalised oligosaccharides
US20120295833A1 (en) 2011-05-10 2012-11-22 Adocia Polysaccharides having an adjustable degree of functionalization
BR112014002986A2 (en) 2011-08-10 2017-06-13 Adocia composition in the form of a solution for injection, and single dose formulation
CN113730555A (en) 2012-01-09 2021-12-03 阿道恰公司 Injectable solution of basal insulin and substituted copoly (amino acid) having pH7 and at least PI 5.8 to 8.5
FR2985429B1 (en) 2012-01-09 2016-07-29 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS
FR2985428B1 (en) 2012-01-09 2016-05-27 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACIDE
EP2814459A1 (en) 2012-02-17 2014-12-24 Massachusetts Institute Of Technology Self-regulated peptide hydrogel for insulin delivery
SG10201703742SA (en) 2012-11-13 2017-06-29 Adocia Substituted anionic compounds consisting of a backbone consisting of a discrete number of saccharide units
EP2919804B1 (en) 2012-11-13 2018-01-31 Adocia Quick-acting insulin formulation including a substituted anionic compound

Also Published As

Publication number Publication date
DK2741765T3 (en) 2016-06-13
EP2741765B1 (en) 2016-03-30
WO2013021143A1 (en) 2013-02-14
AU2012293463A1 (en) 2014-03-06
US20170182131A9 (en) 2017-06-29
CN103889442B (en) 2016-12-28
AU2012293463B2 (en) 2016-08-04
CA2843586A1 (en) 2013-02-14
RU2578460C2 (en) 2016-03-27
KR101810055B1 (en) 2017-12-18
KR20140051384A (en) 2014-04-30
JP2014521716A (en) 2014-08-28
US9089476B2 (en) 2015-07-28
IL230611A0 (en) 2014-03-31
EP2741765A1 (en) 2014-06-18
JP5950477B2 (en) 2016-07-13
MX2014001190A (en) 2014-05-12
US20150250858A1 (en) 2015-09-10
RU2014108829A (en) 2015-09-20
CN103889442A (en) 2014-06-25
EP3053590A1 (en) 2016-08-10
EP2741765B9 (en) 2016-09-28
ZA201400773B (en) 2016-11-30
BR112014002986A2 (en) 2017-06-13
US20130065826A1 (en) 2013-03-14
IL230611A (en) 2016-10-31

Similar Documents

Publication Publication Date Title
US20180311316A1 (en) Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5
US10335489B2 (en) Injectable solution at pH 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid
US8669227B2 (en) Fast-acting insulin formulation
US10383920B2 (en) Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
JP6111475B2 (en) Stable aqueous composition comprising human insulin or analogs or derivatives thereof
US20180236085A1 (en) Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is comprised in 5.8 and 8.5 and an anionic compound bearing carboxylate charges and hydrophobic radicals
US20120094902A1 (en) Fast-acting insulin formulation
US20190216931A1 (en) Injectable ph 7 solution comprising at least one basal insulin having a pi from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
US10449256B2 (en) Injectable solution at pH 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
US11576952B2 (en) Injectable solution at pH 7 comprising at least one basal insulin for which the pI is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
FR2978918A1 (en) Composition, useful for treating diabetes, comprises basal insulin, and dextran substituted by carboxylate charge carrier radicals and hydrophobic radicals, where composition is in the form of an injectable aqueous solution

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载